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Lactate is a key metabolite in human cells. A regulated transport across membranes is vital for 
cellular function while deregulated transport is a hallmark of cancer. In tumor cells, glycolysis 
as the main route for ATP synthesis even in the presence of oxygen (Warburg effect) demands 
rapid lactate clearance to avoid acidification. Oxygenic cancer cells, in turn, rely on an efficient 
retrieval of extracellular lactate to fuel the citric acid cycle (reverse Warburg effect). To maintain 
an active interchange between cells, four monocarboxylate transporters (MCT1−4) manage bi-
directional, proton-coupled transport across plasma membranes. For its translocation to the 
plasma membrane, MCT1 demands chaperoning by a member of the immunoglobulin 
superfamily, namely basigin. Both proteins remain complexed at the plasma membrane. 
Although frequently suggested, a direct effect of the chaperone on MCT1-mediated transport 
is not resolvable in commonly used expression systems. In this study, MCT1 expression in 
S. cerevisiae Δjen1 Δady2 profited from a basigin-independent translocation in a system with 
zero background from endogenous monocarboxylate transporters or basigin homologs. The 
molecular fusion with truncated basigin constructs revealed an effect on transmembrane 
L-lactate distribution at the domain level. In zero-trans influx experiments using 14C-labeled 
substrate, the presence of basigin’s extracellular Ig-I domain permitted a 4.5-fold intracellular 
L-lactate accumulation in the transport equilibrium. At near-neutral pH, cytosolic L-lactate 
concentrations greatly exceeded those provided with the buffer. The absence of the basigin 
Ig-I domain due to truncation or misfolding reversed this effect. The identification of patches of 
positive and negative surface potentials and evidence from charge-resolving point mutations 
indicated an electrostatic attraction of L-lactate anions and protons. This thesis deduces a 
substrate harvesting function of basigin that creates a “microenvironment” of locally increased 
concentrations and drives L-lactate influx according to Le Chatelier’s principle. This influx was 
physiologically relevant and promoted cell growth on L-lactate medium. According to classical 
and reverse Warburg effects, highly adapted tumor cells require a fine-tuned transmembrane 
L-lactate distribution and basigin might be an important determinant. Hereof, MCTs are 
promising targets in the anti-tumor therapy. The basigin-MCT1 fusion set-up from this study 
further revealed two known MCT1 inhibitors, AZD3965 and p-chloromercuribenzene sulfonate 
(pCMBS), as direct and basigin-independent modifiers. Cys159 in the transporter cavity was 
revealed as selectively targetable by pCMBS leading to a complete transport inhibition. Smaller 
cysteine-modifiers had a less prominent effect and lacked site-specificity. Cys159 is proposed 
to constitute a hinge region of the alternating access transporter and a wedge-like modification 
locks MCT1 in the outward open conformation. This reveals a target region for inhibitor design 
and in the future, Cys159 might serve as a natural anchor to introduce distinct labels and report 





Laktat ist ein zentraler Metabolit in menschlichen Zellen, dessen regulierter Transport durch 
Zellmembranen Bedingung für die Aufrechterhaltung vieler Zellfunktionen ist. Ein deregulierter 
Laktataustausch zwischen Zelle und Zellumgebung ist für Tumoren kennzeichnend. In 
Tumorzellen erfordert die auch unter aeroben Bedingungen verstärkte Glykolyse (Warburg-
Effekt) einen effizienten Export von Laktat, um einer Zellübersäuerung entgegenzuwirken. 
Oxidative Tumorzellen nehmen hingegen extrazelluläres Laktat auf und führen es dem 
Citratzyklus zu (reverser Warburg-Effekt). Vier Monocarboxylat-Transporter (MCT1−4) 
ermöglichen den bidirektionalen, protonengekoppelten Transport von Laktat. Die Trans-
lokation von MCT1 zur Membran erfordert die Interaktion mit Basigin, einem Vertreter der 
Immunoglobulin-Superfamilie. Obwohl beide Proteine an der Membran assoziiert bleiben, 
konnte ein direkter Effekt des Chaperons auf den MCT1-vermittelten Transport in gängigen 
Systemen nie belegt werden. In dieser Arbeit wurde MCT1 in S. cerevisiae Δjen1 Δady2-Zellen 
exprimiert, um von einer Basigin-unabhängigen Translokation und einem System ohne 
endogene Laktat-Transporter oder Basigin-Homologe zu profitieren. Durch Fusion mit 
verkürzten Basigin-Konstrukten und Messungen des Einstroms von 14C-markiertem Laktat 
konnte gezeigt werden, dass Basigins extrazelluläre Ig-I-Domäne im Transport-Gleichgewicht 
eine 4,5-fache Laktat-Anreicherung im Zellinneren ermöglicht. Im annähernd neutralen pH-
Bereich konnten dadurch höhere intrazelluläre Laktatkonzentrationen erreicht werden, als es 
die extrazellulären Pufferbedingungen erlauben würden. Das Fehlen einer korrekt gefalteten 
Ig-I-Domäne hob diesen Effekt auf. Die Identifizierung von positiven und negativen 
Oberflächenpotentialen und der Effekt von ladungskompensierenden Mutationen deuteten auf 
eine elektrostatische Anziehung von Laktat-Ionen und Protonen hin. Diese Arbeit schreibt der 
Ig-I-Domäne von Basigin eine substratkonzentrierende Funktion am Transportereingang zu, 
die nach dem Prinzip von Le Chatelier den Substrateinstrom in die Zellen begünstigt. Dieser 
Einstrom war physiologisch bedeutend und förderte das Zellwachstum auf Laktatmedium. 
Spezialisierte Tumorzellen bedürfen eines regulierten Laktataustauschs und Basigin könnte 
einen bestimmenden Faktor darstellen. Die Basigin-MCT1-Fusion dieser Arbeit konnte weiter 
genutzt werden, um zwei bekannte MCT1-Inhibitoren, AZD3965 und 4-Chlormercuri-
benzolsulfonat (pCMBS), als direkte und Basigin-unabhängige Modifikatoren zu enthüllen. 
pCMBS adressierte Cys159 selektiv und blockierte den Laktattransport vollständig. Kleinere 
Cystein-Modifikatoren erwiesen sich als ineffizient und nicht selektiv. Diese Arbeit zeigt 
Cys159 in einem „MCT1-Scharnier“ und eine sperrige Modifikation scheint den Transporter in 
der outward open-Konformation festzusetzen. Dies offenbart eine neue Zielregion für 
Inhibitoren und könnte künftig als Bindestelle für Markierungsstudien dienen, um 





Cells are the smallest functional units of prokaryotic and eukaryotic organisms [1]. A cellular 
organization establishes a microenvironment in which physiological processes are separated 
from the environmental entourage. To achieve physical enclosure, biological membranes 
constitute a barrier and isolate the cytoplasmic interior as well as establish individual 
compartments within a cell. Cell membranes are semipermeable and only freely diffusible by 
small uncharged molecules and water [2]. For larger solutes, e.g. metabolic precursors and 
waste products, membranes are less passable and an exchange between in- and outside 
depends on specific transmembrane proteins that span the membrane and allow controlled 
permeability and transport [2]. Roughly 10 % of the human proteome constitute proteins for 
transmembrane transport and mediate the permeability of ions, signal transducers, drugs, 
essential nutrients, metabolites and metabolic waste (refer to the Human Protein Atlas, data 
from 03/12/2021, [3, 4]) [5]. One of these key metabolites in need for efficient transport across 
biological membranes is lactate. 
 
1.1. L-Lactate: a key metabolite in healthy and in tumor cells 
1.1.1. L-Lactate metabolism: formation and clearance in human cells 
Lactic acid is a chiral monocarboxylic acid and a key substrate in human metabolism. The 
L(+)-lactic acid is the physiological abundant enantiomer and with a 𝑝𝐾𝑎 value of 3.86, it is 
largely deprotonated and anionic under physiological conditions. As extensively reviewed by 
Adeva-Andany et al., the metabolic routes of L-lactate are widespread ranging from its 
relevance as a mere waste product of anaerobic glycolysis to its significance as a substrate 
for gluconeogenesis and as an energy source via oxidation in mitochondria [6]. L-Lactate 
metabolism centers around the enzymatic conversion from pyruvate via the lactate 
dehydrogenase (LDH) in the cytosol (Figure 1.1). In humans, the reversible reduction of 
pyruvate to L-lactate using nicotinamide adenine dinucleotide (NADH) is the main route of 
L-lactate formation and recovers NAD+ essential for sustaining glycolysis under anaerobic 
conditions [1]. In that regard, the endogenous formation of L-lactate is tightly linked to pyruvate 
metabolism. Pyruvate itself is mainly formed by two routes: the metabolic breakdown of 
glucose via the above-mentioned anaerobic glycolysis or the pentose phosphate pathway, and 
alanine metabolism via the alanine transaminase (ALT)-catalyzed conversion to pyruvate [1]. 
L-Lactate consumption profits from the reverse LDH-catalyzed oxidation to pyruvate which then 
serves as a substrate for numerous metabolic pathways. In each case, pyruvate is rapidly 




converted to either acetyl coenzyme A by the pyruvate dehydrogenase (PDH) complex or to 
oxaloacetate via the action of pyruvate carboxylase [1]. Acetyl coenzyme A then fuels the TCA 
cycle and ATP synthesis via oxidative phosphorylation, or serves as a direct substrate for 
lipogenesis [1]. Oxaloacetate, on the other hand, feeds the gluconeogenesis which has been 
shown as one of the main routes for metabolic L-lactate clearance [8]. The disturbance of one 
of the rate-limiting steps of L-lactate clearance leads to the accumulation well above the 
physiological concentration of around 1 mM which demands non-metabolic clearance of 
access L-lactate by a rapid efflux from cells and manifests a hallmark in several physiological 




Figure 1.1. L-Lactate metabolism and transport in human cells. L-Lactate metabolism centers around 
the reversible conversion from/to pyruvate by LDH action. L-Lactate is mainly formed as product of 
glucose breakdown and anerobic glycolysis which outlines the main pathway for ATP synthesis in highly 
glycolytic cancer cells (Warburg). In normal cells as well as in oxygenic cancer cells (reverse Warburg), 
pyruvate and L-lactate (via conversion to pyruvate) are fueled into the TCA cycle for oxidative 
phosphorylation (OXPHOS) and ATP synthesis. Inter- and intracellular shuttling of L-lactate is managed 
by monocarboxylate transporters (MCT1−4) and mitochondrial pyruvate carriers (MPCs). For simplicity, 
metabolic pathways are not stoichiometrically balanced. Detailed information can be found in the main 
text. ADP/ATP, adenosine di/triphosphate; ALT, alanine transaminase; LDH, lactate dehydrogenase; 
OXPHOS, oxidative phosphorylation; TCA, tricarboxylic acid; MCT, monocarboxylate transporter; 
mMCT, mitochondrial MCT; MPC, mitochondrial pyruvate carrier; NAD+/NADH, nicotinamide adenine 






1.1.2. L-Lactate metabolism in cancer: the (reverse) Warburg effect 
Cancer cells are known to be highly adapted to changing metabolic requirements and 
deregulated cell energetics secure rapid cell growth, proliferation and angiogenesis (reviewed 
in [13]). 
In normal cells, pyruvate from glucose breakdown is fed into the TCA cycle and processed to 
carbon dioxide for an effective ATP synthesis under aerobic conditions. Only at O2 deprivation, 
cells rely on an anaerobic glycolysis and a NAD+ recovery by L-lactate formation. In 1927, 
Warburg et al. described a metabolic switch of tumor cells to glycolysis even under normoxic 
conditions and a rapid formation and accumulation of L-lactate as a waste product. This is 
nowadays termed as the Warburg effect [14] (Figure 1.1). The metabolic shift of tumor cells to 
“aerobic glycolysis” is thereby partly accomplished by an oncogenic induction of gene 
expression for enzymes of the glycolytic machinery [15, 16]. Over the years, various 
explanations for the metabolic switch of tumor cells to the less effective glycolytic ATP 
production have been proposed. First, although generating less equivalents of ATP per 
glucose molecule, ATP synthesis rates for glycolysis are much faster enabling cells to rapidly 
consume limited glucose resources [17, 18]. And second, an accelerated glucose breakdown 
provides biosynthetic precursors including glycerol and citrate for fatty acid synthesis, non-
essential amino acids and, via the pentose phosphate pathway, NADPH as an essential 
component for rapid cell growth and proliferation [19]. Strikingly, beyond highly glycolytic tumor 
cells producing vast amounts of L-lactate as a waste product, other cancerous cells have 
recently been shown to actively feed on external L-lactate that enters the TCA cycle for ATP 
production (Figure 1.1, called “reverse Warburg”) [20]. Moreover, other studies indicate 
L-lactate as the preferred substrate that overrules the glucose contribution as a fuel for the 
TCA cycle possibly by sparing effort for the synthesis of glycolytic enzymes [21, 22].  
Beside its deep involvement in cancer energy metabolism, L-lactate has additionally been 
revealed as a key player in the tumorigenic signal transduction to promote migration, cell 
growth and survival, and immunosuppression [23–25]. Thereof, L-lactate has been shown to 
regulate G protein-coupled receptor 81 (GPR81) signaling [24] and affect the expression of 
tumor-promoting transcription factors including hypoxia-inducible factor 1 (HIF-1), Kruppel-like 






1.2. L-Lactate transport across cell membranes: an overview 
To maintain L-lactate homoeostasis and to enable an efficient metabolic exchange of L-lactate 
between glycolytic and oxygenic cells, several L-lactate/pyruvate transporters have been 
identified that sustain L-lactate shuttling between cells and intracellular compartments. 
Respective transporters can roughly be divided into sodium-coupled monocarboxylate 
transporters (SMCTs; SLC5a family), proton-coupled transporters of the SLC16a family 
(MCTs) and mitochondrial pyruvate carriers (MPCs) (reviewed in [9]).  
The electrogenic, Na+-coupled transport of monocarboxylates including L-lactate, pyruvate, 
short-chain fatty acids and ketone bodies by two members of the SLC5a family, namely 
SMCT1 (SLC5a8) and SMCT2 (SLC5a12), has been shown to allow an active metabolite 
resorption and is therefore largely restricted to the epithelial cell lining in the kidney tubules 
and intestine [28–31]. In most cases, L-lactate transport is accomplished by the expression of 
MCTs of the SLC16a family (Figure 1.1). Individual members with a broad range of transport 
characteristics and specifications are expressed at the plasma membrane of numerous cell 
types. All of them mediate proton-coupled, bi-directional transport and allow a dynamic 
substrate shuttling between cells [9]. MCTs are discussed in detail in section 1.3. Finally, 
monocarboxylates (i.e. L-lactate) taken up by cells need subsequent intracellular shuttling and 
transport into mitochondria. Generally, L-lactate is converted to pyruvate which enters via 
specific mitochondrial pyruvate carriers (MPCs) [7] (Figure 1.1). MPCs have been shown to be 
expressed at the mitochondrial membrane and mediate the transport of pyruvate and other 
monocarboxylic acids including α-ketoacids with a very low affinity for L-lactate [32, 33]. More 
recently, MCTs have also been localized at the inner mitochondrial membrane to presumably 






1.3. Human monocarboxylate transporters (MCTs)  
1.3.1. MCTs: members of the SLC16a solute carrier family 
According to the solute carrier (SLC) gene tables (SLC Tables, http://slc.bioparadigms.org, 
[36]), the SLC family of proteins includes over 65 subfamilies and at least 400 transporter 
genes sharing a sequence identity of 20−25 % [37]. All family members facilitate passive 
diffusion or mediate secondary active transport of solutes across membranes [38]. The 
SLC16a family, also known as the monocarboxylate transporter (MCT) family, consists of 14 
members of which four have been revealed as genuine monocarboxylate transporters 
(MCT1, 2, 3 and 4; corresponding to members SLC16a1, 7, 8 and 3, respectively) and are 
found in all examined eukaryotic organisms (refer to the SLC Tables [36]). Most remaining 
members are referred to as orphan transporters with no substantial insight on functionality and 
substrates. Only SLC16a10 (TAT1, aromatic acid transporter [39]) and SLC16a2 (MCT8, 
thyroid hormone transporter [40]) have been expressed and characterized in detail. For MCT6, 
7 and 9, recent studies suggest them as genuine transporters involved in the flux of drugs, 
ketone bodies in hepatocytes, and carnitine, respectively, although information on the function 
and physiological relevance is sparse [41–43]. 
 
1.3.2. Discovery and functional characteristics 
The discovery and characterization of genuine monocarboxylate transporters can largely be 
attributed to the work of A. P. Halestrap and coworkers in the 1990s. From a historical 
perspective, Poole et al. purified a protein of 35−50 kDa from rat and rabbit erythrocytes that 
enabled the transport of pyruvate and L-lactate [44, 45]. Several related studies including an 
N-terminal sequencing identified the protein as a monocarboxylate transporter homolog and 
named it MCT1 [46, 47]. Extensive functional characterization determined MCT1 to 4 as bi-
directional, proton-coupled but electroneutral transporters that mediate the secondary active 
transport of a various spectrum of substrates including L-lactate, pyruvate, short-chain fatty 
acids and ketone bodies (reviewed in [48]). The substrate spectrum and transport kinetics as 
well as the tissue distribution differ between the MCT isoforms designating distinct 
physiological roles. Whereas the MCT3 expression is less systemic and restricted to the retinal 
pigment epithelium [49], MCT1 is ubiquitously expressed. With a 𝐾𝑚 of 3.5 mM for L-lactate 
[50], it was found to mediate both the in- and efflux of L-lactate with directionality determined 
by the substrate and proton availability and gradients (Figure 1.1). MCT2 as a high-affinity 
isoform (𝐾𝑚 of 0.74 mM for L-lactate [51]) is thought to be more destined for L-lactate uptake 
whereas MCT4 (𝐾𝑚 = 28 mM [52]) is dedicated to the efflux from highly glycolytic cells 





1.3.3. Structural characteristics and transport mechanism 
Based on topology plots, proteolytic digestion [53] and the recently published structures of a 
bacterial MCT homolog (SfMCT, 25 % sequence identity with MCT1) [54] and human MCT2 
[55], MCTs were confirmed to consist of 12 highly conserved α-helical transmembrane 
domains (TMs) of which some are discontinuous (depending on MCT member) (Figure 1.2A). 
Accordingly, MCTs display intracellular N- and C-termini and a long, flexible linker between 
TM6 and 7 prone to proteolytic digestion [53]. MCTs form two distinct domains of six helices 




Figure 1.2. Structure and translocation cycle of human MCT1. (A) Structure model for human MCT1 in 
the outward open conformation. The model was calculated with SWISS-MODEL based on the crystal 
structure for SfMCT (PDB #6HCL) and visualized with Chimera. TM1−6 and TM7−12 form distinct 
subunits connected by a long, flexible loop (orange dashed line, not resolved in the SfMCT crystal 
structure). Intracellular N- and C-termini are indicated in black and truncated due to lacking structure 
data. (B) Illustration of the proposed alternating access translocation cycle of MCTs (based on [56]). 
The secondary active transport of L-lactate is coupled to proton co-transport. Critical residues for proton 
and substrate binding (K38, D309 and R313) are indicated. The process is reversible with direction 
determined by the equilibrium constant 𝐾, intra-/extracellular substrate concentrations and pH. 
 
 
Movement and rearrangement of both domains is thought to mediate conformational changes 
(Figure 1.2B). The existence of two conformations constituting an alternating access 
mechanism was initially proposed by Wilson et al. and Manoharan et al. and based on 




(10−15 % sequence identity with MCTs) [56, 57]. Indeed, the resolved structures for SfMCT 
and MCT2 were captured in two distinct conformations proposing a transport mechanism in 
which MCTs toggle between an outward open and an inward open state. MCTs have very early 
been emphasized as pH-sensitive H+/monocarboxylate co-transporters with an electroneutral 
substrate/proton stoichiometry of 1:1 [58–60]. Even before revelation of the molecular identity 
of MCTs, a transport mechanism involving extensive kinetic measurements on cellular 
monocarboxylate transport postulated an alternating access model and a distinct translocation 
cycle. According to Bruijne et al., in influx, the co-transported H+ protonates an exposed 
residue in the transporter cavity generating a positive charge suitable for substrate anion 
attraction. Further passage of the substrate anion leads to electrostatic rearrangements and a 
transporter swiveling to the inward open conformation and release of first the substrate and 
second the accompanying proton [61, 62] (Figure 1.2B). This process is reversible with 
directionality determined by the transporter kinetics and the prevailing substrate concentrations 
and pH. The transporter’s return to the original position is known as the rate-limiting step of 
transport and can be promoted by a substrate exchange from the opposite side of the 
membrane termed transacceleration [63, 64]. In the course of time, structural, mechanistic and 
mutational analyses unveiled distinct residues some of which found reoccurring importance in 
the translocation cycle. For simplicity, the numberings for the below described residues from 
publications for other MCT members are translated to the corresponding positions in the 
human MCT1 sequence. Initially, Wilson et al. suggested Lys38 as the primary proton acceptor 
and consecutive substrate anion attractor in the outward open state with an Asp309/Arg313 
ion pair guiding the passage of H+/L-lactate through the transport path [56, 57, 65] 
(Figure 1.2B). Mutational analyses showed that the substitution of Phe367 in the binding 
pocket by smaller residues allowed the passage of bulkier monocarboxylates attributing a 
relevance in substrate selectivity [47]. More recent studies confirmed the importance of Lys38, 
Arg313, Asp309 and, lately, Asp414 attributing a role in pH dependency and substrate 
recognition, respectively [54, 55, 66, 67]. Further, Zhang et al. presented a three-dimensional 
inward open conformation of MCT2 and proposed Asp309 as the cytosolic proton binding site 
with residues Arg313, Tyr34, Phe367 and Ser371 forming a network for substrate binding from 
the cytosolic side [55]. 
 
1.3.4. Basigin: a member of the immunoglobulin superfamily and a chaperone for MCTs 
Although being a non-glycosylated protein, MCT1 associates with a glycosylated protein for 
targeting to the plasma membrane. Generally, MCTs interact with one of two glycoproteins of 
the immunoglobulin (Ig) superfamily, namely basigin and embigin. Although first evidence from 
rat erythrocytes revealed an association of MCT1 with embigin [68], further investigations 




embigin as a secondary, alternative partner. Contrary, MCT2 relies on the interaction with 
embigin [70]. In the absence of basigin/embigin, MCTs reside in the perinuclear compartment 
suggesting their interaction to be crucial for intracellular trafficking and cell surface expression 
[69, 71].  
Basigin and embigin both belong to the so called basigin superfamily and share structural 
similarity with a sequence identity of 24 %. All basigin (four isoforms) and embigin variants 
(two isoforms) consist of a single transmembrane domain and one to three immunoglobulin 




Figure 1.3. Structure of different basigin and embigin isoforms. All basigin/embigin isoforms display an 
extracellular N-terminus, an intracellular C-terminus, and a single transmembrane (TM) helix domain 
(black). Isoforms differ in the number and type of extracellular Ig-like domains (I-, C2- or V-type, gray to 
white) and are a result of alternative promoter usage or splicing. The proper folding of the Ig-like domains 
depends on the formation of disulfide bridges (dotted lines). Exemplary, the Ig-like domain types 
(labeled), glycosylation sites (orange stars) and the highly conserved glutamate in the TM (gray star) 
are indicated for the most prevalent isoform of basigin/embigin. (A) Basigin isoforms 1−4 are displayed. 
Beside MCTs, basigin interacts with cyclophilins, integrins and other basigin isoforms for intracellular 
signaling processes (see text for details). (B) Embigin isoforms 1 and 2 are shown. Isoforms differ in the 
N-terminal sequences (1−50 missing in embigin variant 2). 
 
 
The amino acids 1−21 in basigin splice variant 2 (1−32 in embigin variant 1) designate a 
putative signal peptide for proper trafficking [74]. Both isoforms of embigin consist of two Ig-
like domains of the V-type [75]. Similarly, the most prevalent and investigated basigin splice 
variant 2 (also named BSG, basigin-2, CD147, EMMPRIN) displays two Ig-like domains. X-ray 
diffraction of the extracellular domain of basigin variant 2 confirmed the specific folds for an 




specific isoform 1 of basigin harbors a third N-terminal Ig-like domain and is associated with 
retinoblastoma [77]. The basigin variants 3 and 4 share the membrane-adjacent Ig-I domain 
but lack an additional Ig-like domain. These isoforms are, along with basigin variant 2, 
expressed in various human cell lines and may be upregulated in cancer [73]. The functional 
differences between basigin isoforms are not completely understood although basigin variant 3 
has been found to inhibit tumor cell proliferation and invasion, and form homo- and 
heterodimers to regulate basigin variant 2 function in tumor progression [73]. Basigin variant 2 
is the most abundant, functionally characterized isoform and MCT studies mainly concentrate 
on this variant. Beside its interaction with MCTs, basigin variant 2 is a receptor for integrins 
and cyclophilins and associated with cell adhesion and inflammation [78–80] (Figure 1.3). Via 
the induction of matrix metalloproteinases, basigin variant 2 is also involved in tumor invasion 
and progression [74, 81]. The physiological importance of basigin and its interaction partners 
were reviewed in detail by Muramatsu [82]. Underlining the wide network of cellular processes 
basigin variant 2 is involved in, it is additionally proposed to be essential for host invasion by 
Plasmodium falciparum and common viruses including the immunodeficiency virus (HIV) and 
the severe acute respiratory syndrome (SARS) coronavirus (CoV)  [83–85]. 
In the context of MCTs, the role of basigin has been limited to its action as a chaperone that 
facilitates trafficking. Most MCT-related studies of basigin concentrated on the investigation of 
the exact mode of interaction of both proteins and the physiological relevance of its 
disturbance. Basigin has been confirmed to form dimers via its extracellular domain [76, 86], 
and earlier studies using fluorescence resonance energy transfer (FRET) revealed a basigin-
MCT1 interaction stoichiometry of a basigin dimer associating with two MCT1 monomers [87]. 
To gather information on the mode of interaction between MCT1 and basigin, Kirk et al. 
constructed chimeras of basigin and a close relative and member of the immunoglobulin 
superfamily (cluster of differentiation 2, CD2) and found that the transmembrane domain 
and/or the C-terminal end of basigin are sufficient for proper interaction [69]. Indeed, the 
transmembrane domain of basigin displays an unusual but highly conserved charged residue 
(Glu218 in basigin variant 2) prone for electrostatic hydrogen bonding to a suitable residue in 
MCT1 [57]. This interaction is assumed to persist at the plasma membrane [69, 87], and 
several studies indicated that basigin further regulates MCT activity beyond chaperoning [88, 
89]. Indeed, at least the activity or efficiency of common MCT inhibitors has occasionally been 
linked to basigin (see next chapter). Information on a more direct effect on the MCT 
functionality is scarce and evidence suffers from the tight dependence of MCTs on basigin to 







1.3.5. MCT1 as a drug target: physiological relevance and inhibition 
MCTs as the key mediators of L-lactate transport across membranes enable a metabolite 
exchange between not only cancer cells but also in the brain (astrocytes and neurons) and in 
skeletal muscle (white and red fibers) (reviewed in [90, 91]). The deep involvement of MCTs 
in lactate homeostasis and lactate being a key metabolite in energy metabolism link a 
deregulated MCT expression to several pathophysiological conditions including exercise-
induced hyperinsulinemia or cryptic exercise intolerance (reviewed in [48]). Most importantly, 
in cancerous tissue, MCTs permit a substrate exchange between the L-lactate-producing, 
glycolytic (Warburg) and the L-lactate consuming, oxygenic tumor cells and are therefore 
recognized as essential for tumor progression [22, 92]. Hence, an increased expression of 
several MCT members is a diagnostic marker of common malignancies [93–95]. The 
overexpression of MCTs has been shown to be under extensive regulation ranging from 
transcriptional to posttranslational mechanisms and mediated by hypoxic conditions or tumor-
related signaling pathways (reviewed in [22]). In most cases, oxidative tumor cells 
predominantly express MCT1 whereas glycolytic cells rely on the expression of MCT4 to 
enforce export [52, 92].  
Due to the metabolic dependency of tumor survival and progression, MCTs are recognized as 
potential therapeutic targets. In that respect, several studies determined the feasibility of 
inhibiting MCT function as treatment approach. They elucidated a vulnerability of cancer cells 
to intracellular acidification and suppressed energetics in glycolytic cells on one hand, and 
decreased lactate-fueled respiration in oxygenic tumor cells on the other hand overall reducing 
tumor growth [92, 96]. Thereof, several more or less specific inhibitors have been found and 
tested some of which already entered clinical testing. Generally, most inhibitors are non-
specific and target several MCT members or other transporters. These include the competitive, 
aromatic monocarboxylate α-cyano-4-hydroxycinnamate (CHC), stilbene disulphonates (i.e. 
4,4’-diisothiocyano-2,2’-stilbenedisulphonic acid (DIDS)), and bioflavonoids (i.e. phloretin, 
quercetin) (reviewed in [48, 97]). Further unspecific inhibitors were suggested to target the 
associated basigin and mediate an indirect inhibition of MCTs. Among those are acriflavine 
(Figure 1.4A) and, most knowingly, p-chloromercuribenzene sulfonate (pCMBS) (Figure 1.4B)  
[70, 98]. Both have been proposed as basigin modifiers to avoid the basigin-MCT interaction. 
Although proven effective in tumor therapy [96], targeting basigin as an abundant protein that 
is linked to numerous signaling pathways might cause adverse side effects. Most recently, 
AstraZeneca developed two compounds, namely AR-C155858 and AZD3965 (Figure 1.4C, D), 
that selectively inhibit MCT1 and, to a lesser extent, MCT2 [99]. Both substances are closely 
related and exhibit a high affinity for MCT1 (𝐾𝑖 of 1.6 nM (AZD3965) and 2.3 nM 
(AR-C155858)) with only slight differences in the pharmacokinetic properties [100, 101]. 




and has been suggested to bind from the cytosolic side of the transporter involving residues 
already elucidated as crucial for transport [102]. Although similarly potent, AZD3965 exhibits 
more favorable pharmacokinetics including the oral bioavailability [100]. It is currently tested in 
a phase I clinical trial to treat advanced solid tumors and lymphomas (www.ClinicalTrials.gov, 




Figure 1.4. Chemical structures of the basigin/MCT inhibitors acriflavine (A), p-chloromercuribenzene 
sulfonate (pCMBS) (B), AZD3965 (C) and AR-C155858 (D). 
 
 
In the stage of finalizing this thesis, MCT1 structures in complex with basigin and in the inward 
and outward open conformation have been resolved using cryo electron microscopy [103]. 
These located AZD3965 in the substrate binding pocket proposing an inhibitory mechanism in 
which AZD3965 locks the transporter in the outward open conformation. In line with the 
previous literature, the substrate binding site was confirmed to consist of residues Tyr34, 
Lys38, Asp309, Arg313, Phe367 and Ser371. The authors further examined the basigin-MCT1 
interaction and identified Asn187 of MCT’s TM6 as the long-sought residue that forms a 
hydrogen bond with Glu218 of basigin and confers complexation. They reported lead evidence 
on the spatial organization of MCT1 and basigin although data on a functional relevance of 






1.4. The aim: basigin-MCT1 fusion and functional characterization in yeast  
The expression of human MCT1 is tightly linked to its association with basigin. In commonly 
used mammalian and Xenopus oocyte expression systems, MCT1 depends on basigin for 
translocation to the plasma membrane as the site of action. Therefore, studies on the MCT1 
functionality regardless of basigin effects are hardly possible. 
This thesis aims at determining unbiased functional and inhibitory characteristics of MCT1-
mediated L-lactate transport and at revealing a long hypothesized direct modulation by basigin. 
For this purpose, MCT1 is expressed alone and in molecular fusion with basigin in the 
eukaryotic yeast Saccharomyces cerevisiae. The protein fusion profits from a constant close 
association of both proteins in a stoichiometric manner. The yeast-based expression system 
employs several advantages in functional studies on MCTs. First, earlier studies with 
S. cerevisiae confirmed the unique property to translocate MCTs to the plasma membrane in 
the absence of basigin [88, 104]. Second, a jen1 ady2 knockout strain is devoid of any L-lactate 
transport activity [105, 106] and does not express endogenous basigin homologs [107]. In 
glucose-rich conditions, the yeast’s end product of glucose breakdown is CO2 (respiration) or 
ethanol (fermentation) [108]. L-Lactate formation and metabolism is virtually absent. These 
properties lay the foundation to examine the transport characteristics of unbiased MCT1 devoid 
of metabolic interference. Using a 14C-based transport assay, the L-lactate influx via MCT1 will 
be monitored in a zero-trans set-up as well as in the equilibrium state while changing external 
modalities including pH, substrate availability and inhibitor treatment. Primarily, the molecular 
fusion to truncated basigin constructs seeks to examine respective basigin-mediated effects 
at the domain level. The functional expression of fusion proteins will finally be used for large 
scale protein synthesis to promote a structural understanding of the basigin-MCT1 complex 









The following listing summarizes materials used in this project. The list is grouped into coding 
sequences, plasmids and oligonucleotides, cell strains, antibodies, chemicals and enzymes, 
and kits. It further describes the preparation of used buffers and solutions, and lists lab 
equipment and software. Individual compositions and corresponding producers are specified.  
 
2.1. Coding sequences, plasmids, and oligonucleotides 
2.1.1. Coding sequences 
The coding sequences for human MCT1, basigin splice variant 1 and embigin splice variant 1 
were purchased as ORF clones in pcDNA3.1+/C-(K)DYK (GenScript, Leiden, Netherlands) 
and the respective open reading frames (ORF) are listed below. Stop codons (italic) were 
removed by the supplier. Restriction sites PflMI/BspEI in the ORF of human MCT1 used for 
initial subcloning into pDRTXaLK vector (see section 2.1.2) are highlighted (bold). Customized 
coding sequences for basigin mutant constructs BSG Ig-I Glu→Gln and BSG Ig-I 
Lys,Arg→Ala + R166A including additional, flanking restriction sites were purchased as DNA 
constructs in vector pUC57. Restriction sites used for subcloning (bold) and respective base 
exchanges (small letters) are highlighted. 
 
MCT1, ORF (GenBank NM_001166496): 
 
1 ATGCCACCAG CAGTTGGAGG TCCAGTTGGA TACACCCCCC CAGATGGAGG CTGGGGCTGG 
61 GCAGTGGTAA TTGGAGCTTT CATTTCCATC GGCTTCTCTT ATGCATTTCC CAAATCAATT  
121 ACTGTCTTCT TCAAAGAGAT TGAAGGTATA TTCCATGCCA CCACCAGCGA AGTGTCATGG 
181 ATATCCTCCA TAATGTTGGC TGTCATGTAT GGTGGAGGTC CTATCAGCAG TATCCTGGTG 
241 AATAAATATG GAAGTCGTAT AGTCATGATT GTTGGTGGCT GCTTGTCAGG CTGTGGCTTG 
301 ATTGCAGCTT CTTTCTGTAA CACCGTACAG CAACTATACG TCTGTATTGG AGTCATTGGA 
361 GGTCTTGGGC TTGCCTTCAA CTTGAATCCA GCTCTGACCA TGATTGGCAA GTATTTCTAC 
421 AAGAGGCGAC CATTGGCCAA CGGACTGGCC ATGGCAGGCA GCCCTGTGTT CCTCTGTACT  
481 CTGGCCCCCC TCAATCAGGT TTTCTTCGGT ATCTTTGGAT GGAGAGGAAG CTTTCTAATT 
541 CTTGGGGGCT TGCTACTAAA CTGCTGTGTT GCTGGAGCCC TCATGCGACC AATCGGGCCC 
601 AAGCCAACCA AGGCAGGGAA AGATAAGTCT AAAGCATCCC TTGAGAAAGC TGGAAAATCT 
661 GGTGTGAAAA AAGATCTGCA TGATGCAAAT ACAGATCTTA TTGGAAGACA CCCTAAACAA 
721 GAGAAACGAT CAGTCTTCCA AACAATTAAT CAGTTCCTGG ACTTAACCCT ATTCACCCAC  
781 AGAGGCTTTT TGCTATACCT CTCTGGAAAT GTGATCATGT TTTTTGGACT CTTTGCACCT  
841 TTGGTGTTTC TTAGTAGTTA TGGGAAGAGT CAGCATTATT CTAGTGAGAA GTCTGCCTTC 
901 CTTCTTTCCA TTCTGGCTTT TGTTGACATG GTAGCCCGAC CATCTATGGG ACTTGTAGCC 
961 AACACAAAGC CAATAAGACC TCGAATTCAG TATTTCTTTG CGGCTTCCGT TGTTGCAAAT 
1021 GGAGTGTGTC ATATGCTAGC ACCTTTATCC ACTACCTATG TTGGATTCTG TGTCTATGCG  
1081 GGATTCTTTG GATTTGCCTT CGGGTGGCTC AGCTCCGTAT TGTTTGAAAC ATTGATGGAC  
1141 CTTGTTGGAC CCCAGAGGTT CTCCAGCGCT GTGGGATTGG TGACCATTGT GGAATGCTGT 
1201 CCTGTCCTCC TGGGGCCACC ACTTTTAGGT CGGCTCAATG ACATGTATGG AGACTACAAA 
1261 TACACATACT GGGCATGTGG CGTCGTCCTA ATTATTTCAG GTATCTATCT CTTCATTGGC  
1321 ATGGGCATCA ATTATCGACT TTTGGCAAAA GAACAGAAAG CAAACGAGCA GAAAAAGGAA  
1381 AGTAAAGAGG AAGAGACCAG TATAGATGTT GCTGGGAAGC CAAATGAAGT TACCAAAGCA  







Basigin splice variant 1, ORF (GenBank NM_001728): 
 
1 ATGGCGGCTG CGCTGTTCGT GCTGCTGGGA TTCGCGCTGC TGGGCACCCA CGGAGCCTCC  
61 GGGGCTGCCG GCTTCGTCCA GGCGCCGCTG TCCCAGCAGA GGTGGGTGGG GGGCAGTGTG  
121 GAGCTGCACT GCGAGGCCGT GGGCAGCCCG GTGCCCGAGA TCCAGTGGTG GTTTGAAGGG  
181 CAGGGTCCCA ACGACACCTG CTCCCAGCTC TGGGACGGCG CCCGGCTGGA CCGCGTCCAC  
241 ATCCACGCCA CCTACCACCA GCACGCGGCC AGCACCATCT CCATCGACAC GCTCGTGGAG  
301 GAGGACACGG GCACTTACGA GTGCCGGGCC AGCAACGACC CGGATCGCAA CCACCTGACC  
361 CGGGCGCCCA GGGTCAAGTG GGTCCGCGCC CAGGCAGTCG TGCTAGTCCT GGAACCCGGC  
421 ACAGTCTTCA CTACCGTAGA AGACCTTGGC TCCAAGATAC TCCTCACCTG CTCCTTGAAT  
481 GACAGCGCCA CAGAGGTCAC AGGGCACCGC TGGCTGAAGG GGGGCGTGGT GCTGAAGGAG  
541 GACGCGCTGC CCGGCCAGAA AACGGAGTTC AAGGTGGACT CCGACGACCA GTGGGGAGAG  
601 TACTCCTGCG TCTTCCTCCC CGAGCCCATG GGCACGGCCA ACATCCAGCT CCACGGGCCT  
661 CCCAGAGTGA AGGCTGTGAA GTCGTCAGAA CACATCAACG AGGGGGAGAC GGCCATGCTG  
721 GTCTGCAAGT CAGAGTCCGT GCCACCTGTC ACTGACTGGG CCTGGTACAA GATCACTGAC  
781 TCTGAGGACA AGGCCCTCAT GAACGGCTCC GAGAGCAGGT TCTTCGTGAG TTCCTCGCAG  
841 GGCCGGTCAG AGCTACACAT TGAGAACCTG AACATGGAGG CCGACCCCGG CCAGTACCGG  
901 TGCAACGGCA CCAGCTCCAA GGGCTCCGAC CAGGCCATCA TCACGCTCCG CGTGCGCAGC  
961 CACCTGGCCG CCCTCTGGCC CTTCCTGGGC ATCGTGGCTG AGGTGCTGGT GCTGGTCACC  
1021 ATCATCTTCA TCTACGAGAA GCGCCGGAAG CCCGAGGACG TCCTGGATGA TGACGACGCC  
1081 GGCTCTGCAC CCCTGAAGAG CAGCGGGCAG CACCAGAATG ACAAAGGCAA GAACGTCCGC  
1141 CAGAGGAACT CTTCCTGA 
 
Embigin splice variant 1, ORF (GenBank NM_198449): 
 
1 ATGCGCGCCC TCCCCGGCCT GCTGGAGGCC AGGGCGCGTA CGCCCCGGCT GCTCCTCCTC  
61 CAGTGCCTTC TCGCTGCCGC GCGCCCAAGC TCGGCGGACG GCAGTGCCCC AGATTCGCCT  
121 TTTACAAGTC CACCTCTCAG AGAAGAAATA ATGGCAAATA ACTTTTCCTT GGAGAGTCAT  
181 AACATATCAC TGACTGAACA TTCTAGTATG CCAGTAGAAA AAAATATCAC TTTAGAAAGG  
241 CCTTCTAATG TAAATCTCAC ATGCCAGTTC ACAACATCTG GGGATTTGAA TGCAGTAAAT  
301 GTGACTTGGA AAAAAGATGG TGAACAACTT GAGAATAATT ATCTTGTCAG TGCAACAGGA  
361 AGCACCTTGT ATACCCAATA CAGGTTCACC ATCATTAATA GCAAACAAAT GGGAAGTTAT  
421 TCTTGTTTCT TTCGAGAGGA AAAGGAACAA AGGGGAACAT TTAATTTCAA AGTCCCTGAA  
481 CTTCATGGGA AAAACAAGCC ATTGATCTCT TACGTAGGGG ATTCTACTGT CTTGACATGT  
541 AAATGTCAAA ATTGTTTTCC TTTAAATTGG ACCTGGTACA GTAGTAATGG GAGTGTAAAG  
601 GTTCCTGTTG GTGTTCAAAT GAATAAATAT GTGATCAATG GAACATATGC TAACGAAACA  
661 AAGCTGAAGA TAACACAACT TTTGGAGGAA GATGGGGAAT CTTACTGGTG CCGTGCACTA  
721 TTCCAATTAG GCGAGAGTGA AGAACACATT GAGCTTGTGG TGCTGAGCTA TTTGGTGCCC  
781 CTCAAACCAT TTCTTGTAAT AGTGGCTGAG GTGATTCTTT TAGTGGCCAC CATTCTGCTT  
841 TGTGAAAAGT ACACACAAAA GAAAAAGAAG CACTCAGATG AGGGGAAAGA ATTTGAGCAG  
901 ATTGAACAGC TGAAATCAGA TGATAGCAAT GGTATAGAAA ATAATGTCCC CAGGCATAGA  
961 AAAAATGAGT CTCTGGGCCA GTGA 
 
BSG Ig-I Glu→Gln (E114,118,120,168,172Q): 
 
1 ACTAGTATGC CCAGAGTGAA GGCTGTGAAG TCGTCAcAAC ACATCAACcA GGGGcAGACG 
61 GCCATGCTGG TCTGCAAGTC AGAGTCCGTG CCACCTGTCA CTGACTGGGC CTGGTACAAG 
121 ATCACTGACT CTGAGGACAA GGCCCTCATG AACGGCTCCG AGAGCAGGTT CTTCGTGAGT 
181 TCCTCGCAGG GCCGGTCAcA GCTACACATT cAGAACCTGA ACATGGAGGC CGACCCCGGC 
241 CAGTACCGGT GCAACGGCAC CAGCTCCAAG GGCTCCGACC AGGCCATCAT CACGCTCCGC 
301 GTGCGCAGCC ACCTGGCCGC CCTCTGGCCC TTCCTGGGCA TCGTGGCTGA GGTGCTGGTG 
361 CTGGTCACCA TCATCTTCAT CTACGAGAAG CGCCGGAAGC CCGAGGACGT CCTGGATGAT 
421 GACGACGCCG GCTCTGCACC CCTGAAGAGC AGCGGGCAGC ACCAGAATGA CAAAGGCAAG 
481 AACGTCCGCC AGAGGAACTC TTCCGGATCC CTGCAG 
 
BSG Ig-I Lys,Arg→Ala + R166A (K108,111,127A / R166,201,203A): 
 
1 ACTAGTATGC CCAGAGTGgc GGCTGTGgcG TCGTCAGAAC ACATCAACGA GGGGGAGACG 
61 GCCATGCTGG TCTGCgcGTC AGAGTCCGTG CCACCTGTCA CTGACTGGGC CTGGTACAAG 
121 ATCACTGACT CTGAGGACAA GGCCCTCATG AACGGCTCCG AGAGCAGGTT CTTCGTGAGT 
181 TCCTCGCAGG GCgcGTCAGA GCTACACATT GAGAACCTGA ACATGGAGGC CGACCCCGGC 
241 CAGTACCGGT GCAACGGCAC CAGCTCCAAG GGCTCCGACC AGGCCATCAT CACGCTCgcC 
301 GTGgcCAGCC ACCTGGCCGC CCTCTGGCCC TTCCTGGGCA TCGTGGCTGA GGTGCTGGTG 
361 CTGGTCACCA TCATCTTCAT CTACGAGAAG CGCCGGAAGC CCGAGGACGT CCTGGATGAT 
421 GACGACGCCG GCTCTGCACC CCTGAAGAGC AGCGGGCAGC ACCAGAATGA CAAAGGCAAG 




Sequences for fusion constructs as well as additional basigin and embigin variants were 
produced by molecular cloning techniques using the above-mentioned sequences as template 
and are described in section 3.1.1. 
The expression construct for the plasmodial formate-nitrite transporter (PfFNT) in the yeast 
expression vector pDRTXa has been described earlier [109] and was kindly provided by Marie 
Wiechert.  
 
2.1.2. Expression plasmids 
For the recombinant expression in S. cerevisiae, coding sequences were cloned into the 
expression vectors pDRTXa, pDRTXaLK and pUG35 (U. Güldener and J. H. Hegemann, 
University of Düsseldorf, Germany) (Figure 2.1A, B). The plasmid pDRTXaLK resulted from 
two-step modification of commercial plasmid vector pDR196 [110] (Addgene #36029). First, 
the previously described introduction of an N-terminal HA-tag and a C-terminal His-tag gave 
rise to plasmid pDRTXa [109]. Further modification in this study introduced additional 
restriction sites via a linker sequence (pDRTXaLK, see section 3.1.1 for protocol). The multiple 
cloning sites (MCS) of pDRTXa and pDRTXaLK including respective restriction sites are 
displayed in Figure 2.1A. For the expression in P. pastoris, constructs were subcloned into a 
modified pPink-HC vector of the PichiaPink™ Expression System (Invitrogen). The 
modification has previously been described (see dissertation of J. Holm-Bertelsen [111]) and 
included the insertion of a C-terminal His-tag and additional restriction sites. pPink-HC carrying 
optPfFNT was kindly provided by L. Petersen and was used as a template for further cloning 
purposes (Figure 2.1C). Cell-free expression was induced from the vectors pIVEX2.3w or 
pIVEX2.3w-GFPΔM1 (Figure 2.1D, E) which are modified versions of the commercially 
available vector pIVEX2.3 (Roche). Modifications have been introduced previously and are 
described elsewhere (see dissertation A. Müller-Lucks [112, 113]). The sequences of the MCS 





Figure 2.1. Vector maps. Shown are maps for the yeast expression vectors pDRTXa/pDRTXaLK 
including magnified excerpts of corresponding multiple cloning sites (MCS) (A), pUG35 (B) and 
pPink-HC carrying PfFNT as insert (C). The MCS of pDRTXaLK contains N- and C-terminal sequences 
complementing PflMI/BspEI-inserted MCT1 (orange). (D, E) Maps for cell-free expression plasmid 
pIVEX2.3w with and without the coding sequence for green fluorescent protein (GFP). The endogenous 
start-methionine of GFP was deleted (see dissertation S. Bock [114]). In all maps, promoter/terminator 
sequences, selection genes (AMPr, ampicillin resistance; URA3, Orotidine-5'-phosphate decarboxylase; 
ADE2, phosphoribosylaminoimidazole carboxylase), potential tags (HA, hemagglutinin) and relevant 





Oligonucleotides for molecular cloning, site-directed mutagenesis and sequencing purposes 
are summarized in Table 2.1, Table 2.2 and Table 2.3, respectively. All oligonucleotides were 
purchased from Thermo Fisher Scientific (Schwerte, Germany) and dissolved in ddH2O to a 
final concentration of 100 µM. 
For constructing full-length and truncated basigin and embigin constructs, oligonucleotides 
were designed to introduce a start-methionine and suitable restriction sites for cloning 
purposes (Table 2.1). Relevant restriction sites (bold) and codons for start-methionines (italic) 
are highlighted. Bases complementary to BSG or MCT1 template DNA are written in capitals. 
Oligonucleotide descriptions include the construct identifier used in this work and specify 
deleted DNA segments for each construct (in brackets; numbering refers to full-length 
sequence of BSG var1 or EMB var1). 
 








Description Oligonucleotide sequence (5’→3’) 
  
MCT1 linker, s  ctagtctgcagATGCCACCAGCAGTTGGTCCGGACCAGAAA 
GACACAGATGGAGGGCCCAAGGAGGAGGAAAGTCCAGTCC 
MCT1 linker, as tcgaGGACTGGACTTTCCTCCTCCTTGGGCCCTCCATCTGT 
GTCTTTCTGGTCCGGACCAACTGCTGGTGGCATctgcaga 
BSGΔIg (Δ1-308), s ttactagtatgTCCGACCAGGCCATCATCACGC 
BSG Ig-I(Δ1-220), s ttactagtatgCCCAGAGTGAAGGCTGTGAAGT 
BSG Ig-I/C2 (Δ1-139), s ttactagtatggctgccGGCACAGTCTTCACTACCGTAG 
BSG var2 (Δ24-139), s ttactagtatggcggctgcgctgttcgtgctgctgggattc 
gcgctgctgggcacccacggagcctccggggctgccgGCAC 
AGTCTTCACTACCGTAG 
BSG var1, s  ttactagtatgGCGGCTGCGCTGTTCGTGC 
BSG, as ttctgcagggatccGGAAGAGTTCCTCTGGCGGACG 
EMBΔIg (Δ1-239), s ggactagtatgCTATTCCAATTAGGCGAGAGTG 
EMB, s ttactagtatgCGCGCCCTCCCCGG 





Oligonucleotides for site-directed in vitro mutagenesis of basigin and MCT1 are listed in 
Table 2.2. Base exchanges for the introduction of point mutations are written in lower case 
letters. 
 














Description Oligonucleotide sequence (5’→3’) 
  
BSG Ig-I K108,111A, s GCCCAGAGTGgcGGCTGTGgcGTCGTCAGAAC 
BSG Ig-I K108,111A, as CACTCTGGGCATACTAGTGTCCGCGTAGTCAGG 
BSG Ig-I R201,203A, s CATCACGCTCgcCGTGgcCAGCCACCTGG 
BSG Ig-I R201,203A, as GAGCGTGATGATGGCCTGGTCGGAGCCCTTGG 
BSG Ig-I A166R, s CCTCGCAGGGCcgGTCAGAGCTACACATTG 
BSG Ig-I A166R, as GCCCTGCGAGGAACTCACGAAGAACCTGC 
BSG E(27)R, s CTGGGCATCGTGGCTagaGTGCTGGTGCTG 
BSG E(27)R, as AGCCACGATGCCCAGGAAGGGCCAGAGG 
BSG Ig-I C23S, s ACGGCCATGCTGGTCTcCAAGTCAGAGTCCGTG 
BSG Ig-I C23S, as  GACCAGCATGGCCGTCTCCCCCTCGTTGAT 
BSG Ig-I C82S, s GGCCAGTACCGGTcCAACGGCACCAGCTCCAA 
BSG Ig-I C82S, as CCGGTACTGGCCGGGGTCGGCCTCCATGTT 
MCT1 C159S, s AGCCCTGTGTTCCTCTcTACTCTGGCCCCCCTC 
MCT1 C159S, as GAGGAACACAGGGCTGCCTGCCATGGCCAG 
MCT1 C399S, s GTGACCATTGTGGAAagcTGTCCTGTCCTCCTG 
MCT1 C399,400S, s GTGACCATTGTGGAAagctctCCTGTCCTCCTG 
MCT1 C400S, s GTGACCATTGTGGAATGCtctCCTGTCCTCCTG 





Oligonucleotides for sequencing purposes are listed in Table 2.3. Oligonucleotides include 
vector- and insert-specific complementary sequences to cover full-length coding regions and 
ensure gapless sequence verifications. Complementary sequences are written in capital 
letters.  
 
Table 2.3. Oligonucleotides for DNA sequencing. 
 
  







BSG_139, s ttactagtatgCCCGGCACAGTCTTCACTACCG 
BSG_208, s GAGCCCATGGGCACGGCCAACAT 
BSG_190, as GAACTCCGTTTTCTGGCCGGG 
EMB_64, s CTGACTGAACATTCTAGTATGCC 
EMB_158, s atactagtatgGTCCCTGAACTTCATGGG 
MCT1 F367D, s TTCTTTGGATTTGCCgaCGGGTGGCTCAGCTC 
MCT1 F367D, as GGCAAATCCAAAGAATCCCGCATAGACACA 





2.2. Organisms and strains  
This work includes work with bacteria and yeasts. The following list specifies the individual 
strains and their respective genotypes (Table 2.4). 
 
Table 2.4. Organisms, strains and relevant genotype. 
 
2.3. Antibodies  
The following table lists primary and secondary antibodies used in this project (Table 2.5).  
 
Table 2.5. Antibodies for Western blot and flow cytometry. 
Organism (Strain) Genotype Source 
   
Escherichia coli  
(DH5α) 
F- φ80lacZΔM15 Δ(lacZYA-argF)U169 
recA1 endA1 hsdR17(rK-, mK-) phoA 






MATa, can1-100, ade2-1oc, his3-11-15, 
leu2-3,-112, trp1-1-1, ura3-1, 
jen1::kanMX4, ady2::hphMX4  
(Δjen1 Δady2) 
M. Casal  
(Braga, Portugal) [115] 
 
   
Pichia pastoris 
(PichiaPink™ Strain 1) 
Δade2 Invitrogen (Carlsbad, USA) 
   
Antibody Host Producer Cat. Nr. Purpose 
     
Penta-His antibody, BSA 
free (0.2 mg/ml) 
Mouse Qiagen  34660 Western blot 
Anti-GFP (FL) antibody  
(0.2 mg/ml) 
Rabbit Santa Cruz 
Biotechnology 
sc-8334 Western blot 
Peroxidase AffiniPure 
Goat anti-Mouse IgG, 
HRP conjugate 
(0.4 mg/ml) 
Goat Jackson Immuno 
Research 
115-035-174 Western blot 
Peroxidase AffiniPure 
Goat anti-Rabbit IgG,  
HRP conjugate 
(0.4 mg/ml) 
Goat Jackson Immuno 
Research 
111-035-003 Western blot 
MCT1 antibody 
(0.5 mg/ml) 
Rabbit Biorbyt orb312305 Flow cytometry 
Goat anti-Rabbit IgG, 
APC conjugate  
(0.5 mg/ml) 
Goat Southern Biotech 4050-11S Flow cytometry 




2.4. Chemicals and enzymes  
Chemicals and enzymes are listed below (Table 2.6). Corresponding manufacturers are 
indicated. For cell-free protein synthesis, S30 cell extracts and the T7 RNA polymerase were 
produced in-house. Respective protocols were adapted from Schwarz et al. [116] and were 
described in detail by A. Müller-Lucks [112]. S30 extracts were produced under the technical 
guidance of L. Petersen and B. Höger and the T7 polymerase was kindly provided by 
F. Helmstetter. MSP1E3D1-DOPG/POPG-nanodiscs were produced by C. Hansen according 
to protocols adapted from Rues et al. [117]. 
 
Table 2.6. Chemicals and enzymes, and respective suppliers.  
Substance Producer 
  
Acetic acid J.T. Baker, München 
Acetyl phosphate (Li+/K+ salt) Sigma Aldrich, München 
Acriflavine Sigma Aldrich, München 
Adenine hemisulfate salt Sigma Aldrich, München 
Adenosine-5'-triphosphate disodium salt (ATP, hydrate) Sigma Aldrich, München 
Agar bacteriological Oxoid, Basingstoke, USA 
Agarose LE Genaxxon BioScience, Ulm 
L-Alanine Fluka Chemie, Buchs, Switzerland 
Ammonium persulfate Carl Roth, Karlsruhe 
Ampicillin (Na+ salt) Genaxxon BioScience, Ulm 
L-Arginine monohydrochloride Sigma Aldrich, München 
L-Asparagine (monohydrate) Sigma Aldrich, München 
L-Aspartic acid (Na+ salt, monohydrate) Sigma Aldrich, München 
AZD3965 (MCT1 inhibitor) Hycultec, Beutelsbach, Germany 
Bacto™ Peptone BD Biosciences, San Jose, USA 
Bacto™ Yeast Extract BD Biosciences, San Jose, USA 
Benzyl methanethiosulfonate (BMTS) Interchim, Montluçon, France 
Bovine albumin fraction V (pH 7.0) Genaxxon BioScience, Ulm 
Brij®35 AppliChem, Darmstadt 
Brij®58 AppliChem, Darmstadt 
Brij®78  Sigma Aldrich, München 
Brij®98 Sigma Aldrich, München 
Bromophenol Blue (Na+ salt) Carl Roth, Karlsruhe 




p-Chloromercuribenzene sulfonate (Na+ salt, pCMBS) Toronto Research Chemicals Inc., 
North York, Canada 
Clarity™ ECL Western blotting substrate Bio-Rad, München 
Cloned Pfu reaction buffer (10X) Agilent Technologies, Waldbronn 
cOmplete™ protease inhibitor cocktail (EDTA-free) Roche Diagnostics, Mannheim 
L-Cysteine Sigma Aldrich, München 
Cytidin-5’-triphosphate disodium salt (CTP) Sigma Aldrich, München 
Deoxyribonucleic acid (Na+ salt, single-stranded, from 
salmon testes) 
Sigma Aldrich, München 
2’-Deoxyadenosine-5'-triphosphate (dATP, 100 mM) Thermo Fisher Scientific, Schwerte 
2’-Deoxycytidine-5'-triphosphate (dCTP, 100 mM) Thermo Fisher Scientific, Schwerte 
2’-Deoxyguanosine-5'-triphosphate (dGTP, 100 mM) Thermo Fisher Scientific, Schwerte 
2’-Deoxythymidine-5'-triphosphate (dTTP, 100 mM) Thermo Fisher Scientific, Schwerte 
Difco™ Yeast Nitrogen Base w/o amino acids and 
ammonium sulfate 
BD Biosciences, San Jose, USA 
Dimethyl sulphoxide (DMSO, ≥ 99.8 %) Sigma Aldrich, München 
Dipotassium hydrogen phosphate (K2HPO4) Carl Roth, Karlsruhe 
Disodium hydrogen phosphate (Na2HPO4, dihydrate) Carl Roth, Karlsruhe 
Dithiothreitol (DTT) Carl Roth, Karlsruhe 
n-Dodecyl-β-D-maltopyranoside (DDM) Anatrace, Maumee, USA 
E. coli S30 extract Beitz lab, CAU Kiel 
Ethanol (≥ 99.8 %) Carl Roth, Karlsruhe 
Ethidium bromide (EtBr) MP Biomedicals, Illkirch, France 
Ethylenediaminetetraacetic acid (EDTA, ≥ 99 %) Carl Roth, Karlsruhe 
Ethylenediaminetetraacetic acid disodium salt (Na2-EDTA, 
dihydrate, ≥ 99 %) 
Carl Roth, Karlsruhe 
Ethylenediaminetetraacetic acid disodium salt solution (Na2-
EDTA, 0.5 M)  
Sigma Aldrich, München 
FastAP Thermosensitive Alkaline Phosphatase (1 U µl−1) Thermo Fisher Scientific, Schwerte 
2-[(5-Fluoresceinyl)aminocarbonyl]ethyl 
methanethiosulfonate (MTS-4-Fluorescein) 
Interchim, Montluçon, France 
Folinic acid (Ca2+ salt) Sigma Aldrich, München 
G153 developer and fixation solution  Agfa-Gevaert, Mortsel, Belgium 
D(+)-Glucose (monohydrate)  Carl Roth, Karlsruhe 
L-Glutamic acid (K+ salt, monohydrate) Fluka Chemie, Buchs, Switzerland 
L-Glutamine Sigma Aldrich, München 
Glycerol (≥ 98 %, anhydrous) Carl Roth, Karlsruhe 
Glycine  Carl Roth, Karlsruhe 
Guanosine 5′-triphosphate sodium salt (hydrate, GTP) Sigma Aldrich, München 




Hydrochloric acid J. T. Baker, München 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES, ≥ 99.5 %) 
Carl Roth, Karlsruhe 
Imidazole Sigma Aldrich, München 
L-Isoleucine Sigma Aldrich, München 
Isopropyl alcohol (≥ 99.8 %) Carl Roth, Karlsruhe 
L(+)-Lactate (Na+ salt) AppliChem, Darmstadt 
L-[1-14C]-Lactic acid (sodium salt, 0.1 mCi ml−1, 
55 mCi mmol−1) 
Hartmann Analytic, Braunschweig 
Lambda DNA  Thermo Fisher Scientific, Schwerte 
LB agar (Lennox) Carl Roth, Karlsruhe 
LB medium (Lennox) Carl Roth, Karlsruhe 
L-Leucine Carl Roth, Karlsruhe 
Lithium acetate (> 99 %) Carl Roth, Karlsruhe 
L-Lysine monohydrochloride Sigma Aldrich, München 
Magnesium acetate (tetrahydrate) Sigma Aldrich, München 
Methanol (HPLC grade) J. T. Baker, München 
L-Methionine Sigma Aldrich, München 
Methyl methanethiosulfonate (MMTS) Sigma Aldrich, München 
Milk powder (blotting grade) Carl Roth, Karlsruhe 
2-(N-morpholino)ethanesulfonic acid (MES) Carl Roth, Karlsruhe 
MSP1E3D1-DOPG/POPG-nanodiscs C. Hansen, Beitz lab, CAU Kiel 
Ni2+-NTA agarose Qiagen, Hilden  
OneTaq® DNA polymerase (5 U µl−1) New England Biolabs, Frankfurt a. M. 
OneTaq® Standard Reaction Buffer (5X) New England Biolabs, Frankfurt a. M. 
Orange G Carl Roth, Karlsruhe 
PeqGOLD Protein Marker III (prestained) Peqlab, Erlangen 
PfuTurbo DNA polymerase (2.5 U µl−1) Agilent Technologies, Waldbronn 
L-Phenylalanine  Sigma Aldrich, München 
Phosphoenolpyruvate (K+ salt, PEP) AppliChem, Darmstadt 
Polyethylenglycol (PEG) 3350 Sigma Aldrich, München 
Polyethylenglycol (PEG) 8000 Sigma Aldrich, München 
Potassium acetate Carl Roth, Karlsruhe 
Potassium chloride Carl Roth, Karlsruhe 
Potassium dihydrogenphosphate (KH2PO4) Carl Roth, Karlsruhe 
Potassium hydroxide AppliChem, Darmstadt 




Propyl methanethiosulfonate (PMTS) Interchim, Montluçon, France 
Pyruvate kinase (10 mg ml−1) Roche Diagnostics, Mannheim 
Restriction Endonuclease Buffers  
(Orange, Green, Tango, 10X) 
Thermo Fisher Scientific, Schwerte 
Restriction Endonucleases (various, 10 U µl−1) Thermo Fisher Scientific, Schwerte 
RiboLock RNase inhibitor (40 U µl−1) Thermo Fisher Scientific, Schwerte 
Roti®-Quant concentrate (5X) Carl Roth, Karlsruhe 
Rotiphorese® Blue R concentrate Carl Roth, Karlsruhe 
Rotiphorese® Gel 40 (40 %, 29:1) Carl Roth, Karlsruhe 
Scintillation cocktail (Quicksafe A) Zinsser Analytic, Frankfurt 
L-Serine Fluka Chemie, Buchs, Switzerland 
Sodium acetate buffer solution (3 M, pH 5.2) Sigma Aldrich, München 
Sodium azide (NaN3) Carl Roth, Karlsruhe 
Sodium chloride (NaCl) Carl Roth, Karlsruhe 
Sodium dihydrogen phosphate (NaH2PO4, monohydrate) Carl Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS) AppliChem, Darmstadt 
Sodium hydroxide Carl Roth, Karlsruhe 
D-Sorbitol (≥ 98 %) Carl Roth, Karlsruhe 
2-Sulfonatoethyl methanethiosulfonate (MTSES) Biotrend Chemikalien GmbH, Köln 
T4 DNA ligase (5 U µl−1) Thermo Fisher Scientific, Schwerte 
T4 DNA ligase buffer Thermo Fisher Scientific, Schwerte 
T4 DNA polymerase (5 U µl−1) Thermo Fisher Scientific, Schwerte 
T7 RNA polymerase Beitz lab, CAU Kiel 
N,N,N′,N′-tetramethylethane-1,2-diamine (TEMED) Genaxxon bioscience, Ulm 
L-Threonine Sigma Aldrich, München 
Tris(hydroxymethyl)aminomethane Carl Roth, Karlsruhe 
Triton X-100 Carl Roth, Karlsruhe 
tRNA (E. coli, MRE 600) Roche Diagnostics, Mannheim 
L-Tryptophan Sigma Aldrich, München 
Tween® 20  AppliChem, Darmstadt 
L-Tyrosine Sigma Aldrich, München 
Uridine-5’-triphosphate trisodium salt (UTP, hydrate)  Sigma Aldrich, München 










2.5. Consumables and kits 
The following table lists consumables and commercially available kits used in this work 
(Table 2.7).  
 
Table 2.7. Consumables and kits, and respective suppliers. 
Consumable or kit Producer 
  
Amersham™ Hybond™ P 0.45 PVDF membrane GE Healthcare, Freiburg 
Amersham™ Hyperfilm ECL chemiluminescence films GE Healthcare, Freiburg 
Amicon Ultra-4 PLTK Ultracel-PL Membrane (30 kDa)  Merck, Darmstadt 
Centrifuge tubes (15 ml and 50 ml) Sarstedt, Nümbrecht 
Conical flasks for cell culture (various sizes) Schott AG, Mainz 
Cuvettes, polystyrol (10 x 4 x 45 mm) Sarstedt, Nümbrecht 
Cuvettes, precision cells of quartz, 10 mm  Hellma, Jena 
Dialysis tubing, Visking® (14 kDa MWCO)  Carl Roth, Karlsruhe 
Falcon™ polypropylene round-bottom tube (5 ml, flow 
cytometry) 
Corning Inc., Corning, USA 
FluoroDish™ World Precision Instruments, Friedberg 
Gene Pulser® Electroporation Cuvettes, 0.2 cm gap Bio-Rad, München 
GenomeLab™ DTCS Quick Start Kit Beckman Coulter, Krefeld 
Glass beads (acid-washed, Ø 425-600 µm) Sigma Aldrich, München 
HiYield® PCR Clean-up / Gel Extraction Kit Süd-Laborbedarf, Gauting 
Micro tubes (1.5 ml, 2 ml) Sarstedt, Nümbrecht 
NORM-JECT® syringes Eydam, Kiel 
NucleoBond® PC 500 Macherey-Nagel, Düren 
Parafilm “M” American National Can, Chicago, USA 
PCR strips (8-strip opt. clear flat caps)  Sarstedt, Nümbrecht 
PCR tubes Multiply®-Pro 0.2 ml, PP Sarstedt, Nümbrecht 
Pipette tips (various sizes) Sarstedt, Nümbrecht 
Poly-Prep® Chromatography Columns  Bio-Rad, München 
Polypropylene tubes (1.5 ml, ultracentrifuge) Beckman Coulter, Krefeld 
Quick Start™ Bradford Protein Assay Bio-Rad, München 
QuikChange Site-Directed Mutagenesis Kit Agilent, Santa Clara, USA 
Scintillation vials, Snaptwist® (6.5 ml, HDPE tube) VWR, Darmstadt 
Serological pipettes Sarstedt, Nümbrecht 




Sterile filter, Filtropur S 0.2  Sarstedt, Nümbrecht 
Sterile filter, Filtropur S 0.45  Sarstedt, Nümbrecht 
Whatman Grade GF/C Glass Micro-fiber filter (25 mm). GE Healthcare, Freiburg 
Whatman™ Grade 3MM CHR Blotting Paper GE Healthcare, Freiburg 








2.6. Preparation of buffers, solutions, and cell culture media 
The following sections list the specifications, compositions, and recipes for used buffers, stock 
solutions and cell culture media. Utilized chemicals and their suppliers are listed in chapter 2.4. 
 
2.6.1. Molecular biological methods 
 
TAE buffer (50X) TAE buffer (1X) 
Tris base 242 g (≙ 2 M) TAE (50X) 20 ml 
Na2-EDTA (0.5 M) 100 ml (≙ 0.05 M) ddH2O ad 1 l 
glacial acetic acid 57.1 ml (≙ 1 M) (final 40 mM Tris-acetate, 1 mM EDTA) 
ddH2O ad 1 l   
(final pH 8.5)    
    
Orange G loading buffer (10X) EtBr (10 mg ml−1) 
Orange G 
Glycerol (≥ 98 %) 
Na2-EDTA (0.5 M) 
0.04 g (≙ 0.4 %) 
3 ml (≙ 30 %) 
2 ml (≙ 100 mM) 
Ethidium bromide 
ddH2O 
(stored at 4 °C) 
5 tablets (à 0.1 µg) 
ad 50 ml  
 
ddH2O ad 10 ml   
(stored at 4 °C)    
    
Na2-EDTA (100 mM) dNTP mix (2.5 mM)  
Na2-EDTA (0.5 M) 10 ml dATP (100 mM) 0.25 ml 
ddH2O ad 50 ml dGTP (100 mM) 0.25 ml 
 dCTP (100 mM) 0.25 ml 
  dTTP (100 mM) 0.25 ml 
  ddH2O 9 ml 
Lambda DNA PstI digest   
Lambda DNA 200 µl   
Buffer Orange (10X) 108 µl   
PstI restriction enzyme 12 µl   
ddH2O 760 µl   
(incubated overnight, 37 °C)   
After digestion, 120 µl of Orange G loading buffer 











2.6.2. Cell culture, transformation, and storage 
 
LB medium  LB agar plates  
LB medium (Lennox) 20 g LB agar (Lennox) 35 g 
ddH2O ad 1 l ddH2O ad 1 l 
(autoclaved)  (autoclaved)  
For LB Amp selection media, media were supplemented with 1 ml 1000X ampicillin (1 g ad 
10 ml ddH2O, filter sterilized) to a final concentration of 100 µg ml−1. 
 
YPD medium  YPD agar plates  
Bacto™ Peptone 20 g Bacto™ Peptone 20 g 
Bacto™ Yeast Extract 10 g  Bacto™ Yeast Extract 10 g  
D-Glucose 20 g D-Glucose 20 g 
ddH2O ad 1 l Agar bacteriological 20 g 
  ddH2O ad 1 l 
(autoclaved)  (autoclaved)  
    
SD medium (+ AHLW) SD agar plates (+ AHLW) 
Difco™ Yeast Nitrogen 
Base (w/o ammonium 
sulfate and amino acids) 
1.7 g Difco™ Yeast Nitrogen 
Base (w/o ammonium 
sulfate and amino acids) 
1.7 g 
Ammonium sulfate 5.0 g Ammonium sulfate 5.0 g 
D-Glucose 20 g D-Glucose 20 g 
(pH adjusted to 5.6 with NaOH) (pH adjusted to 5.6 with NaOH) 
ddH2O ad 1 l Agar bacteriological 20 g 
  ddH2O ad 1 l 
(autoclaved)  (autoclaved)  
For SD AHLW media and agar plates, 5 ml 200X adenine (≙ final 25 mg l−1), 1 ml 1000X L-histidine (≙ 
final 20 mg l−1), 5 ml 200X L-leucine (≙ final 100 mg l−1) and 2 ml 500X L-tryptophan (≙ final 10 mg l−1) 
were added after autoclaving. 
    
Adenine (200X) L-Histidine (1000X) 
Adenine hemisulfate salt 1 g (≙ 5 g l−1) L-Histidine monohydro- 
chloride (monohydrate) 
4 g (≙ 20 g l−1) 
ddH2O ad 200 ml ddH2O ad 200 ml 









L-Leucine (200X) L-Tryptophan (500X) 
L-Leucine 4 g (≙ 20 g l−1) L-Tryptophan 1 g (≙ 5 g l−1) 
ddH2O ad 200 ml ddH2O ad 200 ml 
(filter sterilized) (filter sterilized, stored at 4 °C) 
    
L-Lactate medium (1 %, pH 6.0) L-Lactate agar plates (2 %, pH 5.8 or 6.8) 
Difco™ Yeast Nitrogen 
Base (w/o ammonium 
sulfate and amino acids) 
1.7 g Difco™ Yeast Nitrogen 
Base (w/o ammonium 
sulfate and amino acids) 
1.7 g 
Ammonium sulfate 5 g Ammonium sulfate 5 g  
MES (1 M, pH 6.0) 50 ml (≙ 50 mM) MES 9.76 g (≙ 50 mM) 
  Agar bacteriological 20 g 
ddH2O ad 850 ml ddH2O ad 900 ml 
(autoclaved) (pH adjusted to 5.8 or 6.8 with NaOH, auto-
claved) 
 
After autoclaving, add 150 ml of L-lactate 
(66.7 g l−1, filter sterilized) and 5 ml 200X adenine 
(≙ final 25 mg l−1), 1 ml 1000X L-histidine (≙ final 
20 mg l−1), 5 ml 200X L-leucine (≙ final 100 mg l−1) 
and 2 ml 500X L-tryptophan (≙ final 10 mg l−1). 
After autoclaving, add 100 ml of L-lactate 
(200 g l−1, filter sterilized) and 5 ml 200X adenine 
(≙ final 25 mg l−1), 1 ml 1000X L-histidine (≙ final 
20 mg l−1), 5 ml 200X L-leucine (≙ final 
100 mg l−1) and 2 ml 500X L-tryptophan (≙ final 
10 mg l−1). 
    




ad 1 l 
Difco™ Yeast Nitrogen 
Base (w/o ammonium 
sulfate and amino acids) 
34 g 
(pH adjusted to 6.0)  Ammonium sulfate 100 g 
  ddH2O ad 1 l 
  (filter sterilized)  
    
BMGY medium  BMMY medium  
Peptone / yeast extract 700 ml Peptone / yeast extract 700 ml 
Phosphate buffer  
(1 M, pH 6.0) 
100 ml Phosphate buffer  
(1 M, pH 6.0) 
100 ml 
Glycerol (10X) 100 ml Methanol (10X) 100 ml 
YNB (10X) 100 ml YNB (10X) 100 ml 
    
Peptone / yeast extract Phosphate buffer (1 M, pH 6.0) 
Bacto™ Peptone 20 g K2HPO4 (1 M) 132 ml 
Bacto™ Yeast Extract 10 g KH2PO4 (1 M) 868 ml 
ddH2O ad 700 ml (pH adjusted to 6.0, autoclaved) 




Glycerol (10X, ≙ 10 %) Methanol (10X, ≙ 5 %) 
Glycerol (≥ 98 %) 100 ml Methanol 12.5 ml 
ddH2O ad 1 l ddH2O ad 250 ml 
(filter sterilized) (filter sterilized, stored at 4 °C) 
    
Single-stranded carrier DNA (2 mg ml−1) TE buffer 
DNA (single-stranded, from 
salmon testes) 
200 mg Tris base 121 mg (≙ 10 mM) 
TE buffer ad 100 ml EDTA 29.2 mg (≙ 1 mM) 
(stored at −20 °C)  ddH2O ad 100 ml 
  (pH adjusted to 8.0, autoclaved) 
    
PEG 3350 (50 % w/v) Glycerol (80 % w/v) 
Polyethylenglycol 3350 50 g Glycerol (≥ 98 %) 80 g 
ddH2O ad 100 ml ddH2O ad 100 ml 
(autoclaved)  (autoclaved)  
    
LiAc (1 M) Sorbitol (1 M) 
Lithium acetate  33 g D-Sorbitol 18.2 g 
ddH2O ad 500 ml ddH2O ad 100 ml 
(autoclaved, final pH 8.4−8.9) (autoclaved)  
    
YPD (+ 25 % glycerol) YPDS 
YPD medium 17.2 ml Bacto™ Peptone 20 g 
Glycerol (80 %) 7.8 ml Bacto™ Yeast Extract 10 g 
  D-Glucose 20 g 
  D-Sorbitol 182.2 g 
  ddH2O ad 1 l 
 
 
 (autoclaved)  
CaCl2 (0.1 M / 0.2 M) CaCl2 (+ 20 % glycerol) 
Calcium chloride  
(dihydrate) 
7.35 g  CaCl2 (0.2 M) 25 ml 
ddH2O ad 500 ml / 250 ml Glycerol (40 %) 25 ml 








2.6.3. Biophysical transport assay using 14C-labeled substrates 
 
HEPES/Tris assay buffer (50 mM, pH 6.8) MES/Tris assay buffer (50 mM, pH 5.8) 
Tris base 606 mg (≙ 50 mM) Tris base 606 mg (≙ 50 mM) 
HEPES 1192 mg (≙ 50 mM) MES 976 mg (≙ 50 mM) 
ddH2O ad 100 ml ddH2O ad 100 ml 
(pH adjusted to 6.8 ± 0.1, filter sterilized) (pH adjusted to 5.8 ± 0.1, filter sterilized) 
    
L-Lactate stock (0.25 M) L-Lactate stock (0.05 M) 
L-Lactate (Na+ salt) 0.2801 g L-Lactate (0.25 M) 0.2 ml 
ddH2O (sterile)  ad 10 ml Assay buffer  
(pH 5.8 or pH 6.8) 
0.8 ml 
(stored at 4 °C)  (stored at 4 °C)  
    
Substrate solution (5X),  
for uptake over time and inhibition 
Substrate solution (5X), 
for kinetic measurements 
L-Lactate stock (0.05 M) 2 µl (≙ 5 mM) L-Lactate stock  
(0.05 M or 0.25 M) 
2−12 µl 
(≙ 5−50 mM) 
L-[1-14C]-Lactic acid 
(Na+ salt, 0.1 mCi ml−1, 
55 mCi mmol−1) 
0.4 µl (≙ 0.04 µCi) L-[1-14C]-Lactic acid 
(Na+ salt, 0.1 mCi ml−1, 
55 mCi mmol−1) 
1 µl (≙ 0.1 µCi) 
Assay buffer  
(pH 5.8 or pH 6.8) 
ad 20 µl  Assay buffer  
(pH 5.8 or pH 6.8) 
ad 20 µl  
Preparations are exemplary for a single probe. Substrate solutions were always prepared as master 
mix for a total number of probes. In each assay, L-lactate is finally diluted 1:5 with cell suspension 
leading to a final L-lactate concentration of 1−10 mM. 
    
2 % Glucose (for washing) HEPES/Tris assay buffer  
(2 % glucose, 50 mM, pH 6.8) 
D-Glucose  
(monohydrate) 
10 g D-Glucose 
(monohydrate) 
0.5 g (≙ 110 mM) 
















2.6.4. Flow cytometry  
 
Phosphate Buffered Saline (PBS, 1X) FC buffer (1 % BSA) 
NaCl 8 g (≙ 137 mM) Bovine serum albumin 1 g 
KCl 0.2 g (≙ 2.7 mM) PBS (1X) ad 100 ml 
Na2HPO4 ∙ 2 H2O 1.78 g (≙ 10 mM) (stored at 4 °C)  
KH2PO4 0.27 g (≙ 2 mM)   
ddH2O ad 1 l   
(pH adjusted to 7.4, autoclaved)   
 
 
2.6.5. Cell lysis, SDS-PAGE, Coomassie staining, and Western blot 
 
Extraction Buffer  Solubilization Buffer (pH 8.0) 
Tris base 3 g (≙ 25 mM) Na2HPO4 (1 M) 93.2 ml 
Na2-EDTA (0.5 M) 10 ml (≙ 5 mM) NaH2PO4 (1 M) 6.8 ml 
ddH2O ad 1 l NaCl 2.9 g (≙ 50 mM) 
(pH adjusted to 7.5 with HCl, autoclaved) ddH2O ad 1 l 
  (pH adjusted to 8.0, final 100 mM sodium 
phosphate, autoclaved) 
    
Electrophoresis buffer (10X) Electrophoresis buffer (1X) 
Glycine 144 g (≙ 1.92 M) Electrophoresis buffer 
(10X) 
100 ml 
Tris base 30.3 g (≙ 0.25 M) ddH2O ad 1 l 
SDS 10 g (≙ 1 %) (final 0.192 M glycine, 25 mM Tris, 0.1 % SDS) 
ddH2O ad 1 l   
(pH at 8.2−8.6)    
    
SDS loading buffer (4X) APS (10 %) 
Tris base (1 M, pH 6.8) 2.5 ml (≙ 0.25 M) Ammonium persulfate 5 g 
Glycerol (≥ 98 %) 4 ml (≙ 40 %) ddH2O ad 50 ml 
Bromophenol Blue 2 mg (≙ 0.02 %) (stored at −20 °C)  
SDS 0.8 g (≙ 8 %)   
DTT 0.62 g (≙ 400 mM)   
ddH2O ad 10 ml   
(stored at −20 °C) 
 
 




Separation gel buffer (4X) Stacking gel buffer (4X) 
Tris base 18.2 g (≙ 1.5 M) Tris base 12.1 g (≙ 0.5 M) 
SDS 0.4 g (≙ 0.4 %) SDS 0.8 g (≙ 0.4 %) 
ddH2O ad 100 ml ddH2O ad 200 ml 
(pH adjusted to 8.8)  (pH adjusted to 6.8)  
    
Rotiphorese® Blue R solution Destaining solution 
Rotiphorese® Blue R 
concentrate 
600.0 ml Acetic acid 100 ml (≙ 10 % v/v) 
ddH2O 397.5 ml Ethanol (≥ 99.8 %) 300 ml (≙ 30 % v/v) 
  ddH2O ad 1 l 
    
Transfer buffer (5X)  Transfer buffer (1X)  
Tris base 7.6 g (≙ 0.125 M) Transfer buffer (5X) 10 ml 
Glycine 36.0 g (≙ 0.96 M) Methanol 10 ml 
SDS 0.934 g (≙ 0.19 %) ddH2O ad 50 ml 
ddH2O ad 500 ml (final 25 mM Tris, 192 mM glycine and 
0.038 % SDS) 
    
Tris-buffered saline (TBS, 10X) TBS-T (1X) 
NaCl 80 g (≙ 1.35 M) TBS (10X) 100 ml 
Tris base 24.3 g (≙ 0.2 M) ddH2O 900 ml 
ddH2O ad 1 l Tween® 20 1 ml 
(pH adjusted to 7.6)  (final 135 mM NaCl and 20 mM Tris) 
    
3 % Milk powder in TBS-T   
Milk powder 1.2 g   
TBS-T (1X) ad 40 ml   














2.6.6. Cell-free protein synthesis 
All stocks and solutions used for cell-free protein synthesis were kindly prepared and provided 
by B. Höger and C. Hansen. 
 
NaN3 (10 %) tRNA (E. coli, 40 mg ml−1) 
Sodium azide 100 mg tRNA (E. coli) 46 mg 
ddH2O (sterile) ad 1 ml ddH2O (sterile) ad 1.15 ml 
(filter sterilized, stored at −20 °C) (filter sterilized, stored at −20 °C) 
    
PEG 8000 (40 %)  AcP (1000 mM) 
PEG 8000 20 g Acetyl phosphate 
(Li+/K+ salt) 
368.2 mg 
ddH2O (sterile) ad 50 ml ddH2O (sterile) ad 2 ml 
  (pH adjusted to 7, stored at −20 °C) 
    
COmplete™ protease inhibitor (50X) Folinic acid (10 mg ml−1) 
COmplete™ protease 
inhibitor 
1 tablet Folinic acid 10 mg 
ddH2O (sterile) ad 1 ml ddH2O (sterile) ad 1 ml 
(stored at −20 °C) (stored at −20 °C)  
   
NTP mix (75 X) DTT (500 mM) 
ATP  409.7 mg 
(≙ 90 mM) 
Dithiothreitol 154 mg 
GTP 251.1 mg 
(≙ 60 mM) 
ddH2O (sterile) ad 2 ml 
CTP 253.0 mg 
(≙ 60 mM) 
(filter sterilized, stored at −20 °C) 
UTP 272.6 mg 
(≙ 60 mM) 
  
ddH2O (sterile) ad 8 ml   
(pH adjusted to 7, filter sterilized, stored at −20 °C)  
    
PEP (1000 mM)  KOAc (4000 mM)  
Phosphoenolpyruvate  
(K+ salt) 
412.2 mg Potassium acetate 19.63 g 
ddH2O (sterile) ad 2 ml ddH2O (sterile) ad 50 ml 





Mg(OAc)2 (1000 mM) 
Magnesium acetate 
(tetrahydrate) 
3.21 g   
ddH2O (sterile) ad 15 ml   
(filter sterilized, stored at −20 °C)   
   
Amino acid stocks  20-Amino acid mix 
  
L-Arginine  316.1 mg  For preparation of the final 20-Amino acid mix,  
L-Asparagine 225.3 mg 2 ml of amino acid stock solutions (10 ml for 
L-Alanine 133.6 mg L-tyrosine) were combined to a final volume of 
L-Aspartate 259.7 mg 50 ml. Final concentration: 4 mM each. 
L-Glutamate 304.9 mg (filter sterilized, stored at −20 °C) 
L-Glutamine 219.2 mg   
Glycine 112.6 mg 6-Amino acid mix (RCWMDE) 
L-Histidine 314.4 mg  
L-Isoleucine 196.8 mg For preparation of the final 6-Amino acid mix,  
L-Leucine 196.8 mg 4 ml of amino acid stock solutions (R, C, W, M,  
L-Phenylalanine 247.8 mg D and E only) were combined to a final volume 
L-Proline 172.7 mg of 24 ml. Final concentration: 16.7 mM each. 
L-Lysine 274.1 mg (filter sterilized, stored at −20 °C) 
L-Serine 157.7 mg   
L-Tryptophan 306.3 mg   
L-Threonine 178.7 mg   
L-Valine 175.7 mg   
L-Cysteine 181.8 mg  
L-Methionine 223.8 mg   
(dissolved in 15 ml sterile ddH2O each,  
final 100 mM) 
 
 
L-Tyrosine 181.2 mg   
















HEPES/EDTA buffer (24X) S30 buffer (50X) 
HEPES 28.6 g (≙ 2.4 M) Tris base 60.6 g (≙ 500 mM) 
EDTA 0.372 g (≙ 0.02 M) Magnesium acetate 
(tetrahydrate) 
150.1 g 
(≙ 700 mM) 
ddH2O ad 50 ml Potassium acetate 2.9 g (≙ 30 mM) 
(pH adjusted to 8 with KOH, filter sterilized, stored 
at −20 °C) 
ddH2O ad 1 l 




For cell-free synthesis, 50X buffer was diluted to 
1X with ddH2O to final 10 mM Tris, 14 mM 
Mg(OAc)2 and 0.6 mM KOAc. 
    
Purification buffer (1X) Purification buffer (1X, + imidazole) 
Tris 0.02 M Tris  0.02 M 
NaCl  0.15 M NaCl  0.15 M 
  Imidazole  0.02−0.5 M 
optional:  optional:  
for detergent screen: 0.05 % DDM (w/v) for detergent screen: 0.05 % DDM (w/v) 
for detergent-based 
synthesis: 
0.05 % Brij®78 (w/v) for detergent-based 
synthesis: 
0.05 % Brij®78 (w/v) 
for nanodiscs-guided 
synthesis: 
no detergent for nanodiscs-guided 
synthesis: 
no detergent 
(pH adjusted to 8.0, 4 °C, filter sterilized) (pH adjusted to 8.0, 4 °C, filter sterilized) 
  
Eluent for SEC  






2.7. Lab equipment and software 
Equipment and devices used in this project are listed in Table 2.8. 
 
Table 2.8. Lab equipment and corresponding manufacturer. 
Lab equipment Manufacturer 
  
ÄKTApurifierTM 10  GE Healthcare, Freiburg 
Analytical balance ABS 120-4  Kern & Sohn, Balingen 
Analytical balance CP225D Sartorius, Göttingen 
Battery-powered pipette controller accu-jet® pro Brand GmbH + CO. KG, Wertheim 
Gallios 3L Flow Cytometer Beckman Coulter, Krefeld 
BioPhotometer 6131 Eppendorf, Hamburg 
CAWO ABS cassette (for film exposure) CAWO, Schrobenhausen 
Cell-free reaction chamber (analytic) Beitz lab, CAU Kiel 
Cell-free reaction chamber (preparative) Beitz lab, CAU Kiel 
Centrifuge Biofuge™ Pico Heraeus, Hanau 
Chemostar Touch ECL & Fluorescence Imager  INTAS Science Imaging Instruments, 
Göttingen 
Climate Chamber Incubator WTC Binder 9010-0021  Binder, Tuttlingen 
Digital pH meter Lab 850  Schott Instruments, Mainz 
DNA Sequencer CEQTM 8000 Beckman Coulter, Krefeld 
DNA SpeedVac® DNA110 Savant Instruments, Farmingdale, USA 
Elektrophoresis Power Supply EPS 300  Pharmacia Biotech, Stockholm, Sweden 
Gene Pulser® II Electroporation System Bio-Rad, München 
Heating block Dri-Block DB20 Techne, Stone, Great Britain 
Heraguard Clean Bench Heraus, Hanau 
Image Document Analyzer Raytest IDA Elysia-Raytest, Straubenhardt 
Incubator Kelvitron® t  Heraeus, Hanau 
Incubator Shaker Minitron Infors HT, Bottmingen 
JEM-1400 Plus Transmission Electron Microscope JEOL, Peabody, USA 
Leica SP5 confocal microscope (HCX PL 
APO CS 63.0×1.40 Oil objective) 
Leica Microsystems, Wetzlar 
Lumi Imager™ F1 Roche Diagnostics, Mannheim 
Magnetic stirrer Ikamag® Ret-GS IKA-Werke, Staufen 
PerfectBlue Dual Gel System Twin S w/ casting base Peqlab, Erlangen 
Power Pac 200 Electrophoresis Power Supply Bio-Rad, München 




Refrigerated benchtop centrifuge 5424 R Eppendorf, Hamburg 
Refrigerated benchtop centrifuge Multifuge 1S-R Heraeus, Hanau 
Refrigerated benchtop centrifuge PerfectSpin 24 R Peqlab, Erlangen 
Rocking Shaker WS 10 Edmund Bühler, Hechingen 
Rotator Grant Bio PTR-30 360-degree  Keison International, Essex, Great Britain 
Rotator TC-7 New Brunswick Scientific, Edison, USA 
Scintillation Counter Tri-Carb 2900TR Packard, Downers Grove, USA 
Shaking table Certomat® MO  Sartorius, Göttingen 
Single channel pipettes Gilson, Middleton, USA 
Superdex 200 10/30 GL GE Healthcare, Freiburg 
Thermocycler Primus HT 25  Clemens, Waldbüttelbrunn 
Trans-Blot® SD Semi-Dry Transfer Cell Bio-Rad, München 
Ultracentrifuge Optima™ XL-80 K Beckman Coulter, Krefeld 
Ultracentrifuge Rotor Type 50.2 Ti Beckman Coulter, Krefeld 
UV-Transluminator UVT-20 S/M  Herolab Laborgeräte, Wiesloch 
Vacuum pump type 400171 (chemically resistant)  Ilmvac, Ilmenau 
Vortex Genie® 2  Scientific Industries, Bohemia, USA 
Water bath Gesellschaft für Labortechnik, Burgwedel 



















This work was written using Microsoft Office. Data analysis was done with SigmaPlot, Kaluza 
and ImageJ, and generation, analysis and visualization of protein structures was conducted 
with Chimera and PyMOL. 
 
Table 2.9. Software and corresponding manufacturer. 
Software Producer 
  
Microsoft Office 365, Version 2010 Microsoft Corporation 
SigmaPlot 11.0 Systat Software Inc. 
Chimera 1.15 Resource for Biocomputing, 
Visualization, and Informatics at the 
University of California [118] 
PyMOL 1.7.4.1 Schrödinger, LLC 
ImageJ 1.52p National Health Institute USA 
Kaluza Analysis 1.3 Beckman Coulter 
SnapGene® Viewer 5.2.3 GSL Biotech LLC 
Lasergene 7.2.1 DNASTAR® 









3.1. Molecular biological methods 
3.1.1. General cloning strategy for basigin/embigin-MCT1 fusion constructs 
This section outlines the general cloning approaches for MCT1 constructs in this work. 
Individual methodic protocols are described in detail in later sections.  
For the recombinant expression of MCT1 constructs in yeast, coding sequences (see 2.1.1) 
were cloned into the modified expression vector pDR196 (pDRTXa, see 2.1.2). To introduce 
suitable restriction sites, the multiple cloning site of pDRTXa was modified by a specific linker 
generating plasmid vector pDRTXaLK. In short, a complementary pair of oligonucleotides 
(Table 2.1, “MCT1 linker”) carrying restrictions sites for PflMI, BspEI and PstI, as well as N- 
and C-terminal flanking sequences of MCT1 (see Figure 2.1A for illustration) was annealed 
and resulting SpeI/XhoI overhangs were ligated into the pDRTXa vector. Subsequently, the 
coding sequence for MCT1 (lacking the respective N- and C-terminal ends) was introduced via 
internal PflMI/BspEI restriction sites. The basigin/embigin variants BSGΔIg/EMBΔIg, BSG Ig-I, 
BSG-Ig-I/C2, BSG var2 and BSG var1/EMB var1 including suitable SpeI and PstI restriction 
sites were produced via PCR using basigin/embigin splice variant 1 as a template (see 
Table 2.1 for respective oligonucleotides). To generate BSG/EMB-MCT1 fusion constructs, 
respective basigin/embigin variants were inserted upstream of MCT1 using SpeI/PstI 
restriction sites. Mutations in coding sequences for basigin and MCT1 were introduced via site-
directed mutagenesis. All constructs were sequenced for verification.  
Additional basigin mutant constructs BSG Ig-I K108,111A and BSG Ig-I R201,203A were 
generated via site-directed mutagenesis using BSG Ig-I as a template (see Table 2.2 for 
oligonucleotides, conducted by K. Geistlinger). The basigin constructs BSG Ig-I E114,118, 
120,168,172Q (BSG Ig-I Glu→Gln) and BSG Ig-I K108,111,127A / R166,201,203A 
(Lys,Arg→Ala + R166A) including SpeI and PstI restriction sites were purchased as synthetic 
DNA fragments (GenScript, Leiden, Netherlands; see section 2.1.1) and inserted upstream of 
MCT1. The putative salt-bridge associated Arg166 was reintroduced via site-directed 
mutagenesis generating BSG Ig-I Lys,Arg→Ala (Table 2.2, “BSG Ig-I A166R”, conducted by 
K. Geistlinger). All constructs were sequenced for verification.  






Figure 3.1. Topology and protein sequence of the BSG var2-MCT1 fusion construct. Highlighted 
are the N-terminal hemagglutinin epitope tag (pink) and the C-terminal His10 affinity tag (blue), the 
cysteine residues forming disulfide bridges in the Ig-like domains Ig-I (dark gray) and Ig-C2 (light gray), 
and the glutamate in the transmembrane helix of basigin (red). The N-terminal signal peptide present in 
BSG var2 is shaded white. The expression constructs of this study were generated by truncations at the 
sites of changed gray levels between the extracellular domains (BSG∆Ig, BSG Ig-I, BSG Ig-I/C2, 
BSG var2); or lacked the basigin fusion altogether (MCT1). 
 
 
To express fusion constructs with C-terminal green fluorescent protein (GFP) in yeast, the 
open reading frames were inserted into the SpeI and XhoI-compatible SalI sites of the pUG35 
plasmid (Figure 2.1B). For the expression in P. pastoris, coding sequences were cloned into 
the pPink-HC vector using blunted upstream SpeI (coding sequence in pDRTXaLK) or EcoRI 
(MCS in pPink-HC) and downstream XhoI restriction sites. For the cell-free expression, coding 
sequences were cloned into the pIVEX2.3w(-GFPΔM1) vectors using SpeI/XhoI restriction 
sites. For the cell-free expression of the BSG var2-MCT1 fusion protein, the ORF was modified 
by C. Hansen to introduce a Factor Xa restriction site between basigin and MCT1 (see Master’s 







3.1.2. Oligonucleotide annealing 
To anneal two single-stranded oligonucleotides with complementary sequences, the 
oligonucleotides were dissolved in double-distilled water (ddH2O) to a final concentration of 
2 µM. An equal volume of both oligonucleotides was combined in a PCR tube (total volume of 
50 µl) and annealed using a suitable thermal profile. In a thermocycler, secondary structures 
were disrupted by heat (95 °C, 2 min) and annealing was achieved by a step-wise decrease 
of temperature to 8 °C (0.5 °C s−1). 
 
3.1.3. Polymerase chain reaction (PCR) 
To amplify specific DNA sequences, to introduce additional restriction sites and to construct 
individual basigin variants, polymerase chain reactions (PCR) with suitable oligonucleotide 
primers (Table 2.1) were conducted. 1−2.5 ng of plasmid DNA were used as a template 
(Table 3.1) for amplification in a thermocycler (Table 3.2). The PCR products were later cloned 
into target vectors and verified by sequencing. 
 
Table 3.1. Components of standard PCR reactions. 
Component  Amount 
  
Plasmid DNA (200-500 µg ml−1, 1:100 diluted) 0.5 µl 
dNTPs (2.5 mM each) 4.0 µl 
Oligonucleotide primer (25 µM) each 1.5 µl 
OneTaq DNA polymerase (5 U µl−1) 0.5 µl 
OneTaq Standard Reaction Buffer (5X) 10.0 µl 
ddH2O ad 50.0 µl 
  
 
Table 3.2. Thermal profile of standard PCR reactions. 
Step Temp. Duration  
    
Initial Denaturation 94 °C 5.0 min  
Denaturation 94 °C 0.5 min  
Annealing *55-70 °C 1.0 min    30 cycles  
Elongation 68 °C †1−1.5 min  
Final Elongation  68 °C 5.0 min  
Storage 8 °C ∞  
    














To confirm the successful integration of plasmids in P. pastoris, white colonies of yeast 
transformants were resuspended in 10 µl ddH2O. 1.5 µl of resuspended cells were lysed by 
heat and released DNA was used as a template to perform target insert-specific PCR 
(Table 3.3, Table 3.4). The successful integration was subsequently evaluated using agarose 
gel electrophoresis. 
 
Table 3.3. Components of colony PCR reactions. 
Component  Amount 
  
Template 1.5 µl 
dNTPs (2.5 mM each) 4.0 µl 
Oligonucleotide primer “AOX1” (25 µM) 0.5 µl 
Oligonucleotide primer “CYC1” (25 µM) 0.5 µl 
OneTaq DNA polymerase (5 U µl−1) 0.5 µl 
OneTaq Standard Reaction Buffer (5X) 10.0 µl 
ddH2O ad 50.0 µl 
  
 
Table 3.4. Thermal profile of colony PCR reactions. 
Step Temp. Duration  
    
Initial Denaturation 94 °C 5.0 min  
Denaturation 94 °C 1.0 min  
Annealing 54 °C 1.0 min    30 cycles  
Elongation 68 °C †1.0−3.0 min  
Final Elongation  68 °C 5.0 min  
Storage 8 °C ∞  
    
          † depending on product size (1 min per 1-2 kilobases) 
 
 
3.1.5. Site-directed mutagenesis  
In vitro mutagenesis was based on the QuikChange Site-Directed Mutagenesis Kit (Agilent). 
In short, plasmid DNA encoding the protein of interest was used as a template to conduct a 
complete plasmid amplification. For site-specific base substitutions, the forward 
oligonucleotide primers contained respective nucleotide exchanges. The reverse 
oligonucleotide primers were designed to complementary bind sequences flanking the 
mutation region. See Table 2.2 for the respective oligonucleotide primer pairs. The plasmid 
amplification was conducted using the high fidelity PfuTurbo DNA polymerase (Table 3.5, 




Table 3.5. Components of PCR reactions for in vitro mutagenesis. 
Component  Amount 
  
Plasmid DNA (200-500 µg ml−1, 1:100 diluted) 1.0 µl 
dNTPs (2.5 mM each) 4.0 µl 
Oligonucleotide primer (25 µM) each 1.5 µl 
PfuTurbo DNA polymerase (2.5 U µl−1) 0.8 µl 
Pfu Standard Reaction Buffer (10X) 5.0 µl 
ddH2O ad 50.0 µl 
  
 
Table 3.6. Thermal profile of PCR reactions for in vitro mutagenesis. 
Step Temp. Duration  
    
Initial Denaturation 94 °C 0.5 min  
Denaturation 94 °C 0.5 min  
Annealing *55-70 °C 1.0 min    16 cycles  
Elongation 72 °C † ~16.0 min  
Final Elongation  72 °C 20.0 min  
Storage 8 °C ∞  
    




† depending on product size (1 min per kilobase) 
 
After thermocycling, the PCR products were DpnI-digested to eliminate E. coli-methylated 
template DNA. Subsequently, competent E. coli DH5α cells were transformed with the nicked 
plasmid DNA. Sequences and mutations were confirmed by sequencing and subcloned into 
verified vectors. 
 
3.1.6. Restriction digest 
For the subcloning of PCR products and target sequences, DNA was digested using suitable 
restriction enzymes. Approximately 1 µg of plasmid DNA / 16 µl of purified PCR product were 
digested in compatible, commercial buffers using 2−10 U of restriction enzymes (10−20 µl total 
volume). Usually, digestions were conducted at 37 °C (3 h to overnight). The digestion with 
non-compatible restriction enzymes was conducted in a two-step process including DNA 
purification (by PCR Clean-up, see 3.1.9) followed by buffer and digest condition adjustments. 
For later ligation of non-compatible overhangs, digested sticky ends were blunted by the action 
of T4 DNA polymerase. In short, sticky overhangs of restriction digests (10 µl) were “filled in” 
by topping up to a final volume of 20 µl to introduce 5 U of T4 DNA polymerase and dNTP mix 
(0.25 mM each). The restriction digest buffer conditions were preserved. The reactions were 




3.1.7. Dephosphorylation of linearized plasmid vectors 
To increase the cloning efficiency and avoid background vector re-circulation, the 5’-phosphate 
ends of linearized vectors were enzymatically removed by the action of FastAP Alkaline 
Phosphatase. In short, 1 µl (1 U) of phosphatase was added to restriction digests and cleavage 
was induced by incubation at 37 °C (10 min). Prior to following fragment ligation steps, the 
phosphatase was heat-inactivated (5 min, 75 °C). 
 
3.1.8. Agarose gel electrophoresis 
To visualize and analyze DNA fragments, the samples were separated by size using agarose 
gel electrophoresis. The gels were prepared by dissolving agarose powder (final 1 % w/v) in 
50 ml TAE buffer (1X) in a microwave and adding 1 µl of DNA-intercalating ethidium bromide 
(10 mg ml−1). The DNA samples were mixed 1:10 with Orange G loading buffer (10X), and up 
to 20 µl were loaded per lane and separated in an electric field (120 V, 20−40 min). The DNA 
was visualized by exciting ethidium bromide fluorescence at 312 nm using a UV 
transilluminator. Fragment sizes were estimated using PstI-digested lambda phage DNA (5 µl 
per lane) as size standard. 
 
3.1.9. DNA purification and isolation from agarose gels 
For the DNA recovery from agarose gel electrophoresis and PCR, the HiYield® PCR 
Clean-up/Gel Extraction kit was used according to the manufacturer’s protocol (Süd-
Laborbedarf). For the isolation from agarose gels, gel sections of interest were excised using 
a scalpel and dissolved according to the producer’s guidelines. Purified DNA was finally eluted 
using 15−20 µl of ddH2O. 
 
3.1.10. Ligation of DNA fragments 
The ligation of sticky and blunt ends after restriction digestions or oligonucleotide annealing 
with sticky overhangs was based on the enzymatic action of T4 DNA ligase. DNA fragments 
(e.g. linearized plasmid, ORFs, PCR products, annealed oligonucleotides) with compatible 
ends were ligated in a final volume of 10 µl of 1X T4 DNA ligase buffer (Table 3.7). The ligation 









Table 3.7. Components of DNA fragment ligation. 
Component  Amount 
  
Plasmid DNA, linearized 1.0 / 3.0 µl 
Insert  7.0 / 5.0 µl 
T4 DNA ligase buffer (10X) 1.0 µl 




3.1.11. Preparation of competent E. coli strains 
E. coli competent cells were prepared by technical assistant A. Fuchs using the previously 
described calcium chloride method. Briefly, E. coli DH5α cells were grown overnight on LB 
agar plates (37 °C) and inoculated in 5 ml liquid LB media. After approximately 9 h, the cells 
were inoculated in a 100 ml main culture (LB) and incubated overnight at 20 °C on a shaker 
(200 rpm). The cells were harvested at an optical density (OD600) of 0.4−0.6 by centrifugation 
(2,000 g, 4 °C, 10 min). The cells were resuspended in 30 ml of ice-cold CaCl2-solution (0.1 M) 
by swirling and gently shaking for 10 min and kept on ice for additional 10 min. The cells were 
again pelleted (2,000 g, 4 °C, 10 min) and resuspended first in 20 ml ice-cold 0.1 M CaCl2 and 
cooled on ice (20 min), and secondly in 10 ml ice-cold 0.1 M CaCl2 additionally containing 
20 % glycerol. The cells were kept on ice for at least 4 h and stored at −80 °C (100 µl aliquots). 
 
3.1.12. Transformation of E. coli strains  
To amplify and store plasmid DNA, competent E. coli cells were transformed with respective 
plasmids. The competent cells were gently thawed on ice (~3 min), 10 µl of DNA (e.g. ligation 
reactions) were subsequently added and the cells were incubated on ice (30 min). The 
transformation was induced by a heat shock (42 °C, 45 s) and the cells were cooled down on 
ice. 900 µl of LB medium were added and the cells were rotated at 37 °C for 45−60 min. Finally, 
the cells were centrifuged at maximum speed (21,000 g, 30 s), resuspended in 100 µl of 
supernatant and 50−100 µl were plated and grown on ampicillin-containing LB agar plates. 
For the transformation of cells with purified, highly concentrated plasmid DNA, the protocol 
was simplified. Thawed cells (100 µl) were incubated with 0.5 µl of DNA (15 min, on ice) and 









3.1.13. Long-term plasmid storage and glycerol stocks of E. coli transformants 
Cells on solid agar medium were inoculated in 5 ml liquid LB Amp medium, grown overnight 
(37 °C, under rotation) and stored in 27 % glycerol at −80 °C (1 ml cell culture + 0.5 ml 
80 % glycerol). 
 
3.1.14. Plasmid isolation from E. coli strains  
Small-scale isolation of plasmid DNA (yielding ~10−25 µg) from transformed E. coli was done 
using the Wizard® Plus SV Minipreps DNA Purification kit (Promega). To recover DNA from 
glycerol stocks, the cells were initially plated on LB Amp agar medium using a sterile pipette 
tip. Subsequently, single cell colonies from solid medium (glycerol stocks or transformants) 
were inoculated in 5 ml of liquid LB Amp medium and grown overnight (37 °C, under rotation). 
Plasmid DNA was finally isolated according to the manufacturer’s protocol (the alkaline 
protease step was skipped) and purified DNA was eluted using 50 µl of ddH2O. 
Large-scale isolation of plasmid DNA (yielding ~50−100 µg) was done with the NucleoBond™ 
PC 500 kit (Macherey-Nagel). Again, the cells from LB Amp agar plates were inoculated in 
5 ml LB Amp liquid media and grown under rotation for approximately 6 h at 37 °C. 
Subsequently, a 250 ml-main culture was inoculated and incubated overnight on a rotary 
shaker (37 °C). Finally, plasmid DNA was isolated according to the manufacturer’s protocol, 
and the purified, air-dried DNA was resuspended in 50−100 µl ddH2O. 
DNA concentrations were determined by measuring the absorbance at 260 nm and employing 
the correlation that an absorbance of A260 = 1.0 equals 50 µg ml
−1 (equation 1). 
 
DNA concentration (µg ml−1) = 50 (µg ml−1) ∙ A260 ∙ dilution factor     (1) 
 
The DNA purity was evaluated by determining the absorbance ratio A260/A280 with ratios of 
1.7−2.0 confirming high quality.  
 
3.1.15. Sanger sequencing 
The sequencing of distinct DNA segments (PCR, mutagenesis) was either done externally or 
in-house using the DTCS Quick Start Kit. 
For external sequencing, the DNA was diluted to a final concentration of 100 µg ml−1 and 3 µl 
of DNA sample were mixed with 1 µl of a suitable oligonucleotide primer (4.8 µM). The probes 
were sent to the Institute of Clinical Molecular Biology, Kiel for Sanger sequencing. 
In-house sequencing relied on the DTCS Quick Start Kit. Generally, DNA segments were PCR-
amplified using suitable oligonucleotide primers as well as deoxynucleotides (dNTPs) and 
fluorescently labeled dideoxynucleotides (ddNTPs). The incorporation of ddNTPs resulted in 




labeled according to the terminating nucleotide. The DNA fragments were size-separated via 
capillary electrophoresis and sequences were traced back using the DNA 
Sequencer CEQ™ 8000. Based on the manufacturer’s protocol, 50−150 fmoles of DNA in 
ddH2O (total volume of 9.5 µl) were preheated in a thermocycler (5 min, 86 °C) and cooled 
down to 8 °C. Subsequently, the preheated DNA template was mixed with a suitable 
oligonucleotide primer and DTCS Quick Start Master Mix containing all essential components 
for sequencing PCR reactions and DNA template extension was finally induced using the 
depicted thermal profile (Table 3.8, Table 3.9).  
 
Table 3.8. Components of sequencing reactions. 
Component  Amount 
  
DNA template, preheated 9.5 µl 
Oligonucleotide primer (5 µM) 1.5 µl 
DTCS Quick Start Master Mix 2.0 µl 
  
 
Table 3.9. Thermal profile of sequencing reactions. 
Step Temp. Duration  
    
Denaturation 96 °C 20 s  
Annealing 50 °C 20 s    30 cycles  
Elongation 60 °C 4.0 min  
Storage 8 °C ∞  
    
   
 
Reactions were stopped by the addition of 5 µl of stop solution/glycogen mixture containing 
2 µl of 3 M sodium acetate buffer solution (pH 5.2), 2 µl of 100 mM Na2-EDTA (pH 8.0) and 
1 µl of 20 mg ml−1 glycogen on ice. Finally, DNA fragments were precipitated by adding 60 µl 
of 95 % (v/v) ethanol (ice-cold) and by centrifugation (18,000 g, 4 °C, 15 min), and washed 
twice with 200 µl of 70 % (v/v) ethanol (ice-cold). For each rinse, the samples were centrifuged 
at 18,000 g (4 °C, 5 min). The supernatant was discarded, and the DNA pellet was dried by 
centrifugation under vacuum (up to 30 min) and resuspended in 30 µl of manufacturer’s 
sample loading solution. The samples were kept at 4 °C until analyzed by technical assistant 








3.2. Recombinant expression and functionality in S. cerevisiae 
3.2.1. Transformation of S. cerevisiae, and storage 
For recombinant expression in S. cerevisiae, cells were transformed with pDRTXa/pUG35 
plasmids encoding the protein of interest using a protocol adapted from the previously 
described LiAc/single-stranded carrier DNA/PEG method [120]. 
First, the naive yeast strain was plated on a YPD agar plate and grown for 3-5 days (29 °C). A 
single colony was inoculated into 5 ml liquid YPD medium and incubated overnight in a rotary 
shaker (29 °C, 220 rpm). Next day, the cells were inoculated in a 50 ml main culture with an 
initial OD600 of 0.2 and incubated on a rotary shaker (29 °C, 220 rpm) to a final OD600 of 0.6. 
The cells were harvested by centrifugation (2,500 g, 4 °C, 5 min) and washed once with 25 ml 
of sterile water. The cell pellet was resuspended in 1 ml of sterile water and aliquoted (100 µl 
per transformation). The cells were again pelleted (21,000 g, 30 s) and resuspended in 360 µl 
of transformation mix (Table 3.10). For each transformation, 0.5 µl of target plasmid were 
added and the samples were mixed by vortexing. Transformation was induced by incubation 
in a heating block (42 °C, 45−60 min). The transformation mix was removed by centrifugation 
(21,000 g, 30 s) and the cells were resuspended in 1 ml of sterile water. Approximately 100 µl 
of 1:10-dilutions were finally plated on SD AHLW selection agar and grown for 3-4 days in a 
29 °C-incubator. 
 
Table 3.10. Transformation mix. 
Component  Amount 
  
PEG 3500 (50 % w/v) 240 µl 
LiAc (1 M) 36 µl 
Single-stranded carrier DNA (boiled*, 2 mg ml−1) 50 µl 
Sterile water 34 µl 
  
*Single-stranded carrier DNA was boiled at 100 °C for 5 min prior to use 
 
 
For the long-term storage of transformed cells, glycerol stocks of transformants were prepared. 
Single colonies were inoculated in 5 ml liquid SD AHLW medium, grown overnight (29 °C, 
under rotation) and stored in 40 % glycerol at −80 °C (0.5 ml cell culture + 0.5 ml 








3.2.2. Cell culture  
To induce recombinant expression and prepare expressing cells for analyses including 
transport assays, confocal microscopy and flow cytometry, the transformed cells were 
inoculated in 5 ml SD AHLW and incubated as 20−24 h-precultures. After up to two 
precultures, 50−100 ml-main cultures were inoculated and grown in SD AHLW medium to a 
final OD600 of 1.0 ± 0.1. Finally, the cells were immediately harvested by centrifugation 
(4,000 g, 4 °C, 5 min) and prepared for further analyses (see sections 3.2.3 to 3.2.15). 
  
3.2.3. Cell lysis and protein extraction from S. cerevisiae 
To evaluate protein synthesis and expression in yeast, the harvested cell cultures from section 
3.2.2 (50 ml-main cultures) were washed once with 50 ml of ice-cold water and once with 10 ml 
of cold extraction buffer (25 mM Tris, pH 7.5, 5 mM EDTA). For each washing step, the cells 
were pelleted by centrifugation at 4,000 g (4 °C, 5 min). After removal of supernatant, the 
pelleted cells were frozen at −80 °C for at least 30 min (up to several weeks) and finally 
resuspended in 0.5 ml of extraction buffer (on ice). Roughly 0.5 g of acid-washed glass beads 
(~0.5 mm in diameter) were added, and the cells were broken by 10−15 intervals of vortexing 
(30 s) and cooling down (1 min, on ice). The cell extracts were separated from glass beads by 
centrifugation (1,000 g, 4 °C, 5 min) and transferred to a micro tube. Remaining glass beads 
and non-broken cells were washed with 0.5 µl of extraction buffer and subject to a second 
round of 10−15 cycles of vortexing. The cell extracts from both vortexing intervals were 
combined (total volume of 1 ml) and larger cell compartments and cell debris (mitochondria, 
nuclei, larger plasma membrane fractions) were separated by centrifugation at 10,000 g (4 °C, 
5 min). The supernatants were transferred to ultracentrifuge tubes and the microsomal 
fractions were isolated from cytosolic components by centrifugation at 100,000 g (4 °C, 
45 min). The isolated fractions were resuspended in 100 µl of solubilization buffer (100 mM 
sodium phosphate, pH 8.0, 50 mM NaCl) on ice. 
 
3.2.4. Biophysical transport assay using 14C-radiolabeled substrates 
The functional analysis of expressing cells was based on the uptake of 14C-radiolabeled 
substrates via functional transporters. 14C is an instable radioisotope going through radioactive 
low-energy beta decay to stable 14N with a half-life of 5,730 years [121, 122]. Cells expressing 
L-lactate-transporting proteins were extracellularly exposed to L-lactate solutions spiked with 
14C-labeled L-lactate. Active transporters led to the accumulation of radioisotopes inside the 
cells and emitted beta particles were quantified by detecting the light emission from excited 





Figure 3.2. Transport assay using 14C-radiolabeled substrates. A 14C-labeled substrate is 
transported into cells by transporters. Intracellularly accumulated 14C-labeled substrate emits beta 
particles that excite scintillation (SC) molecules. Excited SC molecules relax under the emission of light. 
Signals are multiplied by a photomultiplier and detected as counts per minute and kilo-electron volts. 
 
The characterization and evaluation of transport properties of recombinantly expressed 
proteins in yeast was based on a protocol established in-house by J. Rambow [123] and B. Wu 
[109]. Generally, uptake experiments were conducted as follows. Specifications for each 
individual experimental setting are indicated in sections hereinafter. Unless otherwise 
indicated, harvested cells (see 3.2.2) were washed with 50 ml of ddH2O and centrifuged 
(4,000 g, 4 °C, 5 min) to remove the supernatant. The dried pellets were kept on ice (0.5 to 
3 h) and resuspended in ice-cold HEPES/Tris (50 mM, pH 6.8) or MES/Tris (50 mM, pH 5.8) 
assay buffer to a final OD600 of 50 ± 5 just prior to conducting the uptake assay and kept on ice 
until the experiment was started. Common to all individual assay methods, 80 µl of cell 
suspension (± inhibitor/modifying reagent, prewarmed) were subject to 20 µl of substrate 
solution (5X, in respective assay buffer, spiked with 14C-labeled substrate) in 1.5 ml tubes and 
mixed by pipetting. The probes were incubated (non-shaken) for various time periods, and the 
uptake was abruptly stopped by the addition of 1 ml ice-cold water and immediate transfer to 
GF/CTM glass microfiber filters. The cells were cleared from excess substrate solution by 
vacuum filtration. To reduce background, substrate adhesion to filters / cells was minimized by 
washing with 7 ml of ice-cold water. The dried filters were transferred to 3 ml of scintillation 
cocktail (Quicksafe A, Zinsser Analytic) and the cells were left to dissolve over 20−24 h in 
scintillation vials. The light emission from scintillation molecules excited by beta particles from 
14C-decay was detected via a photomultiplier and events were counted over 2 min using the 
Scintillation Counter Tri-Carb 2900TR (Packard). Data was collected as counts per minute 
(cpm) in an energy range of 4−156 keV. In the following sections, the specifications of 




3.2.5. Transport parameters, data conversion and normalization 
Data collected as counts per minute (cpm) were translated to molar quantities of substrate (in 
nmol) to estimate the absolute substrate uptake. For each experiment, 20 µl of 14C-spiked 
substrate solution were transferred to 3 ml of scintillation cocktail to get an estimate of maximal 
activity resulting from complete substrate uptake into cells. The maximum activity was 
determined for each individual experiment and was measured in triplicates. The determination 




max.  activity (cpm)
∙ max. substrate (nmol)             (2) 
 
Total molar quantities of substrate were ultimately normalized to the cell mass per sample. To 
get an estimate, the cells from section 3.2.2 were collected, washed once with 50 ml of sterile 
water and finally resuspended in sterile water to a final OD600 of 40 ± 4 (this equals the final 
OD600 of samples after addition of substrate solution in uptake assays, see section 3.2.4). For 
accuracy, 1 ml of cell suspension was centrifuged (21,000 g, 5 min) and the supernatant was 
carefully discarded. The cell pellets were weighed and referred to 100 µl sample volumes. The 
determined weights from a total of 8 samples from 4 individual cell cultures was averaged 
obtaining a mean of 5.6 mg of cell mass per 100 µl sample volumes in uptake assays. The 
factor of 5.6 mg was finally used to normalize molar quantities of substrate to 1 mg of cells 
(→ nmol mg−1). 
  
3.2.6. Substrate uptake over time 
To monitor L-lactate uptake over time, cells resuspended in assay buffer of desired pH (see 
section 3.2.4) were prewarmed to either room temperature (19 ± 1 °C, for 10−15 min) or 30 °C 
(heating block, for 5 min). Uptake was initiated by a final 1 mM inward gradient of L-lactate 
(spiked with 0.04 µCi of 14C-labeled L-lactate) and monitored for 0.5 min to 32 min at the given 
assay temperature. For each time point, the cells were left undisturbed over the respective 
time span. 
The background leakage into cells was estimated by monitoring the uptake of non-expressing 
cells transformed with empty vectors. The uptake was corrected for filter adhesion by 
subtracting values determined for 20 µl substrate solution pipetted directly onto filters. For the 
uptake of expressing cells after each time point, the determined uptake of non-expressing cells 
was subtracted as background. Uptake-over-time curves were fitted according to the equation 
f(t) =  a ∙  (1 −  e−kt). Initial transport rates as nmol min−1 mg−1 were determined as the slope at 
t = 0. Maximal uptake capacities in nmol mg−1 result from the determination of the upper limit 
of each curve (lim
t→∞




otherwise indicated, curves depict mean ± SEM (standard error of the mean) of three biological 
replicates where each replicate itself is an average of duplicate or triplicate measurements. 
The calculations on the initial transport rate and the uptake capacity result from individual fits 
for each biological replicate and represent mean ± SEM.  
In individual cases (indicated in the respective figure legends), the initial transport rates from 
mutant constructs lacking a resolved uptake-over-time curve were determined via single time 
point measurements in the initial phase of transport (2 min for human MCT1-related mutant 
constructs; 4 min for rat MCT1). 
 
3.2.7. Impact of increasing preparation times on the transport activity of cells 
To estimate cell fitness and transport activity drop over time, harvested cells resuspended in 
assay buffer (pH 6.8) (see section 3.2.4) were prewarmed to RT for 5, 15 and 30 min just prior 
to conducting the assay. Transport was subsequently initiated by adding substrate solution 
(1 mM L-lactate spiked with 0.04 µCi 14C-L-lactate) and transport rates were determined by 
monitoring uptake over 2−4 min. The rates per minute were calculated and averaged as 
mean ± SEM of three biological replicates each resulting from technical triplicates. The 
background of non-expressing cells was subtracted. 
 
3.2.8. Determination of intracellular L-lactate concentrations 
To estimate achieved intracellular L-lactate concentrations, the correlation of 0.28 nmol mg−1 
equaling a cytosolic concentration of 1 mM (see results section 4.1.7) determined by A. Jansen 
was used to translate uptake capacities in nmol mg−1 to molar concentrations in mM using 
equation 3.  
 
concentration (mM) = capacity (nmol mg−1)
1 mM
0.28 nmol mg−1
       (3) 
 
The results were averaged as mean ± SEM from the conversion of uptake capacities for each 
individual biological replicate. 
 
3.2.9. Determination of Michaelis-Menten kinetics 
For kinetic measurements, cells resuspended in assay buffer (pH 6.8) (see section 3.2.4) were 
prewarmed to RT (10−15 min) and zero-trans influx was initiated with inward L-lactate 
gradients ranging from 1 mM to 10 mM (each supplemented with 0.1 µCi 14C-L-lactate). 
Transport rates in nmol min−1 mg−1 were calculated via single time point measurements in the 
initial phase of transport (2 min for all examined transporters). For each individual 




fitted according to the equation f(x) =  a ∙  (1 − e−kx). Maximum transport velocities result from 
the determination of the upper limit of each curve ( lim
x→∞
( f(x)) = a = 𝑣𝑚𝑎𝑥). 𝐾𝑚 values result from 
the determination of respective concentrations for f(x) =  0.5 a . The curves depict 
mean ± SEM of three biological replicates where each replicate itself is an average of duplicate 
measurements. Calculations on the kinetic parameters result from individual fits for each 
biological replicate and represent mean ± SEM.  
 
3.2.10. Determination of transport inhibition and IC50 values 
The protocol for inhibitory studies was adapted from A. Golldack [124]. Cells resuspended in 
assay buffer (pH 6.8) (see section 3.2.4) were subject to preincubation with several 
compounds to estimate their inhibitory potential. In general, the compounds were dissolved in 
suitable solvent (ddH2O / DMSO) to an 80X stock concentration. In a 1.5 ml-tube, 1 µl of 80X 
compound solution were joined with 80 µl of cell suspension, mixed by vortexing and 
preincubated for 15 min. After incubation, L-lactate uptake was immediately determined by 
single time point measurements in the initial phase of transport dependent on the examined 
transport protein (see figure legends for details; pH 6.8, RT, 1 mM inward gradient, spiked with 
0.04 µCi of 14C-L-lactate). The residual transport activities in % of compound-exposed cells 
expressing the protein of interest were determined by subtracting the background of non-
expressing cells (solvent-exposed; control for 0 % activity) and referring to expressing cells 
lacking compound treatment (solvent-exposed; 100 % activity). 
IC50 curves were determined by calculating the % activity after pretreatment with up to six 
increasing compound concentrations. The % activity for each concentration was measured in 
technical triplicates and averaged. The mean ± SEM was plotted over compound 
concentration and resulting curves were fitted according to the Hill equation. The IC50 values 
were calculated as the concentration leading to 50 % of residual activity and were confirmed 
with three biological replicates. 
The compound concentrations and the durations of pretreatment for all tested compounds are 
summarized in Table 3.11. The final concentration of DMSO was kept at 1.25 %. 
 








     
AZD3965 DMSO 800−160,000 nM 10–2,000 nM 15 min 
DTT ddH2O 80 mM / 800 mM 1 mM / 10 mM 15 min 
ACF ddH2O 80 mM 1 mM 15 min 






3.2.11. Transporter modification by cysteine-reactive agents 
The relevance of cysteine residues in MCT1 were investigated by cysteine-modifying 
compounds including p-chloromercuribenzene sulfonate (pCMBS) and methanethiosulfonate 
(MTS) reagents. Whereas pCMBS targets thiols via its mercurial portion, MTS reagents form 




Figure 3.3. Reaction equations of cysteine modification by p-chloromercuribenzene sulfonate (pCMBS) 
(A) and methanethiosulfonate (MTS) reagents (B). Residue R1 defines the transferred group and differs 
between individual MTS reagents. 
 
 
According to the supplier (Interchim), the covalent modification with MTS reagents under mild 
conditions is irreversible in the absence of reducing agents and the complete conversion is 
usually achieved within 5 min and with concentrations of 1 mM to 10 mM. 
In this work, the cysteine modification was done according to the above-mentioned protocol 
for transport inhibition (see section 3.2.10). A time-dependent inhibition was achieved by 
pretreatment with compounds for 5−15 min. The concentrations and solvents for all 
compounds can be found in Table 3.12. L-Lactate transport activity was immediately 
determined by single time point measurements (see figure legends for details) and at a 1 mM 
inward gradient of L-lactate (spiked with 0.04 µCi of 14C-L-lactate, pH 6.8, RT). For each 
treatment duration, controls were treated similarly with compounds substituted by the 
corresponding solvent.  
To test for covalent and irreversible modification via MMTS, the protocol was slightly modified 
to remove excess reagent prior to determining L-lactate uptake activities. After compound 
pretreatment for 5 min (1 mM, RT, technical replicates were pretreated in a bulk), the cells 
were centrifuged at top speed (12,225 g, RT, 1 min) and washed twice with respective volumes 
of assay buffer. The cells were subsequently resuspended in a respective volume of assay 
buffer (RT), split into 80 µl-aliquots and transport was initiated (1 mM, 0.04 µCi of 14C-L-lactate, 




To examine pCMBS inhibition after the modification with MTS reagents, the cells were first 
pretreated with MTS reagents (1 mM, RT, 5 min, replicates were treated in a bulk). Excess 
compound was removed by centrifugation (see above) and the cells were split into 80 µl-
aliquots. The cells were subsequently exposed to further treatment with pCMBS (final 30 µM, 
RT, 15 min) or solvent (100 % controls). For 0 % activity controls (non-expressing cells), both 
treatment steps were conducted with solvent. Transport activity was again determined with a 
1 mM inward gradient of L-lactate (0.04 µCi of 14C-L-lactate, pH 6.8, RT). 
In all cases, transport activities in % are averages from three biological replicates 
(mean ± SEM) with each replicate itself determined in technical triplicates. 
 








     
pCMBS ddH2O 2.4 mM 0.03 mM 5 / 15 min 
MMTS ddH2O 80 mM 1 mM 5 / 15 min 
MTSES ddH2O 80 mM 1 mM 5 min 
PMTS DMSO 80 mM 1 mM 5 min 
BMTS DMSO 80 mM 1 mM 5 min 
MTS-4-
fluorescein 
DMSO 80 mM 1 mM 5 min 
     
 
 
3.2.12. Determination of glucose effects on transport 
To determine the impact of glucose on L-lactate transport, the cells from 3.2.2 were 
alternatively washed with 50 ml of 2 % glucose (in ddH2O) and resuspended in glucose-
supplemented assay buffer (2 % glucose, HEPES/Tris 50 mM, pH 6.8). Transport was initiated 
by adding 1 mM L-lactate (spiked with 0.04 µCi 14C-L-lactate) in the presence of 2 % glucose. 
To analyze the direct inhibitory potential of glucose on L-lactate transport, glucose was 
employed just prior to conducting the uptake assay and according to the general protocol for 
transport inhibition (see 3.2.10). In short, expressing cells were preincubated (15 min, RT) with 
1 µl of 80X glucose stock solution (final concentration 25 mM). Transport was initiated by 
employing a 1 mM inward gradient of L-lactate (spiked with 0.04 µCi of 14C-L-lactate, RT) and 
monitored for 2 min (initial phase) and 8 min (equilibrium state). 
 
3.2.13. Phenotypic transport assay (solid and liquid) 
To estimate the metabolic turnover of L-lactate and the ability of cells to adapt to glucose-
deprived conditions dependent on L-lactate as sole carbon source, cells were initially prepared 




(OD600 = 1.0 ± 0.1) was harvested and washed twice with 1 ml of sterile water to thoroughly 
remove excess glucose (centrifugation at 4,000 g, 4 °C, 5 min). Finally, the 1 ml-cell 
suspension was inoculated in 50 ml of 1 % L-lactate medium (MES-buffered to pH 6.0) and 
incubated at 29 °C in a rotary shaker (220 rpm). The cell growth was monitored by regular 
OD600 determinations over a time span of 9 days. 
To evaluate metabolic advantages of cells expressing functional L-lactate transporters when 
subject to L-lactate as sole carbon source, 20 ml of main cultures prepared in section 3.2.2 
were harvested (4,000 g, 4 °C, 5 min) and washed twice with 10 ml of sterile water. Collected 
cell pellets (4,000 g, 4 °C, 5 min) were kept on ice for at least 30 min to delay cell proliferation 
and metabolism and resuspended in sterile water to an OD600 of 1.00 ± 0.05. Finally, 5 µl of 
cell suspensions as well as two serial, ten-fold dilutions were spotted on agar plates 
supplemented with 2 % L-lactate (MES-buffered to pH 6.8 or pH 5.8) or 2 % glucose (SD AHLW 
agar plates, growth control) and grown for up to 12 days (29 °C). The plates were visualized 
using a commercial scanner and images were edited using Photoshop® Elements to improve 
contrast. 
 
3.2.14. Confocal live-cell imaging of GFP fusion proteins 
Confocal live-cell imaging was done in close cooperation with Christine Desel (Institute of 
Biochemistry, CAU Kiel, Germany). Cells transformed with pUG35 plasmids encoding the 
protein of interest were prepared as described in section 3.2.2. The cells were harvested and 
washed with 50 ml of sterile water and the cell pellet was kept on ice until ready for imaging. 
Just prior to confocal imaging, the cells were resuspended in 1 ml sterile water and transferred 
to a confocal dish. Proteins with C-terminally fused GFP were imaged at a Leica SP5 confocal 
microscope system with a HCX PL APO CS 63.0x1.40 OIL objective. For quantification, 
fluorophores were excited by an argon laser line at 488 nm (14 % LP power). The emission 
was detected at 500 nm to 540 nm. Z stacks including up to 8 layers were taken in a window 
of 27.39x27.39 µm and over a depth of 5.879 µm to 7.904 µm (512x512, 8-Bit). Up to five 
stacks of different regions were imaged for each sample. Estimations on relative transporter 
amounts at the cell surface were done using the ImageJ 1.52p software (Java 1.8.0_172). 
Layers capturing cells in a central plane were chosen from each stack. The mean gray value 
per pixel (normalized to 1 µm depth) of single cells was determined on a line manually drawn 
on the cellular border as determined by corresponding bright field images. At least ten 
individual cells of highest intensities and up to five different areas were analyzed and averaged 
to obtain an averaged mean gray value per pixel on the cellular surface. The amounts of 
transporter present at the cell surface were derived from confocal GFP intensity of the basigin 
fusion constructs relative to unfused MCT1 of which the mean gray value per pixel at 1 µm 




3.2.15. Flow cytometry 
The protocol for flow cytometric (FC) analyses was modified from [125]. The harvested cells 
from section 3.2.2 (50 ml-main cultures) were washed once with 10 ml PBS and the pellets 
were cleared from supernatant by centrifugation (4,000 g, 4 °C, 5 min). The cells were kept on 
ice for at least 30 min to delay cell proliferation and were finally resuspended in 20 ml of FC 
buffer (1 % BSA in PBS). The number of cells was determined by OD600 measurements (with 
OD600 = 1 equaling 1.6∙107 cells ml−1, correlation determined by J. Rambow) and 2∙106 cells 
(non-expressing cells, i.e. controls lacking primary antibody treatment) or 107 cells 
((non-)expressing cells with primary antibody treatment) were transferred to 1.5 ml-tubes. The 
cell suspensions were cleared by centrifugation (4,000 g, 4 °C, 5 min) and resuspended in FC 
buffer ± primary antibody (orb312305, 1 µg per sample) to a final volume of 100 µl. The 
samples were incubated on ice for 50 min. The cells were again cleared from excess antibody 
(4000 g, 4 °C, 5 min) and washed twice with 1 ml of FC buffer. The cells were resuspended in 
FC buffer ± APC-conjugated secondary antibody (Goat anti-Rabbit IgG, 4050-11S, 1 µg per 
sample) to a final volume of 100 µl and incubated for 50 min under the exclusion of light (on 
ice). The cells were washed twice with 1 ml PBS and finally resuspended in 500 µl PBS. The 
samples were transferred to FC tubes, analyzed in cooperation with S. Riethmüller 
(Pharmaceutical Biology, CAU Kiel) using the Gallios 3L Flow Cytometer, and evaluated using 
















3.3. Recombinant expression in P. pastoris 
3.3.1. Preparation of plasmid DNA for transformations  
For the transformation of P. pastoris strains, the target plasmid DNA (pPink-HC vector 
including the coding DNA for the protein of interest) was prepared by linearization. In short, 
10 µg of purified plasmid DNA were digested with SpeI restriction enzyme in a total volume of 
30 µl (30 U, 37 °C, overnight). The digestion was stopped by adding 8 µl of 100 mM Na2-EDTA 
(pH 8.0; final concentration: 20 mM) in a final volume of 40 µl. The linearization was evaluated 
by agarose gel electrophoresis. DNA was finally precipitated by adding 4 µl of 3 M sodium 
acetate buffer solution (pH 5.2) and 100 µl of ethanol (95 %) and centrifugation (21,000 g, 4 °C, 
15 min). The DNA was purified by gentle rinsing with 100 µl of 70 % ethanol done twice. The 
DNA was carefully cleared from supernatant and dried by vacuum centrifugation for 
approximately 30 min. The linearized DNA was resuspended in 10 µl of ddH2O and stored at 
−20 °C until usage. 
 
3.3.2. Transformation of P. pastoris by electroporation, and storage 
The protocol for transformation of P. pastoris strains was adapted from the PichiaPink™ 
Expression System (Invitrogen). The commercially purchased native strains were first streaked 
on YPD complete medium and cultivated for 3−5 days (29 °C) for distinct colony formation. 
Around 1−3 colonies were inoculated in precultures of 5−10 ml of respective medium and 
grown for 20−24 h (29 °C, 220 rpm, rotary shaker). The precultures were used to inoculate 
main cultures (100 ml, 1 l-flask) and were grown to an optical density OD600 of 1.3−1.5 
(16−20 h, 29 °C, 220 rpm). The cell cultures were harvested by centrifugation (1,500 g, 4 °C, 
5 min) and washed first with 250 ml, and second with 50 ml of ice-cold, sterile water. For each 
step of washing, the cells were cleared from supernatant by centrifugation (1,500 g, 4 °C, 
5 min). The cells were subsequently washed with 10 ml of ice-cold sorbitol (1 M) and finally 
resuspended in 0.3 ml thereof. In a micro tube, 80 µl of prepared cells were mixed with 10 µl 
of linearized target plasmid (see above), transferred to a precooled electroporation cuvette, 
and kept on ice for 5 min. The cells were instantly pulsed in an electroporator for approximately 
4−5 ms (200 Ω, 2 kV, 25 µF). The cells were immediately supplied with 1 ml of YPDS medium 
and incubated for 2−4 h inside the cuvettes (29 °C). Finally, 100−300 µl of pulsed cells were 
plated on SD selection agar and incubated for 3−10 days (29 °C). Single white colonies from 
transformations were again streaked on SD plates to achieve proper colony separation. The 
plasmid integration was confirmed by colony PCR (see section 3.1.4) and suitable colonies 
were used for induced protein production by P. pastoris. 
For the long-term storage of successful transformants, single colonies were inoculated in 10 ml 




100 ml-main cultures (in YPD). The cultures were grown to an OD600 of 2.0−2.5 (29 °C, 
220 rpm) and harvested by centrifugation (1,500 g, 4 °C, 5 min). The harvested cells were 
resuspended in 25 % glycerol (in YPD) to a final OD600 of 100 and stored at −80 °C. 
 
3.3.3. Cell culture and induction of gene expression 
The protocol for induction of gene expression in P. pastoris was again adapted and modified 
from the PichiaPink™ Expression System (Invitrogen). For inducing gene expression and 
protein synthesis in transformed P. pastoris cells, single colonies of successful transformants 
(see sections 3.1.4 and 3.3.2) were picked and inoculated in precultures of 10 ml glycerol-
based BMGY medium (29 °C, 220 rpm, 20−24 h).  
For small-scale production of BSG var1-MCT1 fusion protein, the cells were inoculated in 
50 ml-main cultures and grown to an OD600 of 5.0 ± 0.5 (identical growth conditions). The cells 
were harvested by centrifugation (1,500 g, RT, 5 min) and resuspended in 50 ml of methanol-
based BMMY medium to induce protein production (OD600 = 2 at induction; 500 ml-flasks).  
For medium-scale production of MCT1 alone and under optimized growth and induction 
conditions, precultures from above were used to inoculate 200 ml-main cultures. The cells 
were grown to an OD600 of 2.0 ± 0.1, harvested (1,500 g, RT, 5 min) and resuspended in 40 ml 
of methanol-based BMMY medium to induce protein production (OD600 = 10 at induction; 
500 ml-flasks). 
After 24 h, methanol was added to a final concentration of 0.5 % to compensate for 
metabolization and vaporization. The cells were finally harvested 30−40 h after induction of 
protein biosynthesis by centrifugation (4,000 g, 4 °C, 5 min) and the protein production was 
evaluated by cell lysis (see section 3.3.4) and protein detection methods. 
 
3.3.4. Cell lysis and protein extraction from P. pastoris  
To evaluate protein production in the P. pastoris expression system, the protein extraction 
protocol was adapted from S. cerevisiae (see section 3.2.3). Due to larger cell cultures and 
higher obtained cell masses, the procedure was upscaled and the cells were resuspended in 
1 ml (small scale) or 2 ml (medium scale) of extraction buffer and cell breakage was done with 











3.4. Protein synthesis by detergent- and nanodisc-based cell-free techniques 
3.4.1. General strategy for cell-free protein synthesis 
Cell-free synthesis of proteins in the continuous exchange cell-free (CECF) system was 
adapted from [116] and established in the Beitz lab by A. Müller-Lucks [112] and S. Bock [114]. 
The expression in the CECF system uses two compartments separated by a semipermeable 
membrane. The gene transcription as well as the translation take place in the reaction mixture 
(RM) compartment and the diffusion of low-molecular weight compounds across the 
membrane allows continuous exchange of limited reaction precursors and amino acids from 
and constant removal of reaction-impeding byproducts to the feeding mixture (FM) 
compartment. During cell-free synthesis, membrane proteins demand solubilization of 
transmembrane domain structures for stabilization and proper folding. 
The CECF system used in this work relied on the in vitro transcription and translation from 
plasmid vectors pIVEX2.3w and pIVEX2.3w-GFPΔM1 encoding the gene of interest. The gene 
expression was under the control of the T7 promoter from T7 bacteriophage and is only 
induced in the presence of the T7 RNA polymerase. The necessary cell machinery (i.e. 
ribosomes and transcription/translation factors) for in vitro protein synthesis was obtained by 
the fermentation of E. coli BL21 (DE3) cells and the sedimentation of cell extracts at 30,000 g 
(S30 extract). The S30 extracts were kindly provided by L. Petersen and B. Höger and the 
protocols are described in detail elsewhere [112]. 
The protein solubilization was achieved by detergent-based (D-CF) and nanodisc-assisted 
(ND-CF) cell-free protein synthesis. The nanodiscs were produced by C. Hansen as part of his 
Master’s thesis and the methodic development and realization are described in detail therein 
[119]. In general, the protocol for preparation and assembly was adapted from Rues et al. 
[117]. The nanodiscs were produced using recombinantly expressed membrane scaffold 
protein 1E3D1 (MSP1E3D1) to encapsulate the anionic lipids 1,2-dioleoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (DOPG) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-
glycerol) (POPG) with a final nanodisc diameter of 12.1 nm [126, 127]. The assembled 
nanodiscs were added to the CECF protein synthesis reactions for co-translational 
reconstitution. The nanodisc-based cell-free protein synthesis of MCT1 constructs in this study 
was done in close cooperation with C. Hansen and in equal participation. 
 
3.4.2. Cell-free protein synthesis (analytical scale) 
The cell-free protein synthesis in an analytical scale allowed for estimations on optimal 
methodical conditions and detergent/nanodisc concentrations for an ideal protein 
reconstitution and solubilization. To evaluate successful reconstitution, GFP fusion proteins 




for proper protein folding [113]. The reaction chambers for CECF synthesis in analytical scale 
were adapted from [116] and designed in-house. A small cylindric container was sealed at the 
lower end with a dialysis membrane (14 kDa MWCO, hydrated in sterile ddH2O) secured by a 
small Teflon ring and served as the reaction mixture compartment. This compartment was 
mounted in 12-well plates containing the feeding mixture and allowed contact of both 
compartments via the semipermeable membrane. The reaction (RM) and feeding mixtures 

































Table 3.13. Pipetting scheme for CECF synthesis in an analytical scale. Listed volumes are exemplary 
for a total of (10+1) tested conditions and were accordingly adjusted for different sample amounts.   
 Stock conc. Final conc. Volume (µl) 
    
MM-M    
    
NaN3  10 % 0.05 % 50.8 
PEG 8000  40 % 2 % 508.3 
KOAc  4000 mM 150.8 mM 383.2 
Mg(OAc)2† 1000 mM 5.1 mM 51.8 
HEPES/EDTA buffer  24X 1X 372.7 
COmplete™ protease inhibitor  50X 1X 203.3 
Folinic acid  10 mg ml−1 0.1 mg ml−1 101.7 
DTT  500 mM 2.0 mM 40.7 
NTP  75X 1X 135.5 
PEP  1000 mM 20 mM 203.3 
AcP  1000 mM 20 mM 203.3 
20-Amino acid mix  4 mM 0.5 mM 1270.6 
6-Amino acid mix (RCWMDE)  16.67 mM 1 mM 609.9 
Final volume   4135.1 
    
MM-R    
    
MM-M   290.9 
DNA template* variable 0.015 mg ml−1  X 
tRNA (E. coli) 40 mg ml−1 0.7 mg ml−1 12.5 
T7 RNA polymerase 350 U µl−1 15.0 U µl−1 30.6 
RiboLock RNase inhibitor 40 U µl−1 0.3 U µl−1 5.4 
Pyruvate kinase 10 mg ml−1 0.08 mg ml−1 5.7 
S30 extract 1X 0.35X 250.3 
ddH2O (sterile)   ad 715.0‡ 
    
MM-F    
    
MM-M   3844.2 
20-Amino acid mix 4 mM 1.05 mM 1299.0 
S30 buffer 1X 0.35X 3308.0 
ddH2O (sterile)   ad 9450.0 
*For analytical scale, pIVEX2.3w-GFPΔM1 plasmids were used as template. The DNA template volumes used 
varied among plasmid preparations. †The optimal magnesium concentration for the S30 extract was determined 
beforehand by L. Petersen and B. Höger and adjusted to 10 mM. The final K+ concentration was set to 290 mM. 








Table 3.14. Preparation of reaction (RM) and feeding mixes (FM) including detergent/nanodisc supple- 
mentation. Listed volumes are exemplary for duplicate tests of each condition.  
Detergents     
 Brij®35 (5 %) Brij®58 (15 %) Brij®78 (15 %) Brij®98 (5 %) DDM (2.5 %) 
Final conc. (%) 0.2 1.5 0.8 0.2 0.1 
RM      
MM-R (µl) 118.4 118.4 118.4 118.4 118.4 
Detergent (µl) 5.2 13.0 6.9 5.2 6.5 
ddH2O (sterile) ad 130 µl 
     
FM      
MM-F (µl) 1614 1614 1614 1614 1614 
Detergent (µl) 72.0 180.0 96.0 72.0 72.0 
ddH2O (sterile) ad 1800 µl 
     
Nanodiscs*       
 DOPG-ND (320 µM) POPG-ND (290 µM) Brij®78 (15 %) 
Final conc. (µM) 15 30 60 15 30 60 0.8 % 
RM        
MM-R (µl) 99.7 99.7 99.7 99.7 99.7 99.7 99.7 
Nanodiscs / 
detergent (µl) 
6.1 12.2 24.4 6.7 13.5 26.9 6.9 
ddH2O (sterile) ad 130 µl 
       
FM        
MM-F (µl) 1614 1614 1614 1614 1614 1614 1614 
Nanodiscs / 
detergent (µl) 
- - - - - - 96 
ddH2O (sterile) ad 1800 µl 
 *MSP1E3D1-DOPG/POPG-nanodiscs were produced and kindly provided by C. Hansen. The nanodiscs were 
only added to the RM. 
 
 
Generally, a shared master mix containing components for both mixes (MM-M) was prepared. 
The individual master mixes for reaction and feeding mixes (MM-R and MM-F) were prepared 
by completing MM-M master mixes by specific compounds. For testing the reconstitution with 
different detergent and nanodisc concentrations, respective MM-F and MM-R mixes were 
supplemented with varying amounts of detergent/nanodiscs (Table 3.14). 
For each test condition, 55 µl of finalized reaction mixture were gently pipetted onto the 
semipermeable membrane in the reaction mixture chamber and immerged air-bubble free in 
850 µl of feeding mixture (volume FM:RM at 15:1). The reaction chambers were covered with 
parafilm and the protein synthesis was started by incubation at 30 °C in a shaking water bath 
(20−24 h). After synthesis, the reaction mixtures were transferred to a micro tube and kept on 




3.4.3. Cell-free protein synthesis (preparative scale) 
The CECF protein synthesis in a preparative scale was again adapted from [116] and the 
protocol and reaction chambers from analytical scale were upscaled for the synthesis of larger 
protein yields and further structural analysis of proteins. The reaction mixture volumes were 
adjusted for a total volume of 0.7−1.0 ml. For a preparative scale, pIVEX2.3w plasmid vectors 
encoding MCT1 constructs without C-terminal GFP were used as the DNA template. 
The reaction chambers containing the feeding mixture were constructed in-house and were 
built to fit Slide-A-Lyzer™ dialysis cassettes (10 kDa MWCO, 3 ml) that served as the reaction 
mixture compartment. The feeding (15.3−17.0 ml) and reaction mixtures (0.7−1.0 ml) were 
pipetted into the respective compartments (volume FM:RM at 22:1−17:1) and were incubated 
for 20−24 h at 30 °C in a shaking water bath. The reaction mixture was transferred to 15 ml-
tubes and kept on ice for roughly 1 h. Pipetting schemes for the preparation of the reaction 


























Table 3.15. Pipetting scheme for CECF synthesis in a preparative scale. Listed volumes are exemplary 
for a final reaction mixture volume of 1 ml and were accordingly adjusted for different sample volumes.   
 Stock conc. Final conc. Volume (µl) 
    
MM-M    
    
NaN3  10 % 0.05 % 90.0 
PEG 8000  40 % 2 % 900.0 
KOAc  4000 mM 150.8 mM 678.6 
Mg(OAc)2† 1000 mM 5.1 mM 91.8 
HEPES/EDTA buffer  24X 1X 660.0 
COmplete™ protease inhibitor  50X 1X 360.0 
Folinic acid  10 mg ml−1 0.1 mg ml−1 180.0 
DTT  500 mM 2.0 mM 72.0 
NTP  75X 1X 240.0 
PEP  1000 mM 20 mM 360.0 
AcP  1000 mM 20 mM 360.0 
20-Amino acid mix  4 mM 0.5 mM 2250.0 
6-Amino acid mix (RCWMDE)  16.67 mM 1 mM 1080.0 
Detergent (Brij®78) 15 % 0.8 % ‡960.0 / 0.0 
Final volume   ‡8282.4 / 7322.4  
    
MM-R (→RM)    
    
MM-M   ‡460.1 / 406.8 
DNA template* variable 0.023 mg ml−1  X 
tRNA (E. coli) 40 mg ml−1 0.7 mg ml−1 17.5 
T7 RNA polymerase 350 U µl−1 15.0 U µl−1 42.9 
RiboLock RNase inhibitor 40 U µl−1 0.3 U µl−1 7.5 
Pyruvate kinase 10 mg ml−1 0.08 mg ml−1 8.0 
S30 extract 1X 0.35X 350.0 
Nanodiscs 220 µM 30 µM ‡136.4 
ddH2O (sterile)   ad 1000.0 
    
MM-F (→FM)    
    
MM-M   ‡7822.3 / 6916.0 
20-Amino acid mix 4 mM 1.05 mM 2338.0 
S30 buffer 1X 0.35X 5950.0 
ddH2O (sterile)   17000.0 
*For preparative scale, pIVEX2.3w plasmids were used as template. The DNA template volumes used varied 
among plasmid preparations. †The optimal magnesium concentration for the S30 extract was determined 
beforehand by L. Petersen and B. Höger and adjusted to 10 mM. The final K+ concentration was set to 290 mM. 
‡For the detergent-based synthesis, Brij®78 was used and added to RM and FM (in MM-M). For the respective 
reactions of nanodisc-assisted synthesis, MSP1E3D1-POPG nanodiscs (provided by C. Hansen) were only 






3.4.4. Immobilized metal affinity chromatography (IMAC) 
For the purification of proteins carrying a C-terminal His-tag, a Ni2+-NTA affinity 
chromatography was carried out. The preparation of used purification buffers and respective 
specifications of individual buffers for detergent- or nanodisc-based analytical and preparative 
CECF synthesis are listed in detail in section 2.6.6. 
For the purification of synthesized protein in the analytical scale, 15 µl of Ni2+-NTA agarose 
bead slurry were transferred to purification columns (column volume: 7.5 µl) and washed twice 
with 1 ml of 1X purification puffer. The beads were suspended in 0.4−0.5 ml of 1X purification 
buffer and mixed with the reaction mixtures from the analytical CECF synthesis. The protein 
binding to Ni2+-NTA beads was achieved overnight (4 °C, under rotation). In purification 
columns, the beads were cleared from the purification buffer and the respective flow through 
was collected. The beads were washed twice with 75 µl of 20 mM imidazole-containing 
purification buffer to elute non-specifically bound proteins. The beads were finally incubated 
with (15 min, RT) and the protein was eluted by 80 µl of 400 mM imidazole-containing 
purification buffer. The remaining beads were finally suspended in 80 µl of 1X purification 
buffer and collected as the bead fraction.  
For the purification of synthesized protein in the preparative scale, 300 µl of Ni2+-NTA agarose 
bead slurry were transferred to Poly-Prep® chromatography columns (column volume: 150 µl; 
Bio-Rad) and washed twice with 1 ml of 1X purification buffer (no detergent). The beads were 
suspended in 4 ml of 1X purification buffer, added to the reaction mixtures from the preparative 
CECF synthesis and the samples were incubated overnight (4 °C, under rotation). In Poly-
Prep® chromatography columns, the beads were cleared from purification buffer and the flow 
through was collected. For stepwise purification, the beads were first washed with 3 ml of 
20 mM imidazole-containing purification buffer and finally with 0.75 ml of purification buffers of 
increasing imidazole concentrations (60−400 mM). The remaining beads were suspended in 
0.75 ml of 400 mM imidazole-containing purification buffer and collected as the bead fraction. 
The collected fractions were finally denatured with SDS and evaluated by SDS-PAGE and 
in-gel fluorescence, Coomassie staining or Western blotting, or further purified by size-
exclusion chromatography for structural analyses. 
 
3.4.5. Size-exclusion chromatography (SEC)  
The protein purification with size-exclusion chromatography was carried out with the 
ÄKTApurifier™ and a Superdex 200 10/30 GL column. 
Prior to injection, the fractions from IMAC including the highly purified protein of interest were 
merged and diluted with purification buffer to decrease the total imidazole concentration to 
below 100 mM. The protein was concentrated by centrifugation at 5,000 g (4 °C, 5 min) to a 




yielding concentrations of roughly 0.6−2.2 mg ml−1. The protein samples were centrifuged at 
10,000 g (4 °C, 10 min) to precipitate aggregates and larger particles, and finally injected for 
size-exclusion chromatography (flow rate: 0.35 ml min−1; eluent: 20 mM Tris, pH 8.0, 
150 mM NaCl (+ 0.05 % Brij®78)). The protein was detected by absorbance at 280 nm. 
 
3.4.6. Transmission electron microscopy (TEM) 
For the structural elucidation by negative-staining room temperature transmission electron 
microscopy (TEM), fractions from SEC were collected and analyzed by P. Arnold (Anatomical 
Institute, CAU Kiel) [128].  
The samples were transferred to negative flow discharged continuous carbon grids and excess 
volume was removed. The probes were negatively stained with 1 % (w/v) uranyl acetate 
solution and air-dried. Images were obtained at 50,000-fold magnification (2048 x 2048 pixels) 
using the JEOL JEM-1400 Plus electron microscope (acceleration voltage at 100 kV) and a 
TVIPS F416 4 kx4 k camera. Single particles were analyzed using the EMAN2 image 
processing suite [129] and categorized into class-sums. The class-sum images contained 







3.5. Further protein methods 
3.5.1. Determination of protein concentrations  
To quantify protein amounts and yields in cell lysates as well as after cell-free protein synthesis, 
the Quick Start™ Bradford Protein Assay (Bio-Rad) was used. In short, 2-8 µl of protein-
containing samples were diluted with ddH2O (final volume of 800 µl) and mixed with 200 µl of 
Roti®-Quant concentrate (5X). The samples were mixed by vortexing and incubated for 5 min 
at RT. The absorbance of samples against the zero value (solubilization buffer instead of 
protein sample) was measured at 595 nm. The quantification of protein amounts was based 
on a calibration curve of BSA standard solutions ranging from 1−14 µg ml−1. 
 
3.5.2. SDS-PAGE 
Protein samples were size-separated by discontinuous, vertical sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE).  
Polyacrylamide gels were produced in-house between a glass and a ceramic plate separated 
by spacers. First, a separation gel (see Table 3.16, pH 8.8, 12.5 % acrylamide) was cast into 
the mold and sealed by isopropyl alcohol. After polymerization, the alcohol was removed and 
the stacking gel was cast onto the separation gel (see Table 3.16, pH 6.8, 6 % acrylamide). A 
sample comb was inserted to generate sample pockets (10-12 pockets per gel). After complete 
polymerization, the comb was removed, and the gel was covered with electrophoresis buffer. 
For protein sample preparation and denaturation, the samples were mixed 3:1 with 4X SDS-
containing sample loading buffer and incubated for 30 min at 37 °C. The prepared samples 
(2−30 µl, depending on pocket size and sample protein concentrations) were loaded into the 
gel pockets and concentrated in the stacking gel (160 V, 10−15 min). The proteins were finally 
size-separated by migration in an electric field (200 V, 75−90 min). As a molecular weight size 
marker, 5 µl of prestained PeqGOLD Protein Marker III (Peqlab) were loaded. After separation, 
the gels were removed from the electrophoresis chamber, the stacking gel was detached and 
proteins were detected in the separation gel using several staining and visualization methods 
(see sections 3.5.3, 3.5.4 and 3.5.5). 
 
Table 3.16. Preparation of separation and stacking gels (for two gels). 
Component Stacking gel Separation gel 
   
ddH2O                 2.4 ml 5.25 ml 
stacking gel / separation gel 
buffer (4X) 
1 ml 3 ml 
ROTIPHORESE® Gel 40  0.6 ml 3.75 ml 
TEMED 6 µl 10 µl 
APS (10 %) 25 µl 80 µl 




3.5.3. In-gel fluorescence detection 
Protein samples including GFP fusion proteins were analyzed with in-gel fluorescence to 
evaluate the correct folding of synthesized proteins [113]. Gels from SDS-PAGE were 
transferred to thin glass plates and imaged with the Chemostar Touch ECL & Fluorescence 
Imager (INTAS Science Imaging Instruments, Göttingen) or the Lumi Imager™ F1 (Roche 
Diagnostics, Mannheim) by an excitation at 475 nm and the detection of fluorescence emission 
at 520 nm. 
 
3.5.4. Coomassie staining 
For the unspecific detection of proteins in gels from SDS-PAGE, the gels were submerged in 
Rotiphorese® Blue R solution and incubated for roughly 1 h (RT, under shaking). The gels were 
washed with destaining solution (10−30 min, RT, under shaking) to decrease background 
staining and finally rinsed with ddH2O (up to several hours) to sharpen the protein bands. The 
gels were visualized with a commercial scanner and images were modified by Photoshop® 
Elements to optimize contrast. 
 
3.5.5. Western blot  
For the specific detection of target proteins, the gels from SDS-PAGE were blotted onto PVDF 
membranes in a semi-dry procedure. The gels and methanol-activated (30 s) PVDF 
membranes were stacked between three layers of Whatman™ papers and soaked in transfer 
buffer. Blotting occurred in an electric field (17 V) for 60 min. The PVDF membranes carrying 
the transferred protein bands were subsequently submerged in 20 ml of 3 % milk powder in 
TBS-T (1 h, RT, under shaking) to block non-specific binding of antibodies. The blots were 
incubated with 10 ml of a dilution of protein-specific primary antibody overnight (4 °C, under 
shaking), rinsed three times with 10−15 ml of TBS-T (15 min per rinse, RT) and finally 
incubated with 10 ml of a dilution of horseradish peroxidase (HRP)-conjugated secondary 
antibody (1 h, RT, under shaking). All antibodies were diluted in 3 % milk powder in TBS-T 
(Penta-His antibody, 1:5,000; GFP antibody, 1:10,000; Goat anti-Mouse, 1:5,000; Goat anti-
Rabbit, 1:10,000). The blots were again rinsed three times and coated with 1 ml of Clarity™ 
ECL Western blotting substrate (1:1, Bio-Rad). The luminescence was finally detected using 
the Chemostar Touch ECL & Fluorescence Imager (INTAS Science Imaging Instruments, 
Göttingen) or the Lumi Imager™ F1 (Roche Diagnostics, Mannheim). For the manual detection 
and film exposure (P. pastoris-related Western blots), ECL chemiluminescence films were 
pressed onto Western blots in a commercial CAWO ABS cassette and the exposure times 
were manually adjusted. The exposed films were submerged in G153 developer and fixation 





3.6. Bioinformatics and statistics 
3.6.1. Sequence analysis, topology plots and protein structure models 
The DNA and protein sequences for analyses and sequence alignments were derived from the 
NCBI gene and protein databases, respectively [130]. Sequences were aligned using the 
respective tools in the NCBI database (BLAST, https://blast.ncbi.nlm.nih.gov/Blast.cgi, [130, 
131]) or in the Universal Protein Resource (Uniprot, https://www.uniprot.org/align/, [132]). The 
topology plots were generated in TEXtopo [133]. The protein structure data for SfMCT 
(PDB #6HCL [54]), human MCT2 (PDB #7BP3 [55]), basigin (PDB #3B5H [76]), and MCT1 
(PDB #7CKO and PDB #6LZ0 [103]) were received from the RCSB Protein Data Bank [134, 
135] and visualized with the PyMOL Molecular Graphics System, Version 1.7.4.1 
(Schrödinger, LLC.) and the Chimera 1.14 software [118]. The MCT1 structure models were 
calculated using SWISS-MODEL [136, 137].  
 
3.6.2. Calculation of surface potentials 
The calculations of the electrostatic surface potential were done using the PDB structure file 
#3B5H [76] for the extracellular domain of basigin variant 2. For the Poisson-Boltzmann 
electrostatics, the PDB2PQR [138, 139] and APBS tools [140] were used from within Chimera. 
The pH was set to 7.0, the protonation state assignment was done by PROPKA, and the 
PARSE forcefield was applied. Visualization was done using the Chimera 1.14 software [118]. 
 
3.6.3. Data evaluation and statistics 
The data handling for individual experiments is described in detail in each chapter. Generally, 
the biological triplicates from yeast experiments represent three independent yeast 
transformations. The technical replicates represent repetitions within the same experiment. 
The curve fittings were done with SigmaPlot (Systat Software) and the individual equations are 
stated in the corresponding chapters. Statistical significance was tested by unpaired, two-tailed 













4.1. Basigin acts as an extracellular proton and substrate antenna and drives 
intracellular L-lactate accumulation via monocarboxylate transporter 1 
Basigin acts as a chaperone to guide human monocarboxylate transporter 1 (MCT1) to the 
plasma membrane. Additionally, basigin has been suggested as a direct modulator of transport 
via MCTs although commonly used expression systems and techniques failed to confirm 
previous speculations. In this study, human MCT1 alone and in fusion with several distinct 
basigin variants were expressed in Saccharomyces cerevisiae to elucidate basigin effects at 
the domain level. Generally, an expression in S. cerevisiae profits from an easy-to-handle and 
easy-to-manipulate expression system that has already been shown to express 
monocarboxylate transporters at the plasma membrane even in the absence of an accessory 
protein [88, 104]. Moreover, a suitable Δjen1 Δady2 knock out strain is devoid of endogenous 
monocarboxylate transporters [105, 106] and – by nature – homologs of the basigin family 
[107]. To evaluate and compare transport characteristics of MCT1 with and without fusion to 
basigin, a radiolabeling-based technique was used to investigate L-lactate uptake capacities 
in the equilibrium state, transport velocities and Michaelis-Menten kinetics. 
 
4.1.1. Expression of human MCT1 in S. cerevisiae 
For the expression of human monocarboxylate transporter 1 in S. cerevisiae, the open reading 
frame (ORF) was cloned into a pDRTXa expression vector (see section 2.1.2) that allows for 
constitutive expression from the pma (plasma membrane H+-ATPase) promoter. The 
transformation of cells resulted in the expression of functional transporter even in the absence 
of an accessory protein (Figure 4.1A−C). MCT1 was present in the microsomal fraction and 
appeared as a discrete band at the calculated 58 kDa in a Western blot with a faint band of 
lower molecular weight hinting at minor protein fragmentation (Figure 4.1A and B). The protein 
detection with antibodies targeting the C-terminal His-tag (Figure 4.1A) and the N-terminal HA-
tag (Figure 4.1B) confirmed full translation and the presence of full-length protein.  
With the use of 14C-labeled substrate, the uptake of L-lactate was monitored over a time span 
of 32 min. MCT1-expressing cells gave mean values of 200 counts per minute (cpm) (0.5 min 
uptake) to 579 cpm (32 min uptake). Following data conversion (see section 3.2.5 for 
calculations) and background subtraction, this allowed for a maximum uptake of 
0.11 ± 0.01 nmol mg−1 at an initial transport rate of 0.049 ± 0.005 nmol min−1 mg−1 at a near-
neutral pH and an inward-directed gradient of 1 mM (Figure 4.1C). Control cells (−) indicated 




All derived data for MCT1 and further constructs and experiments from following sections are 




Figure 4.1. Expression and functionality of human MCT1 in S. cerevisiae. (A, B) Expression of human 
MCT1 (58 kDa) in the microsomal fraction was evaluated with SDS-PAGE and Western blotting. Protein 
was detected using a His-tag- (A) and a hemagglutinin-(HA-)tag-targeting (B) antibody. 30 µg (A) and 
5 µg (B) of total protein were loaded per lane. Microsomal fractions of non-expressing yeast cells were 
used as negative control (−). Exposure times are indicated. (C) L-Lactate uptake over time into Δjen1 
Δady2 yeast cells at pH 6.8 and a 1 mM inward gradient. Shown are curves for non-expressing cells 
(background, (○), corrected for L-lactate adhesion to filters) and cells expressing MCT1 (●). Data is 
normalized to 1 mg of cells and the background of non-expressing cells was subtracted from uptake 



















Table 4.1. Kinetic parameters  SEM of MCT1 / basigin fusion constructs (nD: not determined). 
Construct uptake rate
* 
nmol min–1 mg−1 
uptake capacity† 








MCT1 0.049 ± 0.005 0.11 ± 0.01 
(0.39 ± 0.05) 
2.8 ± 0.2 0.187 ± 0.009 1.00 ± 0.13 
+ BSG∆Ig 0.037 ± 0.004 0.11 ± 0.01 
(0.39 ± 0.03) 
2.4 ± 0.7 0.125 ± 0.037 0.59 ± 0.07 
+ BSG Ig-I 0.105 ± 0.008 0.50 ± 0.01 
(1.77 ± 0.04) 
3.9 ± 0.1 0.419 ± 0.024 1.66 ± 0.11 
+ BSG Ig-I C23S 0.012 ± 0.001 0.12 ± 0.02 
(0.44 ± 0.07) 
nD nD nD 
+ BSG Ig-I C82S 0.007 ± 0.002 0.05 ± 0.01 
(0.18 ± 0.05) 
nD nD nD 
+ BSG Ig-I/C2 0.098 ± 0.013 0.59 ± 0.01 
(2.11 ± 0.02) 
6.8 ± 3.1 0.431 ± 0.175 0.79 ± 0.06 
+ BSG var2 0.021 ± 0.002 0.51 ± 0.06 
(1.82 ± 0.20) 
1.2 ± 0.2 0.041 ± 0.006 0.58 ± 0.07 
+ BSG Glu→Gln 0.069 ± 0.006 0.25 ± 0.01 
(0.89 ± 0.04) 
nD nD nD 
+ BSG Lys/Arg→Ala 0.005 ± 0.001 0.11 ± 0.01 
(0.39 ± 0.03) 
nD nD nD 
+ BSG Lys108,111Ala 0.133 ± 0.031 0.47 ± 0.07 
(1.70 ± 0.24) 
nD nD nD 
+ BSG Arg201,203Ala 0.013 ± 0.002 0.25 ± 0.01 
(0.91 ± 0.01) 
nD nD nD 
* dependent on the number of active transporters at the plasma membrane  
† independent of the number of active transporters  
 
 
4.1.2. Transport parameters and their validity  
In S. cerevisiae, the metabolism and the formation of L-lactate is virtually absent resulting in a 
generally low endogenous intracellular concentration [108]. This allows for monitoring 
substrate influx in a so-called zero-trans setting. In a zero-trans experiment, an externally 
applied substrate gradient drives inward transport into non-loaded cells. Two main parameters 
characterize the substrate uptake over time: the initial transport rate and the maximal amount 
of substrate taken up by cells (see section 4.1.1 for values for MCT1). The initial transport rate 
ultimately depends on the existing substrate gradient, the amount of transporter present at the 
cell surface and transporter kinetics. A transporter capable of in- and outward-directed 
transport (e.g. the MCTs) will – over time – establish a steady-state of transport in which equal 
transport rates for in- and efflux result in equilibrium concentrations and a maximal L-lactate 
load inside cells. This would appear as the upper limit of a resolved uptake-over-time curve. In 
contrast to transport rates, the position of equilibrium and resulting equilibrium concentrations 
are independent of the amount of transporter available at the plasma membrane. This gives a 




In common mammalian expression systems and transport assays, cellular metabolism, cell 
viability, and technical difficulties restrict prolonged assay times (reviewed in [9]). Studies on 
the equilibrium positions are hardly possible. As a consequence, the transporter characteri-
zation is limited to initial transport rates. To validate and approve the feasibility of this study’s 
assay set-up, the methodic parameters were validated with respect to enduring transport 
activities and a repressed L-lactate metabolism, and the gathered results on transport 
characteristics were verified in different settings.  
In the yeast system, L-lactate metabolism is repressed by glucose [141]. Affirmatively, glucose-
adapted, MCT1-expressing cells from this study were transferred to medium with L-lactate as 
sole carbon source. The determined lag phase of up to 4 days (Figure 4.2A) confirmed their 
inability to rapidly metabolize L-lactate and set grounds to monitor L-lactate accumulation for 
the required longer time periods. Secondly, estimations on equilibrium positions demand 
enduring cell viability and fitness over the required time span. To confirm an adequate cell 
viability and transport activity in the applied assay conditions and buffers (19 °C, pH 6.8), the 
L-lactate uptake rates of cells subject to varying time delays in the glucose-free assay buffer 
were compared (Figure 4.2B). Although the transport rates decreased over time, cells were 
still active even after a 30 min-delay leading to a transport rate of 0.015 nmol min−1 mg−1 (33 % 




Figure 4.2. L-Lactate metabolism and viability / transport activity of S. cerevisiae Δjen1 Δady2 cells. (A) 
Growth (optical density at 600 nm) of cells expressing MCT1 (●) with 1 % L-lactate as sole carbon 
source. Growth of cells not expressing an L-lactate transporter (○) were monitored as control. (B) 
Transport rates per minute (pH 6.8, 1 mM L-lactate) of MCT1-expressing cells after 5, 15 and 30 min of 
preincubation at room temperature. Data was normalized to 1 mg cell weight and background of non-






To experimentally test the validity of the determined equilibrium position for MCT1 at room 
temperature, the uptake of L-lactate over time was additionally monitored at 30 °C (Figure 4.3). 
As expected, the equilibrium of transport was achieved slightly faster (~ 6 min) but allowed for 
a comparable total L-lactate load of 0.07 nmol mg−1 (compare to Figure 4.1C) confirming the 




Figure 4.3. L-Lactate uptake over time by MCT1-expressing cells at 30 °C. Uptake was measured at a 
pH of 6.8 and a 1 mM inward gradient of L-lactate. Data represent mean ± SEM of three technical 




In contrast, initial uptake rates depend on the number of transporters available. First attempts 
on the quantification of surface MCT1 protein via flow cytometry failed due to the lack of a 
yeast cell-approved specific MCT1-antibody. Yeast cells were successfully gated with an 
efficiency of 98.8 % (Figure 4.4A). Unfortunately, control cells not expressing MCT1 that were 
subject to primary and secondary antibody treatment showed fluorescence intensities 
comparable to those achieved by MCT1-expressing cells (Figure 4.4B). Treatment with the 
secondary antibody alone gave no signal indicating a non-specific adhesion of the primary 
antibody to the examined cells. 
To enable a direct comparison of initial rates between differentially expressed constructs, the 
membrane localization of MCT1 was finally estimated using confocal microscopy 
(Figure 4.4C). C-terminally fused green fluorescent protein (GFP) served as a detectable label. 
The confocal microscopy of a layer in the central plane of cells (as estimated by bright field 
images) showed a distribution of soluble GFP throughout the cell ((−), Figure 4.4C). Only a 
small, circular compartment, presumably representing the vacuole, excluded GFP. In contrast, 
MCT1-GFP resided mainly at the cellular rim confirming the translocation to the plasma 
membrane (MCT1, Figure 4.4C). Nonetheless, a substantial portion of MCT1-GFP appeared 
trapped at intracellular membranes. A numerical quantification at the plasma membrane was 




To estimate the membrane localization differences, the resulting value for MCT1 was set to 1 
and the quantification for additional constructs is relative to MCT1 (Table 4.1, see following 
sections). Strikingly, the C-terminal fusion with GFP led to membrane-resident but non-
functional protein. Although the trafficking seemed unaffected, a protein fusion to the 
C-terminal end of MCT1 was not tolerated elucidating a substantial role in transporter function 




Figure 4.4. Quantification of MCT1 at the plasma membrane. (A, B) Flow cytometry of MCT1-
expressing cells. (A) SSC/FSC dot plot and gating of non-expressing S. cerevisiae Δjen1 Δady2 cells. 
Side scatter (SSC, cell volume) is plotted against forward scatter (FSC, granularity) and cells gated for 
analysis are outlined (red). The gating efficiency was 98.8 %. (B) Histogram illustrating the counts per 
fluorescence intensity. Non-expressing (black) and MCT1-expressing (orange) cells were labeled with 
an anti-MCT1 primary antibody (orb312305) and an allophycocyanin (APC)-labeled secondary antibody. 
As control, non-expressing cells lacked any antibody treatment (dark gray) or were only subject to 
secondary antibody (light gray). (C) Visualization of MCT1-GFP at the plasma membrane via live-cell 
confocal microscopy. Cells expressing soluble GFP (−) and GFP fused to the C-terminus of MCT1 are 
shown. Bright field images are in the bottom row. The white scale bar indicates 10 µm. (D) L-Lactate 
uptake via the MCT1-GFP fusion construct over time (pH 6.8, 1 mM inward gradient). Background of 
non-expressing cells was subtracted, and data was normalized to 1 mg of cells. Data represent mean ± 




4.1.3. Fusion of MCT1 with its accessory protein 
The here confirmed MCT1 activity in the absence of basigin in yeast was an excellent and 
unique prerequisite to investigate the interaction and more importantly further effects on the 
transport activity of MCT1 induced via basigin. Generally, the fusion of two functionally and 
structurally different proteins enables the expression in a stoichiometric manner and excludes 
background from one of the partners acting alone. In order to investigate effects of the 
accessory protein (basigin in particular) on the transporter functionality, and additionally reveal 
the importance of the distinct domains, various fusion proteins of human MCT1 and basigin 
were generated. Starting from a minimalistic variant harboring only the transmembrane domain 
and C-terminus (named BSG∆Ig), the TM-associated extracellular Ig-like domain (Ig-I type, 
named BSG Ig-I), the N-terminal C2-type domain (named BSG Ig-I/C2) and finally the 
N-terminal signal peptide were sequentially added to give rise to the full-length, wildtype 
basigin splice variant 2 (BSG var2). All produced constructs are depicted in Figure 4.5 and are 
based on structure models for MCT1, and the crystal structure for the extracellular domain and 
schematic illustrations for the TM-region of basigin. In all cases, the C-terminus of basigin was 
fused to the N-terminal portion of MCT1. Secondary structure predictions for basigin and the 
recently published crystal structure for a bacterial MCT homolog [54] suggested a resulting 
flexible linker of a total of around 60 amino acids ensuring enough flexibility to enable a 







Figure 4.5. Schematic models of basigin-MCT1 fusion constructs. Fusion constructs of basigin 
(black/gray; PDB #3B5H; the transmembrane domain as schematic illustration) with MCT1 (orange; 
structure model based on SfMCT, PDB #6HCL). Disulfide bridges in the extracellular domain of basigin 
are shown as orange spheres and relevant cysteines are labeled. Glu218 (Glu27 in BSGΔIg) in the 
transmembrane domain of basigin is highlighted in red. The N- and C-terminal sequences of constructs 
are indicated and additionally include a hemagglutinin- and a His-tag, respectively (not shown). 
 
 
4.1.4. The transmembrane domain of basigin associates with MCT1 
The fusion of the minimalistic BSGΔIg construct to human MCT1 resulted in almost identical 
expression patterns, levels and membrane localization (Figure 4.6A, B; Table 4.1). The 
BSGΔIg fusion led to an expected band shift in the Western blot and the fusion protein was 
detected at a higher molecular weight of 67 kDa. Most importantly, the fusion of both proteins 
did not alter L-lactate uptake into cells. The maximal uptake capacity as well as the initial 
transport rate corresponded to values determined for MCT1 alone – especially when 
considering slight differences in membrane localization (Figure 4.6C, Table 4.1). To 
investigate whether basigin and MCT1 were in fact interacting, Glu27 in the transmembrane 
domain (corresponding to Glu218 in basigin splice variant 2) was mutated to a positively 
charged arginine. Previous literature proposed Glu218 to engage in the association with MCT1 
and E218R mutants failed to interact with MCT1 [57]. In this study, the expression of a BSGΔIg 




expressed and reached the plasma membrane (Figure 4.6A−C). This effect could not be 




Figure 4.6. Expression and functionality of BSGΔIg-MCT1 fusion constructs. (A) Western blot of 
microsomal fractions showing the expression of MCT1 alone (58 kDa) and fused with wildtype BSGΔIg 
(67 kDa) or the E27R point mutant. 4−6 µg of total protein were loaded per lane and protein was 
detected via a His-tag-targeting antibody. Microsomal fractions of non-expressing cells were blotted as 
control. Exposure time is indicated. (B) Confocal microscopy of the BSGΔIg-MCT1-GFP fusion 
constructs carrying C-terminal GFP. Cells expressing MCT1-GFP in fusion with wildtype BSGΔIg or the 
E27R point mutant are shown. Bright field images are in the bottom row. The white scale bar indicates 
10 µm.  (C, D) L-Lactate uptake over time (pH 6.8, 1 mM inward gradient). Shown are curves for MCT1 
fused to wildtype BSGΔIg (C, ), BSGΔIg E27R (C, ), and full length basigin variants BSG Ig-I/C2 
(D, ) and BSG var2 (D, ) carrying the corresponding point mutant (E27 ≙ E198 in BSG Ig-I/C2 and 
E218 in BSG var2). Data was normalized to 1 mg cell weight and background of non-expressing cells 
was subtracted. As a reference, uptake via MCT1 alone is indicated as dashed line. Data represent 






The abolishment of transporter function via a mutation in the adjacent basigin, e.g. due to an 
induced conformational change, demonstrated the importance of proper transmembrane 
interaction in the basigin-MCT1 fusion protein. Nonetheless, an effect on transport via MCT1 
was not observable. 
Strikingly, the fusion to a minimalistic variant of embigin as the not preferred but alternative 
partner of MCT1 led to only marginally expressed MCT1 (Figure 4.7A). The resulting low 




Figure 4.7. Expression and functionality of EMBΔIg-MCT1 fusion constructs. (A) Western blot (30 µg of 
total protein per lane, detection via a His-tag-targeting antibody, exposure time is indicated) and (B) 
L-lactate uptake (pH 6.8, 1 mM inward gradient) of MCT1 fused to a minimalistic variant of embigin 
(+ EMBΔIg, 68 kDa). Data was normalized to 1 mg cell weight and background of non-expressing cells 
was subtracted. As a reference, uptake via MCT1 alone is indicated as dashed line. Data represent 
mean ± SEM of three technical replicates. 
 
 
4.1.5. The Ig-I domain of basigin drives inward-directed transport via MCT1 
Next, the membrane-proximal Ig-I and the N-terminal Ig-C2 domains of basigin were 
sequentially added to investigate whether an effect on MCT1 transport depends on the 
presence of basigin’s extracellular domains. The generated fusion proteins were less well 
expressed but reached the plasma membrane (Figure 4.8A, B). Generally, the MCT1 fusion to 
basigin variants led to a more or less apparent shift to higher molecular weights (Figure 4.8A). 
The calculated molecular weights expected for each construct can be found in the figure 
legend. In addition to the expected protein fragment at around 30 kDa, additional bands 
mirroring MCT1 alone hints at a minor breakage in the linking sequence between both proteins. 




microscopy (Figure 4.8B, Table 4.1). The apparent differences largely account for differences 
in the determined initial transport rates (Figure 4.8C, D, summarized in Table 4.1). Strikingly, 
the presence of the TM-adjacent Ig-I domain (+ BSG Ig-I) led to an altered L-lactate transport 
profile manifesting in a 4.5-fold total uptake into the cells compared to MCT1 alone 
(0.50 nmol mg−1, Figure 4.8C, Table 4.1). Noteworthy, despite differences in the transport 
rates, the constructs including the second, N-terminal Ig-like domain (BSG Ig-I/C2 and 
BSG var2) allowed for almost identical L-lactate loads accumulated within the cells 
(Figure 4.8D, Table 4.1). Due to low expression levels at the cell surface and low transport 













Figure 4.8.  Expression and functionality of BSG-MCT1 fusion constructs carrying the extracellular 
Ig-I domain. (A) Western blot of microsomal fractions showing expression of MCT1 alone (58 kDa) and 
fused to BSGΔIg (67 kDa), BSG Ig-I (77 kDa), BSG Ig-I/C2 (85 kDa) and BSG var2 (87 kDa). 5 µg of 
total protein were loaded per lane. Protein was detected via a His-tag-targeting antibody. Microsomal 
fractions of non-expressing cells were used as control. Exposure time is indicated. (B) Visualization of 
the BSG-MCT1 fusion constructs at the plasma membrane via live-cell confocal microscopy and 
C-terminally fused GFP. Bright field images are in the bottom row. The white scale bar indicates 10 µm. 
(C, D) Uptake of L-lactate into cells over time (pH 6.8, 1 mM inward gradient). Shown are curves for 
MCT1 fused to BSG Ig-I (C, ), BSG Ig-I/C2 (D, ▼) and BSG var2 (D, ▲). Data was normalized to 1 mg 
cell weight and background of non-expressing cells was subtracted. As a reference, uptake via MCT1 
alone is indicated as dashed line. Note the different scaling when comparing to Figure 4.1C and 
Figure 4.6C. Data represent mean ± SEM of three biological replicates. 
 
 
An additional, less prevalent basigin splice variant (BSG var1) that carries a third Ig-like domain 
was poorly expressed and showed only residual transport activity (Figure 4.9A and B). A fusion 
construct with full-length embigin variant 1 was equally low in activity which obstructed 







Figure 4.9. Expression and functionality of BSG var1/EMB var1-MCT1 fusion constructs. (A) Western 
blot (30 µg of total protein per lane, detection via a His-tag-targeting antibody, exposure time is indicated) 
and (B) L-lactate uptake over time (pH 6.8, 1 mM inward gradient) of MCT1 fused to BSG var1 
( , 100 kDa) and full-length EMB var1 ( , 95 kDa). Data was normalized to 1 mg cell weight and 
background of non-expressing cells was subtracted. As a reference, uptake via MCT1 alone is indicated 




In conclusion, the presence of the extracellular Ig-I domain of basigin increased the intracellular 
load of L-lactate that was achieved in the equilibrium state of transport. To corroborate the 
results, several attempts were made to prevent a basigin-MCT1 interaction and reverse 
basigin-mediated effects. Acriflavine is a chemical agent that has been shown to bind to the 
extracellular domain of basigin leading to the inability to interact with MCTs [98]. Here, 
BSG Ig-I-MCT1-expressing cells were pretreated with acriflavine. Nonetheless, acriflavine 
failed to modulate the basigin-related effect on MCT1 functionality in this study (Figure 4.10A). 
Although acriflavine reduced the amount of L-lactate that was taken up after 4 min, the cells 
expressing MCT1 alone and in fusion with BSG Ig-I were similarly affected hinting at a non-
specific, presumably yeast-toxic effect [142, 143].  
The Ig-like domains of basigin have a distinct and functionally essential folding consisting of 
two β-sheets connected via a disulfide bridge (marked as orange sticks in Figure 4.5). The 
pretreatment with dithiothreitol (DTT) as a disulfide-reducing agent did also not decrease the 
capability of BSG Ig-I-MCT1-expressing cells to accumulate L-lactate (Figure 4.10B, compare 
to Table 4.1). The uptake of 0.172 nmol mg−1 after 4 min (10 mM DTT) was comparable to 
non-treated cells and much higher than the uptake capacities at all achievable by MCT1-
expressing cells not interacting with basigin. Finally, single serine mutants of both cysteines 




corresponding to Cys126 and Cys185 in splice variant 2) were generated (Figure 4.10C, D). 
Although the mutants were well expressed (Figure 4.10C), the prevention of disulfide formation 
in basigin led to low intracellular L-lactate loads comparable to those obtained for MCT alone 
or in combination with the truncated BSG∆Ig construct (Figure 4.10D, Table 4.1). This 
confirmed the necessity of a correctly folded Ig-I domain of basigin to drive cytosolic L-lactate 




Figure 4.10. Reversal of BSG Ig-I-mediated effects on L-lactate uptake via MCT1. (A) Acriflavine 
treatment. Cells expressing MCT1 alone and in fusion with BSG Ig-I with (+) or without (−, solvent 
instead) acriflavine pretreatment (1 mM, 15 min, RT). (B) DTT treatment. Cells expressing the BSG Ig-I-
MCT1 fusion construct with (+) or without (−, solvent instead) DTT pretreatment (1 mM / 10 mM, 15 min, 
RT). For (A) and (B), bars delineate subsequent uptake of L-lactate (pH 6.8, 1 mM inward gradient) after 
4 min. Data was normalized to 1 mg cell weight and background of non-expressing cells was subtracted. 
Data represent mean ± SEM of three technical replicates. (C) Western blot (5 µg of total protein per 
lane, detection via a His-tag-targeting antibody, exposure time is indicated) and (D) L-lactate uptake 
(pH 6.8, 1 mM inward gradient) of MCT1 fused to the BSG Ig-I mutants C23S ( ) and C82S ( ) (77 kDa, 
arrow in Western blot). Data was normalized to 1 mg cell weight and background of non-expressing 
cells was subtracted. As a reference, uptake via MCT1 alone is indicated as dashed line. Data represent 




4.1.6. Michaelis-Menten kinetics and the use of protons 
To investigate the nature of transport modulation by basigin, the Michaelis-Menten kinetics 
were determined for the zero-trans influx of L-lactate at pH 6.8 (Figure 4.11A, B). All obtained 
𝐾𝑚 and 𝑣𝑚𝑎𝑥 values are summarized in Table 4.1. Due to low transport rates, estimations on 
the 𝐾𝑚 value for BSG var2-MCT1 were largely error prone. For MCT1 alone, the obtained 𝐾𝑚 
value of 2.8 mM is comparable to previous literature (3.5 mM determined in Xenopus oocytes 
[50]). Of note, in Xenopus oocytes, endogenous basigin will be associated with MCT1. The 
fusion to BSG Ig-I led to a significant increase to a 𝐾𝑚 of 3.9 mM (p = 0.01, unpaired, two-
tailed t-test). Nonetheless, the required extrapolation of the curve’s upper limits imply imprecise 
𝐾𝑚 determinations. To this end, accurate maximum velocity (𝑣𝑚𝑎𝑥) determinations were 
likewise challenging but values appeared largely unaffected. The observed 2.2-fold increase 
in 𝑣𝑚𝑎𝑥 (0.419 nmol min
−1 mg−1 (+ BSG Ig-I) compared to 0.187 nmol min−1 mg−1 (MCT1)) is 
explainable by the almost equal difference in membrane localization (1.7-fold increase for 
+ BSG Ig-I, Table 4.1). Yet, the apparent lower substrate affinity of MCT1 (higher 𝐾𝑚) when 
accompanied by BSG Ig-I points at an altered substrate availability with respect to the overall 
buffer concentrations.  
As already mentioned, protons are the respected co-substrate of MCT1-mediated L-lactate 
transport. To estimate the overall pH gradient at the given extracellular pH, colleague 
N. H. Epalle loaded expressing cells with a fluorescent pH indicator (according to [144]) and 
determined a near-neutral cytosolic pH for all cells. Upon the addition of L-lactate, the pH 
stabilized at a cytosolic pH of 6.3−6.5 for all constructs demonstrating the efficient endogenous 
pH regulation of yeasts. The knowledge of the cytosolic pH revealed a slightly outward directed 
pH gradient (≈ 0.16 µM [H+]external vs. ≈ 0.4 µM [H+]internal; outward gradient: 2.5). Lowering the 
outside buffer pH to 5.8 to provide more protons and generate an inward directed gradient led 
to a general increase of the intracellular L-lactate load according to Le Chatelier’s principle 
(Figure 4.11C, 1.6 µM [H+]external; inward gradient: 4.0). Still, a fusion to BSG Ig-I favored 
L-lactate influx. Nonetheless, this effect was less prominent at pH 5.8 leading to an only 2.2-fold 
higher intracellular L-lactate load compared to MCT1 alone (Figure 4.11D; compare to 4.5-fold 






Figure 4.11. The effect of substrate and proton concentrations on MCT1-mediated transport. (A, B) 
Michaelis-Menten kinetics for (A) MCT1 alone ( ) and fused to BSG Ig-I ( ) and (B) remaining basigin 
fusion constructs. Initial transport rates result from single time point measurements of L-lactate uptake 
for 2 min (pH 6.8, inward gradient from 1−10 mM). Data represent mean ± SEM of three biological 
replicates. 𝐾𝑚 values (in mM) were determined by three independent exponential fits of three biological 
replicates and are given in mean ± SEM. (C) L-Lactate uptake via MCT1 alone and fused to BSG Ig-I at 
pH 5.8 (1 mM inward gradient). (D) Uptake capacities of cells expressing MCT1 alone (orange) and 
fused with BSG Ig-I (black) at pH 6.8 (based on data from Figure 4.1C and Figure 4.8C) and pH 5.8 
(data from C). Significance was tested by an unpaired, two-tailed t-test (**p < 0.01, ***p < 0.001). In all 
cases, data was normalized to 1 mg of cell weight and background of non-expressing cells was 
subtracted. Data represent mean ± SEM of three biological replicates. 
 
 
4.1.7. Basigin drives L-lactate uptake to concentrations exceeding the inward gradient 
To estimate equilibrium substrate concentrations inside the cell, the uptake capacities in 
nmol mg−1 were translated to intracellular molar concentrations. As part of her dissertation, 
A. Jansen expressed two known and well-characterized glycerol-conducting channel proteins, 
namely murine and human aquaporins (AQP) 7 and 9, in S. cerevisiae. Channels facilitate the 




[145]. A. Jansen loaded cells with 14C-labeled glycerol using a 1 mM inward gradient and 
determined an uptake capacity of 0.28 nmol mg−1 that corresponds to a cytosolic concentration 
of 1 mM. Using this correlation, the uptake capacities for L-lactate of all constructs in this study 
(from Table 4.1) were translated to cytosolic concentrations in mM. Assuming the outside 
buffer volume to be infinitely larger than the total cytosolic volume, the outside L-lactate 
concentration (1 mM) is considered constant. Accordingly, the equilibrium position for L-lactate 
for all constructs can be displayed as the ratio of internal and outside equilibrium 
concentrations (ceq_in / ceq_ex, Figure 4.12A). For MCT1 alone and in fusion with the truncated 
basigin variants, the intracellular accumulation of L-lactate reached concentration ratios 
between 0.18-0.44. Strikingly, the fusion with basigin constructs carrying the Ig-I domain 
enabled the cells to accumulate L-lactate to cytosolic concentrations higher than those 
accomplished by channel-facilitated diffusion and well above those achieved by MCT1 alone. 
An accumulation to concentrations exceeding the inward gradient for L-lactate 
(ceq_in / ceq_ex = 1.8–2.1, Table 4.1) demonstrates that basigin drives an intracellular 
accumulation of L-lactate via its Ig-I domain – possibly by affecting the local L-lactate and/or 
proton availability. 
Considering the previously determined pH gradients (see section 4.1.6), the equilibrium 
constants 𝐾 for all constructs were determined (Figure 4.12B). For MCT1 alone and in fusion 
with the basigin constructs lacking the Ig-I domain, the system was in equilibrium 
(𝐾 ≈  1 =  (ceq_ in ∙  [H
+]eq_in) / (ceq_ex ∙ [H
+]eq_ex)). The presence of the membrane-proximal Ig-I 
domain of basigin led to a disturbance of the system and an apparent equilibrium constant 
𝐾𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 of 4.5 (for BSG Ig-I-MCT1). Thermodynamically, such a disturbance would arise from 
basigin creating a microenvironment of locally increased proton/substrate availability at the 





Figure 4.12. Shifted intracellular L-lactate concentrations and transport equilibrium. (A) L-Lactate 
transmembrane distribution generated by the expression of MCT1 alone (orange) and in fusion with 
basigin variants (black). Shown is the ratio of intracellular and extracellular molar L-lactate 
concentrations at equilibrium. Data represent mean ± SEM of three biological replicates. Significance in 
relation to MCT1 alone was determined by an unpaired, two-tailed t-test (*p < 0.05, ***p < 0.001). (B) 
Equilibrium constants. The internal and external L-lactate (ceq_in, ceq_ex) and proton concentrations 
([H+]eq_in, [H+]eq_ex) determine the equilibrium constant 𝐾. Respective 𝐾 values for basigin-MCT1 fusion 
constructs indicate an equilibrative (𝐾  1) or an accumulating effect (𝐾𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 > 1) on intracellular 
L-lactate with respect to the overall buffer concentrations. 
 
 
To evaluate the physiological relevance, expressing cells were grown on media supplemented 
with L-lactate as sole carbon source (Figure 4.13). The growth was monitored over a time span 
of 12 days and showed only minor colony formation of cells expressing MCT1 alone or in 
association with the truncated or misfolded basigin variants (BSGΔIg, BSG Ig-I C23S/C82S) 
at pH 5.8 as well as pH 6.8. Moreover, the growth was comparable to control cells lacking 
L-lactate transporters. In line with the biophysical results, the presence of basigin variants 





Figure 4.13. Physiological relevance of basigin-driven L-lactate influx. Growth of cells expressing MCT1 
and basigin-MCT1 fusion variants on agar medium containing 2 % sodium L-lactate at pH 5.8 (left) and 
pH 6.8 (middle), or on 2 % glucose medium (growth control; right). Cell suspensions (5 μl) were spotted 
in ten-fold serial dilutions (left to right) from a starting OD600 of 1. 
 
 
4.1.8. Impact of glucose on L-lactate transport via basigin-MCT1 fusion proteins 
Glucose is the key substrate for glycolysis and energy metabolism in yeast. The metabolisms 
of glucose and L-lactate are tightly linked. As part of an attempt to ensure cellular fitness during 
transport assays (see section 4.1.2), the standard buffer compositions were supplemented 
with 2 % (= 110 mM) glucose. Although not prolonging cellular viability, the glucose availability 
during cell preparation and uptake measurements had an impact on L-lactate accumulation of 
cells (Figure 4.14A). The total uptake via MCT1 alone as well as in fusion with BSG Ig-I 
reached a maximum after 2 min leading to uptake capacities below those achieved in glucose-
deprived conditions. For MCT1 alone, the L-lactate influx was only slightly altered giving a 
cytosolic load of 0.04 nmol mg−1. The fusion to BSG Ig-I, in contrast, failed to promote the 
previously disclosed increased influx of substrate leading to uptake capacities almost identical 
to those of unfused MCT1. Strikingly, a short-term exposure (15 min) to more physiological 
glucose concentrations just prior to conducting the assay failed to affect the L-lactate uptake 
(Figure 4.14B). This excluded glucose as a direct MCT1 inhibitor or competitor and points at a 







Figure 4.14. Impact of glucose on L-lactate uptake via MCT1. (A) L-Lactate uptake (pH 6.8, 1 mM inward 
gradient) via MCT1 alone ( ) and in fusion with BSG Ig-I ( ). In contrast to previous measurements, 
cells were supplied with 2 % glucose during preparation and in the uptake assay. Data was normalized 
to 1 mg cell weight. As a reference, uptake via MCT1 alone under glucose-deprived conditions is 
indicated as dashed line. (B) Percental L-lactate uptake of expressing cells pretreated with 25 mM 
glucose (15 min, RT) compared to solvent-exposed cells. Shown are percentages for MCT1 alone and 
in fusion with BSG Ig-I after monitoring L-lactate uptake in the initial (2 min) and in the equilibrating 
(8 min) phase of transport. For (A) and (B), background of non-expressing cells was subtracted, and 
data represent mean ± SEM of two technical replicates. 
 
 
4.1.9. Basigin acts as an electrostatic proton and substrate antenna 
To investigate how basigin modulates MCT1-driven L-lactate influx, the Poisson-Boltzmann 
electrostatics of the extracellular domain were calculated using the available crystal structure 
data (PDB #3B5H, Figure 4.15). The membrane-proximal Ig-I domain of basigin shows a 
negatively charged patch of five clustered glutamates (Glu114,118,120,168,172) suited for an 
electrostatic proton attraction (Figure 4.15, left). Strikingly, this domain displays another, 
positively charged patch consisting of up to six clustered arginine and lysine residues 
(Lys108,111,127 and Arg166,201,203) possibly suited to serve as an additional substrate 





Figure 4.15. Electrostatic surface potential of the extracellular domain of basigin. The Poisson-
Boltzmann electrostatic potential of the extracellular domain of BSG var2 (PDB #3B5H) reveals two 
oppositely charged surface patches suited for proton/L-lactate attraction in the BSG Ig-I domain. The 
red/blue scale covers the range of –3 kT/e to +3 kT/e. Relevant residues for each patch are indicated. 
 
 
The mutation of the five glutamates to non-charged glutamines (BSG Ig-I Glu→Gln) 
neutralized the negative patch as displayed in Figure 4.16A. The mutant was functionally 
expressed but provoked a drop in the uptake capacity when fused to MCT1 (Figure 4.16A, B). 
The cytosolic concentration reached 0.89 mM L-lactate inside the cells (Table 4.1). This hinted 
at basigin as an electrostatic proton collector pooling the co-substrate at the transporter surface 
and driving inward-directed flux of the accompanied L-lactate. Notably, the removal of the 
negative charges did not fully decrease the uptake capacity to the MCT1 base level (lower 
dashed line of Figure 4.16A). This is suggestive of a second, additive effect probably deriving 
from the positive patch acting as a substrate harvesting antenna. Neutralizing the positive 
patch by mutating all respective lysines/arginines to alanines (named BSG Ig-I 
Lys/Arg→Ala + R166A) led to the expression of non-functional protein (Figure 4.16B, C). In 
cooperation with K. Geistlinger, the putative ion-bridge forming arginine at position 166 was 
reintroduced and reinstated functionality (Figure 4.16B, C). The resulting electrostatic surface 
potential of the corresponding BSG Ig-I Lys/Arg→Ala construct is shown in Figure 4.16C and 
highlights a strong negative overall charge of the BSG Ig-I domain. A removal of the positive 
patch fully decreased the uptake capacity to that achieved by non-fused MCT1 (Figure 4.16C, 
Table 4.1). A partial abrogation of the positive patch (constructs BSG Ig-I K108,111A and 
BSG Ig-I R201,203A) led to a partial decrease. Here, the membrane-proximal Arg201 and 
Arg203 unveiled as especially relevant (Figure 4.16D, Table 4.1, conducted by K. Geistlinger).  
Overall, the results ascribe a new role to basigin in MCT1 functionality. Apparently, the 
membrane-proximal Ig-I domain serves as a proton and substrate harvesting antenna to create 




surface and drives L-lactate influx according to Le Chatelier’s principle. This allows for 
apparent thermodynamic equilibrium constants 𝐾 > 1 driving L-lactate influx to concentrations 




Figure 4.16. Effect of neutralizing the charged patches in the BSG Ig-I domain on overall surface 
potentials and L-lactate transport via fused MCT1. (A) The five Glu residues of the negative patch were 
mutated to Gln. The resulting surface potential as well as the L-lactate uptake of cells expressing 
BSG Ig-I Glu→Gln fused to MCT1 is shown. (B) Western blot (10 µl per lane) of the microsomal fractions 
for all mutant constructs. Protein was detected via a His-tag-targeting antibody. Microsomal fractions of 
non-expressing cells were used as control. The exposure time is indicated. (C) The Lys/Arg residues of 
the positive patch were mutated to Ala. The resulting surface potential as well as the L-lactate uptake of 
cells expressing MCT1 fused to the BSG Ig-I mutant Lys/Arg→Ala without ( ) and including ( ) the salt 
bridge-associated R166A mutation (+R166A) is shown. (D) Stepwise mutation of Lys/Arg residues of 
the positive patch and L-lactate uptake of MCT1 fused to the mutants BSG Ig-I K108,111A ( ) and 
R201,203A ( ). In all cases, L-lactate uptake over time was monitored (pH 6.8, 1 mM inward gradient) 
and displayed in nmol mg−1 (left axis) and mM (right axis). The dashed lines indicate the corridor 
between uptake of MCT1 alone (lower border) and fused to wildtype BSG Ig-I (upper border). Data 
represent mean ± SEM of three biological replicates. Data for constructs BSG Ig-I Lys/Arg→Ala, 




4.2. Cys159: a target for cysteine-modifiers in the MCT1 hinge region  
In common mammalian or Xenopus oocyte expression systems, either the expression of 
endogenous basigin variants or an insufficient targeting of MCTs in their absence interferes 
with resolving basigin-independent MCT1 characteristics. The results from section 4.1. have 
demonstrated a functional expression of human MCT1 in the absence of an accessory protein 
in S. cerevisiae. This gave the unique opportunity to investigate specific MCT1 characteristics 
and inhibitor sensitivities without basigin interference. The functional fusion to basigin then 
allowed to unveil the distinct involvement of basigin in MCT1 inhibitor efficacy. MCT1 alone 
and in fusion with basigin exhibited transport activities that allowed for inhibitory studies and 
the determination of initial transport rates from single time point measurements. According to 
the uptake-over-time curves from section 4.1., measurements after 2 min appeared most 
suitable. Transport activities in % were then derived from relating transport rates of substance-
treated and solvent-treated cells. The testing for basigin effects was done with the most active 
BSG Ig-I/C2-MCT1 fusion construct carrying both Ig-like domains (see Figure 4.5) which is 
now referred to as BSG-MCT1. 
 
4.2.1. AZD3965 and pCMBS are direct inhibitors of MCT1 
AstraZeneca developed a potent inhibitor of human monocarboxylate transporter 1, namely 
AZD3965 [100]. To date, the specific mode of action was unresolved as well as the significance 
of basigin for inhibitor potency. Here, MCT1-expressing yeast cells were pretreated with 
increasing concentrations of AZD3965 and resulting transport rates were determined. The 
results identified AZD3965 as a potent and direct inhibitor of MCT1 with a determined IC50 
value of 96 ± 2 nM (Figure 4.17A). Basigin as the interacting partner did not significantly affect 
inhibitor potency (IC50 at 118 ± 15 nM, see Figure 4.17B, unpaired, two-tailed t-test, p > 0.05). 
See Figure 4.17C for the chemical structure of AZD3965. The L-lactate transport via 






Figure 4.17. Inhibition of MCT1-mediated L-lactate transport by AZD3965. (A, B) IC50 curves showing 
the % activity of L-lactate transport by MCT1 alone (A) and fused to basigin (B). Expressing cells were 
pretreated with increasing concentrations of AZD3965 (15 min, RT). L-lactate uptake rates were 
determined in the initial phase of transport (2 min). For % activities, transport rates of inhibitor-treated 
cells were related to solvent-exposed cells. Background of non-expressing cells was subtracted, and 
data represent mean ± SEM of three technical replicates. To confirm IC50 values, the activity at 100 nM 
represents mean ± SEM of 9 technical replicates including three biological replicates. (C) Chemical 
structure of the MCT1 inhibitor AZD3965. (D) L-Lactate uptake rates of cells expressing plasmodial 
PfFNT with (+) and without (−) pretreatment with AZD3965 (500 nM, 15 min). Background of non-
expressing cells was subtracted, and data represent mean ± SEM of three biological replicates. 
 
 
The organomercurial p-chloromercuribenzene sulfonate (pCMBS) (Figure 4.18A), on the other 
hand, has been suggested as an indirect inhibitor of MCT activity via covalent modification of 
its accessory protein basigin [70]. Noteworthy, pCMBS is known for the inhibition of transport 
via MCT1 and 4, but not MCT2 [146]. The exact mode of action remained unclear. In this study, 
the modification of MCT1-expressing cells revealed pCMBS as a direct inactivator of MCT1 
(Figure 4.18B). In the absence of basigin, a time-dependent inhibition of L-lactate uptake 
resulted in an almost complete inactivation after 15 minutes. The fusion to basigin did not alter 




(Figure 4.18C). The advantage of basigin-independent MCT1 expression and functionality in 
yeast therefore allowed to reveal a sensitivity of MCT1 towards cysteine-modifying compounds 





Figure 4.18. Inhibition of MCT1-mediated L-lactate transport by pCMBS. (A) Chemical structure of 
p-chloromercuribenzene sulfonate (pCMBS). (B, C) Cells expressing MCT1 alone (B) and in fusion with 
BSG (C) were preincubated with pCMBS (30 µM, RT) for 5 and 15 min. Shown is the percental L-lactate 
uptake activity in the initial phase of transport (2 min) compared to solvent-exposed cells. Background 
of non-expressing cells was subtracted, and data represent mean ± SEM of three biological replicates.  
 
 
4.2.2. Cys159 of MCT1 is solvent-accessible and the sole target for pCMBS 
The membrane-impermeable pCMBS is known for its reactivity and the covalent modification 
of solvent-accessible cysteine residues in proteins. MCT1 contains 12 cysteines in total 
(highlighted in red/blue/green in Figure 4.19). The exclusion of all cysteines previously 
disqualified as the target for pCMBS inhibition of MCT1 (Cys106,188,189 [70]; colored blue in 
Figure 4.19A) and limiting the potential cysteines to those existing in both pCMBS-sensitive 
MCT members MCT1 and 4 (see Figure 4.19B for sequence alignment) unveiled Cys159 






Figure 4.19. MCT1 structure models in the inward and outward open conformations. (A) MCT1 was 
modeled onto the cryo-EM/crystal structures of human MCT2 (inward open, PDB #7BP3, left) and the 
bacterial MCT homolog SfMCT (outward open, PDB #6HCL, right), respectively. Models are shown in 
side-view (from inside the plasma membrane, top) and in top-view (from the extracellular space, bottom). 
All existing cysteines are highlighted in red, blue (cysteines mutated in [70]) and green (Cys159). Sulfur 
atoms are colored yellow. (B) Sequence alignment of human MCT1−4. Cys159 in MCT1 is marked 
green and respective residues in other MCT members are highlighted in green/black. 
 
 
The recently published structures of human MCT2 [55] and the bacterial homolog SfMCT [54] 
enabled structure modeling in the inward and outward open conformations. Strikingly, Cys159 
sits in a central position of the extracellular binding pocket of MCT1 that appears as a possible 
hinge region of MCT1. Although buried in the closed conformation (MCT2-based model), 
structural reorientation exposes Cys159 as a solvent-accessible residue in the outward open 
conformation (SfMCT-based model). Cys159 was mutated to serine (C159S) in this study and 
the resulting protein expression levels and transport rates were comparable to the wildtype 
protein (Figure 4.20A and B; compare to Table 4.1). The slightly lower transport rates most 





Figure 4.20. Expression and L-lactate transport of MCT1 Cys159 mutants. (A) Western blot of 
microsomal fractions from cells expressing wildtype MCT1 and C159S mutants alone and in fusion with 
BSG (arrowhead). 5 µg of total protein were loaded per lane. Protein was detected via a His-tag-
targeting antibody. Microsomal fractions of non-expressing cells served as control. Exposure time is 
indicated. (B) Initial transport rates of cells expressing MCT1 C159S alone and in fusion with BSG. 
Rates for L-lactate uptake were determined in the initial phase of transport (2 min) and normalized to 
1 mg cell weight. Background of non-expressing cells was subtracted. Data represent mean ± SEM of 
three biological replicates.  
 
 
Strikingly, the C159S mutation rendered MCT1 insensitive to a modification by pCMBS 
(Figure 4.21). Even a prolonged incubation for 15 min did not reduce the transport activity. The 
fusion with basigin did not rescue inhibitor sensitivity again confirming its irrelevance for 




Figure 4.21. Treatment of MCT1 C159S mutants with pCMBS. Cells expressing the MCT1 C159S 
mutant alone and in fusion with BSG were preincubated with pCMBS (30 µM, RT) for 15 min. Shown is 
the percental L-lactate uptake activity in the initial phase of transport (2 min) compared to solvent-
exposed cells. Background of non-expressing cells was subtracted, and data represent mean ± SEM of 




MCT1 in rat erythrocytes (rMCT1) has previously been shown as being non-reactive towards 
pCMBS [70]. This has been attributed to its close association with embigin rather than basigin. 
An alignment of rat and human MCT1 revealed rMCT1 as a natural C159S variant 
(Figure 4.22A). Rat MCT1 has already been shown to be functionally expressed in yeast [104]. 
Here, rMCT1 was expressed in S. cerevisiae although the minor expression level 
(Figure 4.22B) allowed a low initial transport rate of 0.004 ± 0.001 nmol min−1 mg−1 in the 
absence of an accessory protein (Figure 4.22C). Nonetheless, in contrast to human MCT1, 





Figure 4.22. Expression, functionality, and treatment of rMCT1-expressing cells with pCMBS. (A) 
Sequence alignment of human and rat MCT1. Cys159 in MCT1 (green) and the respective serine in rat 
MCT1 (black) are indicated. (B) Western blot of microsomal fractions showing the expression of rMCT1 
(arrowhead) in S. cerevisiae. 5 µg of total protein were loaded per lane. Protein was detected via a His-
tag-targeting antibody. Microsomal fractions of non-expressing cells served as control. The exposure 
time is indicated. (C) Initial transport rates for L-lactate uptake of rMCT1-expressing cells with (+) and 
without (−, ddH2O) pretreatment with pCMBS (30 µM, 15 min) were determined in the initial phase of 
transport (4 min) and normalized to 1 mg cell weight. Background of non-expressing cells was 
subtracted, and data represent mean ± SEM of three biological replicates.  
 
 
4.2.3. Smaller thiosulfonates allow for only partial inhibition of MCT1 
pCMBS as a very bulky compound blocked MCT1-mediated transport completely and 




modification of reactive cysteines with a set of methanethiosulfonate (MTS) reagents differing 
in size, charge and membrane permeability is a common tool to directly alter protein 
characteristics and structural properties without dealing with changed expression levels that 
accompany amino acid substitutions. MTS reagents are usually applied at concentrations of 
1 to 10 mM and allow for complete and – in the absence of reducing agents – irreversible 
conversion of reactive cysteines to the corresponding disulfide in a 1 to 5 min time range. Four 
non-charged MTS reagents of different size (Figure 4.23A) were tested to investigate their 
effect on MCT1-mediated L-lactate transport. Strikingly, all tested substances (1 mM, 
pretreatment for 5 min at RT) decreased the initial transport rates to a residual activity between 
46-75 % (Figure 4.23B). The apparent differences in the efficacy most likely arise from varying 
reactivity and/or accessibility between compounds. Nonetheless, none of the substances was 
able to completely inactivate MCT1 at the applied assay conditions. 2-Sulfonatoethyl methane-
thiosulfonate (MTSES) as a medium-sized, negatively charged compound showed no activity 
towards MCT1. Most importantly, even methyl methanethiosulfonate (MMTS) as the smallest, 
non-charged member introducing only a thiomethyl group decreased the MCT1 activity to 
57 ± 7 %. A prolonged incubation (up to 15 min) with MMTS did not have further effects 
indicating the complete conversion of cysteines. Thereby, a complete transporter inactivation 
could not be achieved with the small-sized MMTS. This hints at a mechanism in which a 
modification of the transporter hinge serves as a wedge and locks the transporter size-





Figure 4.23. Treatment of MCT1-expressing cells with methanethiosulfonate (MTS) reagents. (A) 
Chemical structures of methyl MTS (MMTS), propyl MTS (PMTS), benzyl MTS (BMTS), 
2-sulfonatoethyl MTS (MTSES) and MTS-4-fluorescein (FMTS). The mutual core structure (framed) and 
the respective cysteine-transferred moieties of each reagent are indicated. (B) Cells expressing wildtype 
MCT1 were preincubated with MTS reagents (1 mM, RT) for the time indicated. Shown is the percental 
L-lactate uptake activity in the initial phase of transport (2 min) compared to solvent-exposed cells. 




A persisting inhibition (30.3 % activity) even after the removal of non-reacted, excess MMTS 
prior to the L-lactate uptake assay confirmed a covalent modification and excluded unspecific 
competitive effects (Figure 4.24A). Cells expressing the plasmodial lactate transporter (PfFNT) 
with no apparent solvent-exposed, targetable cysteines were resistant to MMTS treatment 





Figure 4.24. Modification by MMTS is covalent and MCT1-directed. (A) Cells expressing wildtype MCT1 
were preincubated with MMTS (1 mM, 5 min, RT) and, in contrast to the previous protocol, non-reacted 
reagent was removed by centrifugation prior to determining L-lactate uptake rates. The graph depicts 
L-lactate uptake rates with (+) and without (−, ddH2O) MMTS pretreatment. The % activity after MMTS 
treatment compared to solvent-exposed cells is indicated. (B) To confirm MCT1-specific inhibition, cells 
expressing PfFNT were preincubated with MMTS (1 mM, 5 min, RT, standard protocol). In both cases, 
rates were determined in the initial phase of transport (2 min). Background of non-expressing cells was 
subtracted, and data represent mean ± SEM of three biological replicates. 
 
 
To test whether Cys159 was covalently modified by MMTS, the accessibility of Cys159 for 
pCMBS after MMTS treatment was examined (Figure 4.25A). Affirmatively, a MMTS 
pretreatment obstructed the inhibitory effect of pCMBS. The preincubation with non-inhibiting 
MTSES, on the other hand, still allowed a reactivity of pCMBS towards Cys159.  
Strikingly, the mutation of Cys159 to serine did not confer resistance towards the MTS reagents 
(Figure 4.25B). As with the wildtype MCT1, MMTS inhibited transport via the C159S mutant to 
50 ± 4 % activity suggesting that Cys159 is not the only target for MMTS. 
The results demonstrate that although Cys159 was not decisive for inhibition, MMTS modified 






Figure 4.25. Site-specificity of MCT1 modification by MTS reagents. (A) Cells expressing wildtype 
MCT1 were preincubated with MMTS/MTSES (1 mM, 5 min, RT) and subsequently subject to further 
modification by pCMBS (30 µM, 15 min, RT). The L-lactate uptake activity in the initial phase of transport 
was compared to MMTS/MTSES-treated cells lacking the additional pCMBS modification (solvent-
exposed). Efficiency was then determined as 100 %−% activity after pCMBS treatment. After 
MMTS/MTSES treatment, excess inhibitor was removed by centrifugation prior to modification with 
pCMBS. (B) Analogous to Figure 4.23, cells expressing the MCT1 C159S mutant were preincubated 
with MTS reagents (1 mM, RT) for 5 min. Shown is the percental L-lactate uptake activity in the initial 
phase of transport compared to solvent-exposed cells. In both cases, background of non-expressing 
cells was subtracted, and data represent mean ± SEM of three biological replicates. 
 
 
Most cysteines of MCT1 outline a ring within the central plane of MCT1 with only Cys399 and 
Cys400 slightly extending into the transport path and therefore possibly accessible for the 
modification by MTS reagents (see Figure 4.19A). The MCT1 mutants C399S and C400S (as 
single and as C159S double mutants) were expressed and functional (Figure 4.26A, B). 
Noteworthy, a C399S/C400S double mutation was not tolerated leading to expressed but non-
functional protein attributing these two additional cysteines a relevance in transporter function 
and/or folding (Figure 4.26A, B). Nonetheless, the C399S and C400S single mutants still 
showed sensitivity towards MMTS also in combination with the C159S mutant (42−59 % 





Figure 4.26. Expression, functionality, and inhibition of MCT1 mutants C399S and C400S by MMTS. 
(A) Western blot of microsomal fractions showing the expression of MCT1 C399S/C400S single, double 
and triple mutants in S. cerevisiae (arrowhead). 10 µg of total protein were loaded per lane. Protein was 
detected via a His-tag-targeting antibody. Microsomal fractions of non-expressing cells served as 
control. The exposure time is indicated. (B) Initial transport rates for L-lactate uptake of cells expressing 
the respective MCT1 mutants were determined in the initial phase of transport (2 min) and normalized 
to 1 mg cell weight. (C) Percental L-lactate uptake activity of MMTS-treated (1 mM, 5 min) compared to 
solvent-exposed cells. For (B) and (C), background of non-expressing cells was subtracted, and data 
represent mean ± SEM of three biological replicates.  
 
 
In conclusion, two known modifiers of MCT1, AZD3965 and pCMBS, were examined in the 
yeast system elucidating their action as MCT1-directed and basigin-independent. The organo-
mercurial pCMBS inactivated MCT1 and revealed Cys159 as the critical residue. Introducing 
a smaller wedge, i.e. MMTS, substantially reduced the selectivity towards Cys159 and allowed 





4.3. Generation of samples for a structure elucidation of the basigin-MCT1 
complex using electron microscopy 
The expression of human MCT1 as fusion protein with its chaperone unveiled basigin as a 
direct transport modulator. The crystal structure of basigin’s extracellular domain allowed the 
calculation of electrostatic surface potentials and enabled the elucidation of basigin as an 
extracellular substrate antenna that drives L-lactate influx via MCT1. To corroborate the results 
and better understand the exact mechanism, a cell-based and a cell-free strategy launched 
experiments on a structure elucidation of the basigin-MCT1 complex. 
 
4.3.1. Expression of MCT1 constructs in P. pastoris  
S. cerevisiae turned out to be a well-suited and valuable expression system for human MCT1. 
To profit from a system that allows for large-scale production and eukaryote-compatible 
posttranslational modification, Pichia pastoris was tested for recombinant expression of MCT1. 
The coding sequence of MCT1 alone and in fusion with basigin variant 1 (BSG var1; BSG var2 
was not yet produced and available) was cloned into a suitable expression vector and 
electroporated into an adenine-auxotroph P. pastoris strain. The cells were grown on adenine 
dropout medium and transformants appeared as white colonies. The successful integration of 
the coding gene sequence of MCT1 constructs (MCT1: 1660 bp, + BSGvar1: 2821 bp) in 
selected colonies was confirmed via colony PCR with only one colony not carrying the coding 




Figure 4.27. Colony PCR showing a successful transformation of P. pastoris. Transformants (1−4) were 
picked, and colony PCR was conducted using suitable primers to amplify successfully integrated coding 
sequences for MCT1 (A, 1660 bp) and BSG var1-MCT1 (B, 2821 bp). 10 µl of PCR products were 







In several small- and medium-scale set-ups of different tested growth and induction conditions 
(see methods section 3.3.3), the transformants were cultivated and cell mass was produced in 
glycerol-based medium. The gene expression was induced by switching to methanol-based 
medium. Unfortunately, SDS-PAGE and Western blotting failed to show any expression of 
human MCT1 in three tested colonies (Figure 4.28A). The expression of the BSG var1-MCT1 





Figure 4.28. Western blot of lysed P. pastoris cells. After the induction of protein expression, cells were 
lysed, and protein (10,000 g fraction) was separated using SDS-PAGE. 70 µg (A) and 30 µg (B) of total 
protein were loaded per lane. Subsequent Western blotting enabled the detection of recombinant protein 
using a His-tag-targeting antibody. Shown are lysates for 3−4 colonies transformed with plasmids 




In line with previous literature [147], the expression of the plasmodial PfFNT (monomer: 
37 kDa, pentamer: 185 kDa) was successful (Figure 4.28A, B) and ensured a well-working 
protocol and an efficient induction of gene expression. In this study, in contrast to S. cerevisiae, 
P. pastoris emerged as non-suitable to express human MCT1 and excluded subsequent 
experiments for structure elucidation. 
 
4.3.2. Detergent- and nanodisc-based cell-free synthesis of MCT1 constructs 
The cell-free synthesis of recombinant proteins using a cell-extract-based technology profits 
from controllable and rapid production of proteins prone to proteolysis by a living host. The 
method used in this study relied on the transcription and translation from a DNA template 
encoding the protein of interest and using E. coli-based extracts and recombinantly produced 




membrane proteins, e.g. MCT1 and basigin, needed a supplementation by either detergents 
or protein-lipid nanodiscs to provide a membrane-mimicking environment and ensure a 
sufficient protein solubilization and correct folding.  
Here, in a detergent-based, continuous-exchange cell-free system (CECF), MCT1 was initially 
produced as a GFP fusion protein to indicate correct folding of the synthesized protein [113] 
and screen for optimal detergent conditions. In a duplicate set-up using five different 
detergents, the MCT1-GFP fusion protein was synthesized and purified using Ni2+-NTA affinity 
chromatography. The proteins were separated by SDS-PAGE and subsequently detected via 
Western blotting and in-gel fluorescence (Figure 4.29A, B). Whereas n-dodecyl-β-D-
maltopyranoside (DDM) emerged as non-suitable, all four detergents of the Brij® family 
enabled the synthesis of human MCT1. Western blotting confirmed the synthesis of full-length 
MCT1-GFP fusion protein at around 85-100 kDa (theoretical molecular weight: 85 kDa). 
Despite differences in band intensities between duplicates, Brij®58 and Brij®78 enabled the 
synthesis of MCT1 most effectively. The in-gel fluorescence confirmed the detection of 
correctly folded fusion protein at 85 kDa indicating that a considerable amount of synthesized 
protein was misfolded (most bands in Western blots appeared at a slightly higher molecular 
weight). Only the Brij®58- and Brij®78-based synthesis resulted in the appearance of distinct 
bands at 85 kDa in the Western blots confirming Brij®58 and Brij®78 as suitable detergents for 




Figure 4.29. Cell-free synthesis of MCT1-GFP and detergent screen in analytical scale. Elution fractions 
(16 µl) from Ni2+-NTA affinity purification were separated by SDS-PAGE and protein was detected via 
in-gel fluorescence (A) and Western blotting (B) (His-tag-targeting antibody). Four detergents of the 
Brij® series (B35─B98) and n-dodecyl-β-D-maltopyranoside (DDM) were tested as solubilizing agents. 







The successful cell-free production of MCT1 alone laid the foundation of synthesizing MCT1 
in fusion with basigin. Given the basigin splice variant 2 as the most prevalent variant in human 
cells and given its elucidated direct role in MCT1-mediated L-lactate transport, the BSG var2-
MCT1 fusion construct was inserted into the cell-free expression vector and produced as a 
GFP fusion construct. Analogously to the functionality assay, the protein fusion aimed at a 
production in a stoichiometric manner and a close association of both proteins at all times.  
Two techniques were tested to gain high yields of correctly folded BSG var2-MCT1 fusion 
protein: the detergent-based production using Brij®78 as solubilizing agent, and a nanodisc-
based technology. The latter method was developed by C. Hansen who assembled 1,2-
dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (DOPG)- and 1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho-(1’-rac-glycerol) (POPG)-based nanodiscs using MSP1E3D1 as membrane 
scaffold protein (see Master’s thesis of C. Hansen [119]). These nanodiscs were here used to 
support a co-translational reconstitution of the basigin-MCT1 fusion protein. In contrast to 
detergent-based cell-free synthesis, the nanodisc technology mimics the natural lipid-bilayer 
environment of plasma membranes and is an emerging technique to optimize protein folding 
and integrity.  
All following experiments on the protein production and structure elucidation were done in 
collaboration with C. Hansen. The figures shown can also be found in the Master’s thesis of 
C. Hansen [119]. The synthesis of the BSG var2-MCT1-GFP fusion construct using Brij®78 
and three increasing concentrations of DOPG- and POPG-nanodiscs for reconstitution was 
initially evaluated with SDS-PAGE and Western blotting (Figure 4.30A−D). In line with the 
results for MCT1 alone, Brij®78 enabled the synthesis of the fusion construct. The Western blot 
analysis using two specific antibodies detected the full-length construct as a distinct band just 
above 120 kDa. Strikingly, an additional band of higher molecular weight indicated either 
aggregates or the formation of protein dimers that had not been observable when producing 
MCT1 alone. In contrast, DOPG- and POPG-nanodisc-based synthesis resulted in a 
comparably low protein yield only detectable using the GFP-directed antibody and DOPG-
based nanodiscs. A His-tag-directed antibody failed to detect the fusion protein. Bands just 
below 35 kDa represented the His-tag-carrying nanodisc belt proteins. The apparent high 
sensitivity of the GFP-targeted antibody allowed the detection of several weak bands indicating 





Figure 4.30. Brij®78- and nanodisc-based cell-free synthesis of BSG var2-MCT1-GFP fusion protein in 
analytical scale. Synthesized protein was Ni2+-NTA-purified, and elution fractions (20 µl) were separated 
by SDS-PAGE. Protein was detected by Western blotting using a His-tag- ((A) and (C)) and a GFP- ((B) 
and (D)) targeting antibody. Brij®78 (0.8 %) and POPG/DOPG-nanodiscs in three elevating concen-
trations were compared as reconstituting agents. Exposure times are indicated. 
 
 
In-gel fluorescence mirrored the results from synthesizing MCT1 alone and showed distinct 
bands at the expected molecular weights (Figure 4.31A and B). Although the nanodisc 
technology generally resulted in lower yields for the full-length fusion proteins (refer to 
Figure 4.30), the proportion of protein detected by in-gel fluorescence to Western blotting 
appeared higher for the nanodisc-based synthesis than for Brij®78-solubilized protein. This 
indicates a more efficient native folding in the nanodisc environment with more of the protein 








Figure 4.31. In-gel fluorescence of Brij®78- and nanodisc-based cell-free synthesis of BSG var2-MCT1-
GFP. Gels used for Western blotting in Figure 4.30A and C were analyzed via in-gel fluorescence. 
Synthesized protein was Ni2+-NTA-purified and elution fractions (20 µl) were separated by SDS-PAGE. 
Brij®78 (0.8 %) and DOPG- (A) and POPG- (B) nanodiscs in three elevating concentrations were 
compared as reconstituting agents. Exposure times are indicated. 
 
 
In a large-scale, preparative set-up, the BSG var2-MCT1 fusion protein was produced without 
the C-terminal GFP to further purify and prepare protein for transmission electron microscopy 
(TEM). Both Brij®78 and POPG-nanodiscs allowed a sufficient protein synthesis (Figure 4.32). 
The elution fractions from step gradient Ni2+-NTA affinity chromatography were separated by 
SDS-PAGE. Coomassie staining as well as Western blotting showed high protein yields with 





Figure 4.32. Large-scale cell-free synthesis and purification of BSG var2-MCT1 in preparative scale. 
Protein was synthesized and reconstituted with Brij®78 (A, B) or POPG-nanodiscs (C, D). The elution 
fractions from step gradient Ni2+-NTA affinity chromatography (20−400 mM imidazole) as well as the 
bead (B) and flow-through (F) fractions were separated by SDS-PAGE (20 µl per lane) and protein was 
detected with Coomassie staining (A, C) and Western blotting using a His-tag-targeting antibody (B, D). 
Exposure times are indicated. 
 
 
In both approaches, most of the protein was eluted with 60 to 200 mM imidazole with some of 
the target protein lost in the flow-through. Although the first elution fractions included several 
protein bands, later fractions (> 80 mM imidazole) contained highly purified protein. The protein 
fractions (80–400 mM imidazole) were combined and further purified using size-exclusion 
chromatography (Figure 4.33A, C). The size-exclusion chromatography of Brij®78- and 
nanodisc-reconstituted proteins equally showed three peaks eluted at high elution volumes 
and most likely represent imidazole as well as the protein fragments that were already 
observed in Western blot analysis. The purification of Brij®78-reconstituted protein additionally 
showed a broad and intense peak ranging from 7.5 to 12.5 ml elution volume representing at 
least two unresolved and overlapping peaks and a slight shoulder at 11.0 ml (arrow in 
Figure 4.33A). The first peak eluted after 8.5 ml contains larger molecules and emerged in 
both reconstitution approaches therefore most likely containing protein aggregates. In 




(TEM) images from individual fractions were captured. TEM of the largest peak at 9.5 ml 
showed insufficient resolution and separation from aggregates. In contrast, TEM of the fraction 
collecting the peak shoulder elucidated a very homogenous probe (Figure 4.33B). Several 
particles of similar size were visualized and probably represent reconstituted BSG var2-MCT1. 
Due to the limited particle size, class-sum images to further elucidate structural properties were 
not calculated. 
This limitation was overcome by the protein reconstitution in POPG-nanodiscs. Along with an 
improved protein stability, the comparably large size of protein-nanodisc particles favors 
structure elucidation with electron microscopic approaches [148, 149]. Size-exclusion 
chromatography of nanodisc-reconstituted protein showed generally smaller peaks indicating 
lower protein yields (Figure 4.33C). In addition to the aggregate peak at 8.5 ml, the 
chromatogram showed two additional, partly overlapping peak maxima at 10.5 ml and 12.0 ml. 
TEM of corresponding fractions revealed that the later eluted fraction probably contained non-
filled nanodiscs. Along with empty nanodiscs, the 10.5 ml fraction (arrow in Figure 4.33C) 
suggested to additionally contain protein-filled nanodiscs with reconstituted BSG var2-MCT1 
(Figure 4.33D). Single particles were subsequently analyzed to calculate class-sum images 
and refine structural features (Figure 4.33E). Interestingly, the particles were captured in two 
distinct orientations representing a top (class-sums 1−3) and a side-view (class-sums 4−6) of 
assembled nanodiscs.  
These results laid the foundation for future attempts on structure elucidation of the basigin-
MCT1 complex. In cooperation with A. Möller (Max Planck Institute of Biophysics, Frankfurt 
am Main), a first approach including cryo electron microscopy (cryo-EM) confirmed current 
observations of properly reconstituted fusion protein. Although hinting at a reconstitution of 
BSG var2-MCT1 as dimers, a further structure elucidation was limited given the insufficient 
separation of empty and protein-filled nanodiscs and an interference with class-sum 
calculations.  
Strikingly, whilst pursuing the attempts on a structure elucidation of the basigin-MCT1 complex, 
a cryo-EM structure of MCT1 in association with basigin splice variant 2 was resolved at a 
resolution of 3.0─3.3 Å [103]. This underlines this project’s relevance and will, in the future, 
promote an understanding of the basigin-MCT1 interaction and transport modulation (see 





Figure 4.33. Size-exclusion chromatography and TEM of the BSG var2-MCT1 fusion protein. (A, C) 
Pooled fractions (80−400 mM imidazole) were concentrated and approximately 1.1 mg (Brij®78, (A)) or 
0.3 mg (POPG-nanodiscs, (C)) of protein were injected for size-exclusion chromatography (20 mM Tris-
HCl, pH 8.0, 150 mM NaCl, ± 0.05 % Brij®78 as eluent; flow rate 0.35 ml min−1, detection at 280 nm). 
Arrows indicate fractions collected for TEM. (B, D) Transmission electron microscopy (TEM) of collected 
fractions. Representative excerpts are shown. (E) Class-sum images for POPG-reconstituted protein 
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5. Discussion and Perspective 
The primal aim of this study was to investigate if basigin has a direct effect on L-lactate 
transport by human monocarboxylate transporter 1 (MCT1). Due to the tight dependence of 
the plasma membrane expression of MCT1 on basigin in commonly used mammalian cell lines 
and Xenopus oocytes, the answer to this question remained unresolved. In this study, human 
MCT1 was expressed using S. cerevisiae as the expression system. MCT1 was correctly 
targeted to the plasma membrane alone as well as in fusion with basigin. The unique metabolic 
and physiological prerequisites of S. cerevisiae were exploited to monitor 14C-labeled substrate 
uptake not only in the initial phase but also in the equilibrium state of transport. Moreover, the 
use of MCT1 inhibitors and protein modifiers shed light on the inhibitory profile in the absence 
and in the presence of interacting basigin and revealed distinct transporter regions and 
residues crucial to maintain transporter activity. 
 
5.1. S. cerevisiae: a valuable expression system for human MCT1  
To study the functionality, the transport mechanism and the pharmacological properties of 
transmembrane transport proteins, a suitable system that either endogenously expresses or 
allows heterologous expression of the protein of interest is needed. Generally available 
systems range from prokaryotic Escherichia coli to eukaryotic mammalian cells with each 
system employing distinct (dis-)advantages. In the case of human monocarboxylate 
transporters, human cell lines [47, 60, 150] and Xenopus laevis oocytes [50, 151] are most 
common and have proven successful for many issues. The expression of mammalian transport 
proteins in their origin organism (i.e. human cell lines) profits from native protein processing, 
secretory pathways and trafficking. Although human cell lines represent the most natural 
environment, the expression of human MCTs holds several problems. Most importantly, 
examining transmembrane transport via MCTs in mammalian cell lines suffers from 
simultaneous expression of several MCT members of similar substrate specificity but differing 
kinetic properties (reviewed in [152]). Studies on distinct isoforms depend on the availability of 
cell types dedicated to the overexpression of a single isoform or the knockdown of other 
isoforms using e.g. small interfering RNA molecules. Moreover, the presence of up to four 
basigin isoforms of different function [73] interferes with basigin-related studies on MCT 
transport. The investigation of genetically engineered variants relies on an efficient knockdown 
of endogenous proteins and a heterologous expression of the desired protein construct. None 
of these methods fully abolishes endogenous background activity. Therefore, the distinct 
discrimination of heterologous and native transport activity and effects is hardly possible. For 
functional studies, due to the lack of an endogenous MCT homolog, Xenopus laevis oocytes 
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appeared more amendable and have primarily been employed to characterize MCTs [50, 51]. 
Nonetheless, work with Xenopus oocytes is not the standard in most laboratories [153]. Most 
importantly for this study, despite the absence of endogenous MCT activity, Xenopus oocytes 
do express basigin homologs (refer to [132]). 
Ideally, a system used to characterize MCT functionality as well as the role of its chaperone 
should be devoid of any intrinsic activity. It should further enable the heterologous expression 
of a desired isoform as well as manufactured protein constructs. In that respect, the yeast 
system appeared underexploited in the field of human monocarboxylate transporters. The 
yeast S. cerevisiae is a unicellular, eukaryotic organism that has been proven valuable due to 
the robust phenotype, and the extensive knowledge of the genome and metabolic traits 
(reviewed in [154]). The cells allow for cost- and time-efficient cultivation in a broad pH range 
and are resistant to high osmolarities. Due to a similar intracellular organization, the yeast is a 
most valuable model for cells of higher eukaryotes. Most importantly, yeast cells are highly 
amendable to genetic modifications and distinct gene knockouts [154]. Hence, the knockout of 
both transporters that mediate monocarboxylate transport in yeast, namely Jen1 and Ady2 
[105, 106], has been proven very useful for characterizing heterologously expressed 
monocarboxylate transporters with no endogenous background transport. This expression 
system has been used successfully for the functional characterization of non-mammalian 
monocarboxylate transporters including formate-nitrite transporters from Plasmodium 
falciparum (PfFNT), Toxoplasma gondii (TgFNT), and the bacterial formate-transporting FocA 
from Escherichia coli [155–157]. In this study, a jen1 ady2 knockout yeast produced functional 
recombinant human monocarboxylate transporter 1 (MCT1). So far, only a limited number of 
research articles exist that used a yeast-based expression system for the functional 
characterization of MCTs [88, 104]. In studying MCTs, S. cerevisiae seems particularly suited 
given the lack of an intrinsic expression of basigin homologs – a unique property and an ideal 
prerequisite to characterize MCTs free of endogenous basigin interference. Hence, 
Makuc et al. have demonstrated the feasibility of a jen1 knockout yeast to characterize rat 
MCT1 [88]. In line with the results from this study, they showed a functional expression of 
MCT1 at the plasma membrane of S. cerevisiae in the absence of an accessory protein. This 
is in contrast to commonly used expression systems where MCTs fully reside in intracellular 
compartments if basigin is absent preventing any functional characterization [69]. Likewise, in 
this study, the transformation of yeast cells with the coding region for human MCT1 alone led 
to the synthesis of functional protein at the plasma membrane (refer to Figure 4.1A and B, 
Figure 4.4C). Only minor protein fragmentation was visible and indicated protein degradation 
at the long, unstructured linker between TM6 and 7 which was shown before to be susceptible 
for proteolysis [53]. Confocal microscopy indicated that, indeed, some of the protein produced 
was trapped in intracellular membranes (compare with [88]). Nonetheless, a substantial portion 
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reached the plasma membrane and allowed detectable and adequate transport rates for 
L-lactate (refer to Figure 4.1C). The functionality of MCT1 does not depend on posttranslational 
modifications whereas basigin requires processing: basigin is a highly glycosylated protein and 
in the case of splice variant 2, it requires the formation of two disulfide bridges for correct 
folding of the extracellular Ig-like domains [76]. Due to their eukaryotic nature, yeasts share 
similarities with mammalian organisms in protein processing and offer similar membrane 
trafficking mechanisms [158], glycosylation [159] and disulfide bridge formation [160]. Indeed, 
Makuc et al. successfully co-expressed rat MCT1 and basigin in S. cerevisiae and showed an 
enhanced translocation of MCTs to the plasma membrane [88]. This indicated proper synthesis 
and functionality of both proteins and the feasibility of the yeast system in studying the MCT-
basigin interplay. Affirmatively, the results from this thesis likewise showed a successful 
expression of MCT1 and various basigin constructs but in a fusion set-up. The protein isolated 
from transformed cells was detected using immunoblotting techniques and showed respective 
shifts to higher molecular weights with largely smaller overall expression levels (refer to 
Figure 4.8A). Only minor fragmentation indicated some breakage of both proteins in their 
linking sequence. Basigin displays at least three glycosylation sites and non-glycosylated 
(27 kDa) and glycosylated protein (35−66 kDa) differ in the prevailing molecular weight [73, 
161]. Given the rather slight shift in molecular weight in this study (maximum of ~40 kDa for 
fusion of MCT1 with full-length basigin splice variant 2) and especially the appearance of well-
defined protein bands, the recombinantly expressed basigin constructs appeared not or only 
minorly glycosylated in yeast. This is in line with previous studies [88]. A glycosylation of 
basigin is primarily linked to physiological responses and signaling processes and it seems 
rather unlikely that basigin glycosylation plays a role in MCT functionality [162]. Nonetheless, 
given the lack of further insight and the possibility of differences in mammalian and yeast 
glycosylation patterns, glycosylation-related effects would hardly be resolved in the used yeast 
system. More importantly, the β-sheet motifs of basigin’s extracellular Ig-like domains demand 
stabilization by disulfide linkages. Indeed, S. cerevisiae assures a catalytic disulfide bond 
formation with specific disulfide isomerases [163]. Confirmatively, the mutation of involved 
cysteines to serines in this study caused a disruption of observed basigin-mediated effects 
indicating that basigin was properly folded beforehand (discussed in detail in section 5.4). 
Accordingly, the fusion of MCT1 with basigin maintained transporter function and did alter the 






5 Discussion and Perspective 
119 
 
5.2. Molecular fusion of MCT1 and its chaperone basigin 
This study’s set-up differs from previous approaches in the MCT research in two main aspects. 
First, the use of a yeast-based expression system allowed the functional expression of MCT1 
alone and set the ideal grounds to elucidate unbiased, basigin-independent MCT 
characteristics. And second, employing the fusion technology to covalently link basigin and 
MCT1 disclosed further direct basigin effects on transport. 
The fusion of two proteins or domains of different proteins is a valuable concept for various 
purposes. One of the most common uses of the fusion technology is to add small peptide tags 
to the N- or C-terminal end of recombinantly expressed proteins for purification and labeling 
purposes (reviewed in [164]). Generally, a fusion can optimize the biochemical protein 
characteristics such as solubility, stability, trafficking or activity (reviewed in [165]). Exemplary, 
the fusion technology can be used to couple two enzymes that catalyze consecutive steps in 
metabolism. This fusion has been shown to promote the net aldol reaction via the dihydroxy-
acetone kinase and the fructose-1,6-bisphosphate aldolase by an efficient substrate shuttling 
between active centers [166]. In this study, an end-to-end fusion of coding regions for MCT1 
and several natural or artificial constructs of its interacting basigin was employed. In contrast 
to a co-expression approach, the fusion profits from a permanent proximity of both proteins in 
a stoichiometric manner, and an increased probability of both proteins to interact. In the case 
of a stable fusion, this ensures an association of both proteins at all times. At the start of this 
study, only limited information was available on how MCTs and basigin would interact. In 2000, 
Kirk et al. used chimeras of basigin and another non-MCT-related member of the 
immunoglobulin-like family (CD2) to reveal that the C-terminal end and the transmembrane 
domain of basigin are sufficient for an interaction with MCTs [69]. Accordingly, fluorescence 
resonance energy transfer (FRET) studies by Wilson et al. confirmed a close proximity of the 
C-terminus of basigin and the C- and N-terminal ends of MCT1 [87]. These results were further 
specified by elucidating the Glu218 as a charged residue in the transmembrane domain of 
basigin variant 2 to be crucial for interaction [57]. The end-to-end fusion of two proteins dictates 
several requirements to ensure a functional protein expression. As reviewed by Yu et al., the 
fusion of two proteins demands long and flexible C- and N-terminal ends to ensure a linking 
sequence of minimal constraint. These terminal ends should not exhibit a role in protein 
function [167]. In the case of a basigin-MCT1 fusion, the intracellular localization of MCT’s 
termini required a fusion of basigin’s intracellular C-terminus to the N-terminus of MCT1. Based 
on the structure data for SfMCT and secondary structure predictions for basigin, this assured 
a flexible linker of roughly 60 amino acids. Considering that naturally occurring and empirically 
designed linkers between proteins or individual domains stretch from 10 to 15 residues [168], 
60 amino acids should avoid steric hindrance and provide enough flexibility for basigin and 
MCT1 to fall into proper interaction. The predicted spatial orientation of basigin and MCT1 in 
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this work is visualized in Figure 5.1A. During this study, the structure for MCT1 in complex with 
basigin variant 2 was resolved [103] (Figure 5.1B, discussed in detail in section 5.6). This 
structure perfectly mirrors the predictions made for this study. Accordingly, the transmembrane 
domain of basigin is in close contact with the transmembrane helix 6 of MCT1. This orientates 
the extracellular domain of basigin, i.e. the Ig-I domain, in a way that it “covers” the substrate 




Figure 5.1. Comparison of the basigin-MCT1 fusion model and the resolved structure of the complex. 
(A) Schematic model for the fusion construct of basigin variant 2 (black/gray; PDB #3B5H; the 
transmembrane domain as schematic illustration) with MCT1 (orange; structure model based on SfMCT, 
PDB #6HCL). This figure is a modified version of Figure 4.5. (B) Resolved structure of MCT1 in complex 
with basigin variant 2 (PDB #6LZ0). In both images, disulfide bridges in the extracellular domain of 
basigin are shown as orange spheres. Glu218 in the transmembrane domain of basigin is highlighted in 
red, and the interacting Asn187 in MCT1 is marked green.  
 
 
Previous literature proposed Arg86 in helix 3 of MCT1 to be in close distance to the 
transmembrane domain of basigin and to presumably involve in the interaction with basigin’s 
Glu218 – although not via a charge-pair [57]. Wang et al. confirmed the importance of Glu218 
for interaction [103] and further claimed Asn187 of helix 6 to engage in a hydrogen bond with 
Glu218. In this study, a charge-reversing mutation of Glu218 to arginine (E27R in the BSGΔIg 
construct) prevented the MCT1 functionality although it was present at the plasma membrane 
(refer to Figure 4.6). In this context, it can be assumed that MCT1 and basigin were in fact 
interacting, and that a positive charge in basigin prevents interaction and even affects the 
neighbouring MCT1 – either by misfolding that is transmitted to MCT1 or due to charge-
repelling effects. Although some breakage of the fusion construct between MCT1 and basigin 
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was observable in Western blotting (refer to Figure 4.8A), the full abolishment of transporter 
function by a point mutation in basigin and the lack of any residual activity that would arise 
from non-fused MCT1 indicates that even after molecular separation, both proteins appear to 
have remained associated. Afterall, these conclusions support the feasibility of this study’s 
experimental fusion set-up.  
 
5.3. Monitoring L-lactate transport across plasma membranes 
5.3.1. General approaches and modalities 
Over the years, monitoring monocarboxylate transport across plasma membranes has been 
intensively studied using different kinds of methodic approaches each facing its own obstacles 
and challenges (extensively reviewed in [169]). Generally, lactate transport across membranes 
is, according to the Arrhenius equation, temperature-dependent [170] and, given the proton 
co-transport, pH-dependent [61]. Nowadays, a sophisticated laboratory equipment easily 
manages stable and precise pH buffering and temperature control and allows accurate kinetic 
measurements. Due to the difficulties that accompany the direct tracing of monocarboxylates 
(see below), the MCT-mediated transport is commonly followed as the concurrent pH change. 
Using intra- or extracellular pH electrodes or pH-dependent fluorescent dyes (i.e. 2’-7’-bis-
(carboxyethyl)-5-6-carboxy-fluorescein (BCECF)), the transport of the substrate-accom-
panying protons across membranes is monitored [171, 172]. In contrast to measuring the flux 
of the monocarboxylate of interest itself, the pH shift is a real-time and universal measure to 
cover transport by MCTs that exhibit a diverse spectrum of transported substrates. On the far 
side, the proton flux is an indirect measure of transport that might be affected by cellular pH 
buffering in need for diligent experimental calibration. Since MCTs convey bi-directional 
transport, only the net flux of protons is captured, and a mere exchange of protons can not be 
traced. For certain cases, the use of radiolabeled substrates appears more suitable. A 
substrate labeling with β-emitting radiocarbon (14C) gives a sensitive and direct measure of 
transport. This approach has successfully been used to characterize monocarboxylate 
transporters of several species in- and outside the Beitz lab [54, 109, 173]. Nonetheless, in 
living organisms, to monitor monocarboxylate/lactate transport and characterize the 
functionality and kinetics of transporters is a major challenge. First, monocarboxylates all share 
the deprotonatable carboxylic acid function. In the protonated, non-charged form, 
monocarboxylates are able to cross plasma membranes in the absence of any transporter 
[174, 175]. Therefore, substrate diffusion across the plasma membrane might hamper accurate 
transport measurements. Nonetheless, with a 𝑝𝐾𝑎 of 3.9, lactic acid and is largely 
deprotonated (≈ 99.97 %) at a physiological pH of 7.4. Only at low pH values, diffusion 
constants get significant [175]. Nonetheless, passive diffusion does play a role and uptake 
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rates need adequate correction. In human cells lines and Xenopus oocytes, the contribution of 
background diffusion can be estimated by eliminating transporter-mediated flux using specific 
inhibitors (reviewed in [9]). In the yeast system, genetic knockout strains that do not express 
monocarboxylate transporters constitute an ideal system for background correction. 
In co-transporters that allow an electroneutral, bi-directional substrate shuttling, transport is 
defined by substrate concentrations at both sides of the membrane and the prevailing 
concentration gradients [176]. In cell-based systems, any transport-unrelated processes 
affecting substrate concentrations in- and outside the cell will affect measured transport 
parameters. Most importantly, the substrate metabolism and its endogenous intracellular pool 
contribute to prevailing concentrations and inaccuracy. Explicitly, L-lactate plays a major role 
in the energy metabolism of mammalian cells [1]. Therefore, metabolically active cells have an 
undefined intracellular pool of non-radiolabeled L-lactate impairing zero-trans influx 
measurements. Moreover, a constant metabolic conversion of entered L-lactate maintains a 
dynamic steady-state preventing the establishment of a thermodynamic equilibrium. Only in a 
limited number of cell lines or model organisms, L-lactate metabolism is absent or can manually 
be repressed. These include mature red blood cells after mitochondria expulsion [177], and 
yeast cells [141]. In other cellular systems, the rapid metabolic clearance restricts in-deep 
kinetic measurements especially of substrate efflux from preloaded cells or the determination 
of transport equilibria. The transport measurements are essentially limited to initial transport 
rates within the seconds time scale (10−60 s) or to low temperatures to repress metabolic 
activity (reviewed in [169]). 
In this study, a yeast-based system was used to monitor the zero-trans influx of an externally 
applied gradient of 14C-labeled L-lactate into cells that are devoid of the measured substrate. 
For that purpose, a single MCT isoform, i.e. MCT1, was recombinantly expressed in a 
jen1 ady2 knockout strain. At a stable temperature of 19 ± 1 °C and an externally buffered pH 
of 6.8 or 5.8, background diffusion or transport was hardly detectable. Under these conditions 
(pH 6.8, 1 mM L-lactate gradient), MCT1-expressing cells gave values of 200−579 cpm 
(depending on incubation time) with a mean background of 104 cpm (refer to section 4.1.1)  
which ensured a sufficient signal-to-noise ratio even with the least active transporter construct 
examined in this study. Nonetheless, the background was subtracted for each individual 
experiment (refer to Figure 4.1C). In S. cerevisiae, L-lactate consumption and metabolism is 
repressed in the presence of glucose-containing medium [141]. Moreover, yeast cells naturally 
rely on metabolic pathways that do not produce large amounts of L-lactate [108]. These 
conditions met the requirements to conduct zero-trans experiments with no substantial 
metabolic interference. Interestingly, a glucose supplementation throughout uptake 
measurements led to a generally decreased lactate accumulation in cells (refer to 
Figure 4.14A) suggesting that, through enforced glycolysis, a minor intracellular lactate pool 
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was acquired and antagonized substrate influx. Hence, to thoroughly suppress metabolic 
activity and deprive intracellular L-lactate reservoirs to ensure zero-trans conditions, yeast cells 
were early withdrawn from glucose supply and kept on ice until conducting the uptake 
measurements.  
 
5.3.2. Transport rates of basigin-MCT1 fusion constructs: the need for normalization  
Most available studies on transport in general and on transport via MCTs refer to initial 
transport rates in zero-trans influx, zero-trans efflux or equilibrium exchange experiments. In 
that respect, initial transport rates accomplished by one or more expressed MCT isoforms in 
response to applied changes in pH, substrate concentrations, or inhibitor treatment are 
monitored. This gives distinct information on the kinetic properties of the respective isoform. In 
those cases where the modalities of a single isoform are examined in a system where only 
external factors are to be altered, initial rates give a good and comparable measure. 
Nonetheless, initial transport rates are affected by the number of transporting proteins residing 
at the plasma membrane. In this study, the different fusion constructs of MCT1 differed in their 
total expression levels (refer to Figure 4.8A). Since only the proportion of protein that reaches 
the plasma membrane contributes to initial transport rates, normalization was essential. A 
common approach to estimate the protein localization in living cells is confocal microscopy. In 
confocal microscopy, a central plane of the cells is visualized and with the use of a fluorescent 
indicator, proteins can be localized and quantified [178]. The fluorescent labeling can be 
achieved by using tagged protein-specific antibodies and tracer dyes, or by a direct fusion of 
proteins to a marker, i.e. green fluorescent protein (GFP). Both techniques have been 
successfully used in the field of MCT research [69, 87, 88]. Here, GFP was fused to the C-
terminal end of the basigin-MCT1 fusion constructs and gave a good relative measure of how 
much of the fusion construct was displayed at the plasma membrane (refer to Table 4.1). As 
expected, the membrane localization differed between constructs. Of note, the differing total 
expression levels between fusion proteins did not allow to discriminate whether the 
translocation to the plasma membrane was altered or mere differences in the overall 
expression of protein caused a changed membrane localization. Nonetheless, the fusion 
constructs from this study displayed different initial transport rates and maximum velocities 
(𝑣𝑚𝑎𝑥) and largely, these variances correlated with the relative abundance of tagged protein 
constructs at the plasma membrane (refer to Table 4.1). Thus, the initial transport rate and the 
maximum velocity achievable by MCT1 appeared unaffected by a fusion with basigin. 
Nonetheless, a protein quantification using confocal microscopy is error prone. The confocal 
images displayed a rather heterogenous signal distribution with the overall intensity in part 
contradicting expression levels from Western blotting. The non-automated quantification and 
the rather small sample size contribute to the expected large errors in quantification. Notably, 
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the fusion of GFP to the C-terminal end resulted in non-functional MCT1 questioning 
conclusions made for non-GFP-tagged proteins. Interestingly, Wilson et al. were able to fuse 
GFP to the C-terminus of MCT1 without losses in protein function [87]. Makuc et al. produced 
similar GFP fusion proteins in yeast but did not check for sustained functionality [88]. 
Nonetheless, in this study, the abolished transporter function hints at a so far undetected 
importance of the large and flexible C-terminal sequence of MCT1. Despite some evidence 
that propose the C-terminus as an anchor for MCT-associated proteins to regulate the MCT 
function [179, 180], data on a direct role in the transporter function is scarce. Although it can 
be assumed that C-terminal fusion to GFP did not alter membrane translocation of proteins, 
future approaches and save conclusions on initial and maximal transport rates are in demand 
for accurate and confident quantification at the plasma membrane. Alternatively, cell 
fractionation experiments or cell surface protein biotinylation techniques may be tried [88, 181]. 
 
5.3.3. The equilibrium of transport  
Generally, a channel protein facilitates diffusion of a substrate across membranes and along 
its concentration gradient until an equilibrium of substrate in- and outside the cell is reached 
[176]. In secondary active MCT transport, the prevailing gradient of a secondary substrate, i.e. 
protons, drives transport of the co-transported substrate, i.e. L-lactate, for accumulation [176]. 
MCT transport is bi-directional and works equally in both directions [169, 182] (reviewed in [9]). 
In a zero-trans setting, an extracellular L-lactate gradient can be applied to drive influx via the 
transporter. In that case, in the first seconds of transport when the gradient is maximal, 
L-lactate is taken up at maximum speed, i.e. with the above described initial transport rates. In 
a system where the substrate that is accumulated at the trans-side is neither consumed nor 
exported via alternative routes, the system will establish a steady state in which influx equals 
efflux leading to equilibrium concentrations at both sides of the transporter. This would appear 
as a saturation in an uptake-over-time curve and a maximal uptake capacity under the 
prevailing conditions. In analogy to enzymatic catalysis, a transporter accelerates the 
establishment of this equilibrium but it will not affect its position [1]. In an electroneutral 
substrate/proton co-transport, this thermodynamic equilibrium is defined by an inversely 
proportional relation between the concentrations of substrate (ceq) and protons ([H]eq
+ ) in- and 
outside the cells. This correlation is summarized as the “fundamental rule of co-transport” and 
defined by the equation ceq_in ∙ [H
+]eq_in = ceq_ex ∙ [H
+]eq_ex [176] (reviewed for MCTs in [169]). 
According to Le Chatelier’s principle, transport can be stimulated by changes in each of the 
four contributors. 
To date, the transport equilibrium of MCTs could not be resolved since common experimental 
approaches suffer from rapid metabolism of the accumulating substrate (see section 5.3.1). In 
this study, the use of a yeast-based system allowed to monitor L-lactate uptake for time periods 
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long enough to determine equilibrium concentrations for L-lactate (summarized in Table 4.1). 
Confirming the validity of the experimental framework, experiments at different temperatures 
displayed different transport rates but yielded comparable equilibrium concentrations (refer to 
Figure 4.3).   
 
5.4. Basigin: a proton and substrate collecting antenna to drive L-lactate influx 
So far, the role of basigin has been seen purely as a chaperone to guide MCTs to the plasma 
membrane [69]. Interestingly, basigin undertakes this function not only for MCTs but also for 
other membrane proteins, i.e. the plasma membrane Ca2+-ATPase (PMCA) [183, 184]. In line 
with the studies on MCTs, the transmembrane domain of basigin appeared sufficient for 
interaction and chaperoning. In the absence of basigin, MCTs are trapped in intracellular 
compartments [69] and this basigin-dependent plasma membrane localization is associated 
with several disease-related conditions including cancer [185]. Due to this tight dependency, 
MCTs are not accessible for functional studies in the absence of basigin. Hence, earlier studies 
lack unbiased characterization of MCTs and failed to elucidate any potential direct basigin 
effects on MCT functionality. This direct regulation has been occasionally suggested but was 
never confidentially confirmed.  
In this work, the use of a yeast-based expression system offered the unique property that 
MCTs are, indeed, properly targeted to the plasma membrane without the aid of a chaperoning 
basigin. This enabled the determination of intracellular L-lactate equilibrium concentrations 
achievable by MCT1 alone and in fusion to artificial basigin constructs of subsequently added 
protein domains. Strikingly, the functional fusion of MCT1 to basigin constructs that harbored 
the membrane-proximal Ig-I domain enabled an at least 4.5-fold accumulation of L-lactate 
inside the cells (refer to Table 4.1). This was associated with a slight increase in 𝐾𝑚 that has 
previously been linked to an association of MCTs with basigin [88]. An impaired domain folding 
by mutating the cysteines that are involved in a stabilizing disulfide bridge reversed this effect 
(refer to Figure 4.10D). The presence of the second N-terminal Ig-C2 domain of basigin did 
not further affect the L-lactate accumulation (refer to Table 4.1). Of note, the Western blot 
analysis displayed no apparent band shift between the constructs BSG Ig-I-MCT1 and 
BSG Ig-I/C2-MCT1 although the additional Ig-like domain accounts for a calculated molecular 
weight difference of 8 kDa (refer to Figure 4.8A). Hence, an early separation of this domain 
from the fusion constructs cannot fully be excluded and could account for a lack of effect. 
Nonetheless, recognizing the Ig-C2 domain as the membrane- and MCT-distant domain [103] 
agrees with the Ig-I domain as the more likely candidate for any regulation of MCT1. The 
presence of basigin’s Ig-I domain led to an L-lactate accumulation to concentrations well above 
those provided with the buffer, i.e. 1.8−2.1 mM (refer to Figure 4.12A). The knowledge of the 
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external buffer and proton concentrations as well as the experimentally determined internal pH 
allowed an estimation of the equilibrium constants achieved by the different constructs. MCT1 
alone and in combination with basigin lacking a properly folded Ig-I domain (BSGΔIg-MCT1, 
BSG Ig-I C23S/C82S-MCT1) acquired a thermodynamic equilibrium with 𝐾 ≈ 1 meeting the 
requirements of the fundamental rule of co-transport. The presence of the extracellular Ig-I 
domain led to a disturbance of the equilibrium resulting in an apparent 𝐾𝑎𝑝𝑝 of 4.5−5.2 (refer 
to Figure 4.12B). Thermodynamically, such a disturbance could be explained by locally 
increased concentrations at the extracellular side of the transporter. A correct calculation of 
equilibrium constants requires utilizing these local concentrations instead of the now 
underestimating buffer concentrations. According to Le Chatelier’s principle, the locally 
increased concentrations would imply substrate accumulation at the trans side of transport, i.e. 




Figure 5.2. Electrostatic attraction of L-lactate and protons by the Ig-I domain of basigin. (A) In the 
absence of the extracellular BSG Ig-I domain, the buffer concentrations of L-lactate and protons 
determine transport and a thermodynamic equilibrium is reached. (B) The presence of the Ig-I domain 
creates a microenvironment of increased local concentrations of substrate and protons at the transporter 
surface. This drives substrate influx according to Le Chatelier’s principle. Referring to outside buffer 
concentrations, an apparent equilibrium constant 𝐾𝑎𝑝𝑝 > 1 is achievable. Substrate accumulates above 
concentrations provided by the buffer. 
 
 
The experimental evidence of such a substrate-concentrating function of proteins or protein 
domains was recently provided for aquaporin 9 (AQP9) [186]. Rothert et al. confirmed an 
electrostatic attraction mechanism for lactate anions via a positive arginine cluster, driving 
5 Discussion and Perspective 
127 
 
substrate influx [186]. For basigin, the calculation of Poisson-Boltzmann electrostatics revealed 
a strong positive and an adjoining negative patch within the basigin Ig-I domain (refer to 
Figure 4.15). An impaired domain folding and patch formation by disulfide bridge-breaking 
point mutations (refer to Figure 4.10D), or a dissolution of the patches by respective residue 
exchanges by neutral amino acids (refer to Figure 4.16) reversed the basigin-mediated effects. 
Residues situated closer to the transporter surface exhibited the most substantial effect. This 
elucidates the modalities of a bivalent proton and substrate harvesting function of basigin via 
its Ig-I domain. This study hypothesizes that the harvesting creates a “microenvironment” of 
locally pooled substrate anions and protons at the transporter surface. This, in turn, generates 
a steeper substrate gradient driving L-lactate influx (Figure 5.2). In this microenvironment, the 
thermodynamic requirements are met (ceq_in ∙ [H
+]eq_in = ceq_ex ∙ [H
+]eq_ex), but an apparent 
disturbance with respect to buffer concentrations in the overall “macroenvironment” is created. 
This alters the transmembrane substrate distribution and enables an intracellular substrate 
accumulation beyond concentrations the buffer and the pH gradient would thermodynamically 
allow. Interestingly, glucose-rich conditions also eliminated any basigin-mediated effect with 
an overall effect on cytosolic substrate accumulation (refer to Figure 4.14). This establishes 
the basic requirement for zero-trans conditions. In this case, an endogenously built up L-lactate 
pool by glucose breakdown could antagonize and exhaust the harvesting potential and much 
rather reflect equilibrium exchange modalities instead of a zero-trans influx. 
Together, these results point to basigin as an electrostatic antenna for both, substrate and 
protons, and a key regulator in MCT1 function. Strikingly, Updegraff et al. just recently found 
that shedding of the extracellular domain of basigin by the action of the transmembrane 
protease TMPRSS11B forced a substrate efflux from MCT4-expressing cells in a physiological 
setting [89]. Their determined decrease in intracellular lactate content by a factor of 4 is 
perfectly in line with the inverse 4.5-fold shift to influx by basigin in this study. This points at an 
overarching mechanism of basigin that is transferable to other MCT isoforms. This notion adds 
perfectly to a picture that has been drawn in the past several years. Quite recently, two new 
interacting partners of the basigin-MCT complex, namely carbonic anhydrases (CA) II and IV, 
have been found to regulate lactate flux [151, 180]. Together with Forero-Quintero et al. [172], 
these studies revealed a regulating mechanism in which the CAIV binds extracellularly to the 
Ig-C2 domain of basigin and the CAII associates with the intracellular C-terminal end of 
MCT1/4 to act as electrostatic proton antennae that guide protons to the transporter entry and 
release them on the other side. Accordingly, CAII and CAIV enhance an efficient lactate flux 
through MCTs via a mechanism that is unrelated to their enzymatic function. For proton-
coupled transporters, mathematic models show that mere proton diffusion in the medium is too 
slow to maintain the high transport rates observed for MCTs, and that the existence of proton-
collecting subunits would resolve this problem [187]. In that regard, Noor et al. postulated a 
5 Discussion and Perspective 
128 
 
mathematical discrepancy suggesting that MCTs require, beside CAII, additional harvesting 
antennae to sustain transport [180]. One of which is the CAIV, and another is here proposed 
to be MCT’s well-known chaperone basigin. Moreover, basigin appears to act not only as the 
bridging proton antenna between CAIV and MCTs, but also as an additional L-lactate collector 
to drive L-lactate influx even more efficiently. 
Given that MCT1 offers a moderate substrate affinity and is the least destined MCT isoform 
with respect to transport directionality, basigin is now revealed as a key determinant. This is 
particularly important since from a thermodynamic point of view, an enforced substrate influx 
at given L-lactate concentrations would require an intense shift in pH either intra- or 
extracellularly. Here, an outside pH shift of one unit from 6.8 to 5.8 drove substrate influx via 
MCT1 alone to a similar degree as fusion to basigin did at pH 6.8 (refer to Figure 4.11D). This 
underlines the magnitude of the substrate harvesting by basigin which was of particular 
importance at a pH of 6.8 (refer to Figure 4.11D). From a more macroscopic perspective, the 
basigin-favored substrate influx gave a physiologic benefit to expressing yeast cells that 
require L-lactate as carbon source (refer to Figure 4.13). In humans, MCT1 is ubiquitously 
expressed and can, in general, adapt a lactate-releasing and a lactate-receiving function in 
metabolically adapted (reverse) Warburg cancer cells. The expression of basigin and the 
choice of specific isoforms (note that some do not display the critical Ig-I domain [73]) might 
be key in defining the net directionality of MCT1 transport and in determining the fate of cancer 
cells. This underlines its great importance and reveals a new angle for therapeutic 
intervention – especially in cancer. 
 
Collecting antennae in MCT transport: What is next? 
This newly resolved regulation of transport via MCT1 has important implications on the 
functionality of MCTs in general. It will be interesting to test whether basigin can fulfill this 
harvesting function also for other MCT isoforms. Unfortunately, attempts to express other MCT 
isoforms in S. cerevisiae have failed (see Master’s thesis of K. R. Jacks [188]). Nonetheless, 
the fusion of MCTs from other species to basigin would offer insights on a global mechanism 
and a transferability to other proton-coupled monocarboxylate transporters. Rat MCT1, a 
member that has been successfully expressed in this study in yeast, represents one interesting 
candidate – especially considering embigin as its genuine chaperone [56]. Moreover, given the 
proposed mechanism includes an electrostatic substrate anion attraction, it is most likely that 
substrate harvesting by basigin also drives an influx of other known transporter substrates, e.g. 
pyruvate or acetate. Moreover, does the yeast system allow further N-terminal anchoring of 
the carbonic anhydrase to the basigin-MCT fusion proteins to elucidate a potential cooperative 
harvesting of both antennae? In this work, the fusion of MCT1 to embigin variants as the 
preferred partner for MCT2 and an alternative chaperone for MCT1 led to low expression levels 
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and no substantial transport activity (refer to Figure 4.7 and Figure 4.9). However, sequence 
alignments of basigin and embigin reveal a high conservation across species but not between 
both family members at the charge patch-forming positions (Figure 5.3). In contrary, the 
transmembrane domains including the charged glutamate for MCT interaction are highly 
conserved between basigin and embigin. In future attempts, chimeras of the transmembrane 
domain of basigin for proper interaction and the extracellular portion of embigin could reveal 
differences in their regulatory function on MCT transport. Explicitly, does embigin similarly 




Figure 5.3. Excerpt of a sequence alignment of human, mouse and rat basigin (BSG) and embigin 
(EMB). Residues that contribute to the electrostatic surface potential in hBSG are highlighted in red 
(negative charge) and blue (positive charge). 
 
  
To examine the physiological relevance of basigin’s regulatory function, the here ascribed 
implications from yeast should be tested in the human system. In that respect, a cooperation 
with the Schäfer lab at the Institute of Experimental Cancer Research (UKSH Kiel) seeks to 
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5.5. Cys159 in the MCT1 hinge region: a molecular anchor? 
MCTs are implicated as promising drug targets in anti-tumor therapy. So far, most known 
inhibitors are unspecific or at least lack isoform-specificity. Moreover, data on the mode of 
action of common inhibitors is scarce. Given the tight and retained association of MCTs and 
basigin or embigin at the plasma membrane [87], several studies implicate basigin/embigin 
association with drug efficacy and inhibition [70, 189] but reliable evidence is limited. 
Although ineligible when comparing differentially expressed protein constructs, initial transport 
rates constitute a confidential readout in inhibitory studies. Again, the yeast system and its 
expression of functional MCT1 when not associated with basigin appeared most suitable and 
offered the opportunity to compare the efficacy of compounds in the absence and presence of 
basigin. Given its high transport activity and it being the variant carrying both extracellular 
Ig-like domains, the BSG Ig-I/C2-MCT1 fusion construct appeared most suited. MCT1 alone 
and in fusion with basigin exhibited sufficiently high transport rates to carry out inhibitor studies. 
Due to the generally low background signals (refer to Figure 4.1C), signal-to-noise ratios were 
high enough to permit the determination of percent activities with acceptable variances even 
at high degrees of inhibition. To make up for the time-dependent decrease in cell fitness and 
uptake capabilities (refer to Figure 4.2B), non-inhibited cells always underwent the same 
procedure and were assayed as controls. This assured a most reliable reference and save 
conclusions on efficiencies of tested substances. 
Expectedly, the compound AZD3965 was found to directly inhibit MCT1 (refer to Figure 4.17A). 
This is in line with the recently resolved structure of MCT1 that presents AZD3965 in the 
substrate-binding pocket [103]. The fusion to basigin led to a comparable IC50 value indicating 
that basigin is neither essential nor does it modulate inhibitor binding (refer to Figure 4.17B). 
In contrast, the cysteine-modifying reagent p-chloromercuribenzene sulfonate (pCMBS) was 
long accepted as an indirect MCT inhibitor. In 2005, based on an MCT4 structure model on 
the Escherichia coli glycerol-3-phosphate transporter and the lactose permease, Wilson et al. 
predicted solvent-accessible cysteines yet a mutation of such cysteines failed to confer 
pCMBS resistance [70]. Accordingly, the authors proposed the covalent modification of 
disulfide cysteines in basigin’s Ig-C2 domain and misfolding to be transmitted to the 
neighboring MCT. Given that, in the Xenopus oocytes system, misfolded basigin prevents 
proper MCT trafficking, concrete evidence for MCT inhibition beyond a lack of plasma 
membrane translocation is missing. Here, the yeast expression of MCT1 without interference 
from chaperoning proteins was key in elucidating that pCMBS is a direct MCT1 inhibitor with 
basigin having no effect on its inhibitory potential (refer to Figure 4.18). Site-directed 
mutagenesis revealed Cys159 as the sole target for modification by pCMBS. The available 
structure models for MCT1 (refer to Figure 4.19A) delineated Cys159 to be positioned in a 
central hinge region of MCT1. This critical position was now confirmed by the resolved cryo-
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EM structure of MCT1 [103] (Figure 5.4A, B). Cys159 is situated deep in the substrate binding 
pocket but accessible in the outward open conformation. pCMBS transfers a very bulky side 
chain with a van der Waals volume of 135 Å3 (calculated with chemicalize.org by ChemAxon). 
Accordingly, covalent modification of Cys159 might serve as a wedge and hinder free 




Figure 5.4. Structure of MCT1 and modification of Cys159 by pCMBS. (A, B) Structure of human MCT1 
in the outward open conformation (PDB #6LZ0) in side-view (A) and in top-view (view from extracellular 
space) (B). Cysteines are highlighted in red, blue and light green (Cys159). Color coding refers to 
Figure 4.19A. Sulfur atoms are marked yellow. (C) Magnified excerpt of the MCT1 structure showing 




Affirmatively, a covalent modification with the smallest available cysteine-modifier, methyl 
methanethiosulfonate (MMTS, 47 Å3), only partially decreased transport rates (refer to 
Figure 4.23B). MMTS modified Cys159 but was revealed as non-selective with other cysteines 
being additionally modified (refer to Figure 4.25). Given the small size of the transferred moiety 
and the membrane-permeability, it is thinkable that MMTS gains access to additional more 
buried cysteine residues possibly also from the intracellular site. Consecutive studies by 
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K. Geistlinger aimed for the complete cysteine conversion with the medium-sized MTS 
reagents PMTS and BMTS and confirmed a size-dependent inhibition with increasing inhibitor 
size correlating with a selectivity for Cys159.  
In general, cysteines can play important roles in protein function. Although they are of low 
abundance, roughly half of the cysteines present in a protein are solvent-accessible and have 
implications in its functionality [190]. To date, only a limited number of studies addressed the 
role of cysteine residues in MCT transport. Yamaguchi et al. conducted studies with the 
cysteine-modifying reagent 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) but saw no effect on 
transport [66]. They concluded that cysteines in general are not accessible. Nonetheless, 
DTNB, and the equally non-effective MTSES from this study, are medium-sized and charged 
reagents. It is possible that they, due to the limited membrane-permeability, do not gain access 
to the transporter hinge region or other (intracellularly) targetable cysteines. Here, MCT1 
emerged as attackable by cysteine-reactive compounds and engaging cysteines, i.e. Cys159, 
were susceptible for transporter inhibition. Of note, whilst the covalent modification of Cys159 
was not tolerated by MCT1, its substitution by serine had no effect yielding almost identical 
transport rates compared to the wildtype protein (refer to Figure 4.20B). Other reported 
cysteine mutations including the ones presented by Wilson et al. [70] (refer to section 4.2.2), 
rat MCT1 Cys336 (Cys343 in human MCT1) [65] and human MCT1 Cys399 to alanine [191] 
were likewise without effect. With Cys362 of bacterial SfMCT, a single cysteine was revealed 
that did not allow an amino acid substitution and was implicated in the MCT transporter 
function. Single mutation of this cysteine to alanine greatly decreased SfMCT transport activity 
[54]. This cysteine is not conserved among human MCT members but sequence alignments 
locate it right next to the Cys399/Cys400 pair in MCT1. Indeed, in this study, while single 
substitutions of Cys399 and Cys400 did not affect transport, a Cys399/Cys400 double mutant 
was non-functional. Although none of the single cysteine mutations conferred complete 
resistance to MMTS, the complete transport abolishment by an absence of both revealed a 
relevance of some kind (refer to Figure 4.26). Interestingly, this pair of cysteines sits on the 
opposite site of Cys159 with the thiols slightly protruding into the substrate binding pocket 
(Figure 5.4A, B). Together, the presented data reveal several cysteines, and explicitly Cys159, 
that occupy a designated hinge region in the substrate path MCTs potentially pivot around in 
the translocation cycle. The usage of several cysteine-modifying reagents revealed cysteines 
to be accessible. Cys159 in the binding pocket was selectively targeted by larger reagents 
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The transporter hinge region: What is next? 
The accessibility of Cys159 opens doors for covalent modification and labeling in the most 
critical part of the transporter. Thereof, site-specificity is key and would require knowledge of 
all accessible cysteines. Accordingly, the identity of additional MMTS target sites is to be 
resolved in future studies, specifically with regards to a first tested fluorescent MTS reagent 
that proved to be non-specific for Cys159. Nonetheless, future site-specific labeling with 
sophisticated cysteine-modifiers could shed light on the mechanistic basis of MCT-mediated 
substrate transport. To date, the structural data in two transporter conformations and 
implications on distinct residues crucial for transport delineate an alternating access 
mechanism of MCTs. Information on a mechanistic basis and the distinct transporter motion is 
scarce. Using Cys159 as an anchor for fluorescence [192, 193] or electron paramagnetic 
resonance (EPR) labeling [194] could report on local electrostatics and conformational 
changes, and provide detailed information on the transport process of MCTs including 
substrate recognition, attraction and the translocation cycle. 
 
5.6. How will the three-dimensional structure help? 
The elucidation of three-dimensional protein structures provides information essential to 
understand protein dynamics, to identify substrate binding sites, or to define inhibitor binding 
and targeted drug design. Today’s approaches demand the production of large amounts of 
highly purified, rigid protein to make it accessible for structure elucidation by X-ray 
crystallography [195], nuclear magnetic resonance (NMR) spectroscopy [196], or cryo electron 
microscopy (cryo-EM) [197]. Current methodic approaches and developments are progressing 
fast but, still, a structure elucidation of membrane-associated, non-soluble proteins remains 
highly challenging. Given the tight lipid association of membrane proteins, the structure 
elucidation demands sophisticated protein solubilization and reconstitution (reviewed in [198]). 
As of today, only 4058 of a total of 175508 entries in the RCSB Protein Data Bank (RCSB PDB, 
data from 03/12/2021, [134, 135]) are membrane proteins. To date, most of the available 
protein structures relied on an Escherichia coli expression system (refer to the RCSB PDB). 
Due to an alternate codon usage, the lack of native protein processing and improper protein 
folding in E. coli (reviewed in [199]), the recombinant expression of human proteins using 
alternative or eukaryotic expression systems including mammalian cell lines, Sf9 insect cells 
or yeast cells increasingly gained interest in structure elucidation (reviewed in [200]).  
Structural information on the transporter surface, the substrate binding site as well as the 
spatial orientation of complexed basigin and MCT1 would largely contribute to understanding 
the mechanistic basis of the conclusions drawn in this study. The feasibility of functional 
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expression of MCT1 in fusion with its chaperone basigin in a yeast-based expression system 
laid the foundation to launch large-scale protein synthesis for structure elucidation. Here, 
Pichia pastoris was tested for the expression of MCT1 and basigin-MCT1 fusion constructs. In 
general, P. pastoris is advantageous in a way that it allows stable genome integration, 
inexpensive and inducible protein production and growth to much higher cell densities – all 
contributing to high protein yields (reviewed in [201, 202]). Unfortunately, P. pastoris did not 
produce MCT1 in this study (refer to section 4.3.1) whereas the plasmodial formate-nitrite 
transporter (PfFNT) was successfully expressed (refer to Figure 4.28). Given the strong 
dependency on a suitable chaperone for proper MCT expression in other systems [69], their 
autonomy in S. cerevisiae might be unique, and the expression in P. pastoris might require the 
presence of a guiding chaperone. Here, the unguided MCT1 and a fusion construct with the 
rather uncommon basigin splice variant 1 that also lacked proper production in S. cerevisiae 
(refer to Figure 4.9) were not produced in detectable yields. In contrast, a cell-free approach 
for the large-scale protein synthesis appeared promising. Using a detergent- and a lipid-protein 
nanodisc-based strategy, MCT1 in fusion with basigin splice variant 2 was synthesized and 
appeared correctly folded (refer to Figure 4.30 and Figure 4.31). Generally, the cell-free 
production and a subsequent reconstitution in nanodiscs combines highly versatile and 
controllable, large-scale production in short time periods [203] (reviewed in [198]) with a 
reconstitution in protein-stabilizing, membrane-mimicking nanodiscs that increase particle size 
required for analysis by cryo-EM [148, 149] (reviewed in [204]). Protein yields were sufficient 
to carry out transmission electron microscopy (TEM) of nanodisc-reconstituted protein. Initial 
class-sum calculations indicated protein reconstitution but, primarily, samples lacked sufficient 
homogeneity and separation from non-protein-filled nanodiscs (refer to Figure 4.33). On the 
far end, a cell-free synthesis does not necessarily or even unlikely ensure eukaryotic protein 
processing [198] essential to produce at least basigin in its functional and native form. Still, 
first trials on cryo-EM and class-sum calculations elucidated initial structural features and 
implied a dimeric state of the basigin-MCT1 complex.  
During this study, three structures of MCT member were resolved at high resolution. These 
include the bacterial MCT of Syntrophobacter fumaroxidans (SfMCT) [54], human MCT2 [55], 
and human MCT1 in complex with basigin in two conformational states [103]. Together, they 
provide a structural basis for MCT’s alternating access mechanism and substrate recognition 
in their designated conformations. Up to six discontinuous TM helices appear to facilitate the 
conformational reorganization [55]. A multimeric organization declares a cooperative behavior 
of MCTs [55]. Using a co-expression set-up and a Sf9 insect cell-based expression system, 
Wang et al. provided information on the spatial organization of MCT1 and basigin via cryo-EM 
(resolution of 3.0−3.3 Å) (see Figure 5.1) [103]. 
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This recent progress provides deep structural insights and widely confirmed the validity of the 
homology models that served as basis for this study (refer to Figure 5.1 and Figure 5.4). In the 
future, the major profit will be to bring the structural data and the functional conclusions from 
this study together and contribute to a detailed understanding and revelations on the exact 
mechanism of substrate harvesting by basigin and on the transporter toggling around the 
designated Cys159 hinge region. MCTs in general are a key element in human metabolism. 
Cancer cells rely on efficient L-lactate shuttling and deregulated expression and functionality 
of MCTs is a hallmark of cancer. An in-depth understanding of the mechanistic basis of 
transport and the combination of structural and functional data will aid and promote MCT’s 
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In the following, sequences of the open reading frames (ORF) for used plasmid vectors are 
shown. Complete vector maps can be found in section 2.1.2. Detailed information on the 




Supplementary Figure 1. Excerpt of the pDRTXaLK plasmid vector showing the open reading frame 
including the flanking fragments of the PMA promotor and the ADH terminator sequences. To yield 
pDRTXaLK, a linker sequence (green and orange) was introduced into the pDRTXa vector via a pair of 
oligonucleotides and includes N-terminal and C-terminal ends of MCT1 (orange). Commercial MCT1 
was inserted using PflMI and BspEI restriction sites. Further relevant restriction sites are marked, and 
























Supplementary Figure 2. Excerpt of the pUG35 (−) plasmid vector showing the open reading frame 
(ORF) including the flanking fragments of the MET25 promotor and the CYC terminator sequences. 












Supplementary Figure 3. Excerpt of the pPink-HC-optPfFNT plasmid vector showing the ORF 
including the flanking sequences of the AOX1 promotor and the CYC1 terminator and protein tags.  
pPink-HC-
optPfFNT 





Supplementary Figure 4. Excerpt of the pIVEX2.3w (−) plasmid vector showing the open reading frame 
(ORF) including the flanking fragments of the T7 promotor / terminator sequences and sequences for 































Supplementary Figure 5. Excerpt of the pIVEX2.3w-GFPΔM1 (−) plasmid vector showing the open 
reading frame including the flanking sequences of the T7 promotor and terminator, C-terminal GFP and 
protein tags. MCT1 constructs were inserted using SpeI and XhoI restriction sites. HA, hemagglutinin.  
pIVEX2.3w-GFPΔM1 (−) 
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